

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_mpl1p\_wp047, Report 1 of 3

**Request ID:** cder\_mpl1p\_wp047

**Request Description:** In this report, we used the Sentinel Distributed Database (SDD) to examine adherence to FDA's Risk Evaluation and Mitigation Strategy (REMS) absolute neutrophil count (ANC) screening recommendations for clozapine users. This is report 1 of 3 and contains all data returned by Data Partners (DPs). Reports 2 and 3 are DP-specific reports that include members with Medicaid/CHIP and Medicare Fee-For-Service (FFS), respectively.

**Sentinel Routine Querying Module:** Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.3.0, with the Multiple Events module and custom programming.

**Data Source:** We distributed this query to seven Sentinel Data Partners (DP) on August 15, 2022. In addition to data on members with Commercial health insurance, this report also contains data on beneficiaries with Medicare FFS medical and Part D drug coverage, Medicaid/CHIP coverage, and dual Medicare-Medicaid coverage. This report includes data from January 1, 2010 through October 31, 2021. Please see Appendix A for a list of dates of available data for each DP.

**Study Design:** We identified incident clozapine treatment episodes and evaluated ANC screening events in various windows during said episodes among a cohort of members who were at least 12 years of age at the index date, which was defined as the first date of dispensing after all inclusion, exclusion, and washout criteria were met. For each ANC screening evaluation window, we report descriptive statistics on the number of ANC screenings, length of gaps between ANC screenings, and monthly rate of ANC screenings. We use each of these metrics to capture different aspects of adherence to the FDA REMS ANC screening recommendations by reporting the number of clozapine episodes falling into different categories of each metric in the various ANC screening evaluation windows. In addition to describing these adherence metrics overall, this report also stratifies them by various demographic and clinical characteristics at baseline, including U.S. Census Bureau region. We assessed the ANC screening adherence among clozapine episodes in three separate time periods: from January 1, 2010 to September 30, 2015; from October 1, 2015 to December 31, 2019; and from January 1, 2020 to October 31, 2021. Please see Appendix B for a list of states and territories Included in Each Census Bureau Region. This is a Type 2 analysis with the multiple events add-on in the Query Request Package (QRP) documentation.

**Cohort Eligibility Criteria:** We required members to be enrolled in health plans with medical and drug coverage in the 30 days prior to the index date and from the index date through the earlier of the end of the ANC screening evaluation window or the end of the exposure episode; gaps in coverage of up to 30 days were allowed and treated as continuous enrollment. The following age groups were included in the cohort: 12-18, 19-35, 36-50, 51-64, 65-74, and 75+ years.

**Primary Exposure of Interest:** We defined the exposure of interest, clozapine, using outpatient dispensing data and National Drug Codes (NDCs). We defined incident exposure as no prior evidence of clozapine dispensed in the 30 days prior to the first qualifying (index) exposure. Each qualifying dispensing of clozapine (index) was included in the cohort; cohort re-entry was allowed. Please see Appendix C for a list of generic and brand names of medical products used to define exposures in this request.

**Follow-Up Time:** We created exposure episodes based on the number of days of clozapine supplied per dispensing in the outpatient pharmacy dispensing data. If multiple dispensings were supplied on the same day, we used the maximum days supplied to define the episode. We bridged together dispensings separated by gaps of less than 30 days. Minimum clozapine episode length depended on the ANC screening evaluation window being considered and included: 1) at least one day in duration, 2) at least six months in duration (184 days), 3) at least one year in duration (366 days), and 4) at least two years in duration (731 days). Follow-up began on the index date and continued until the first occurrence of: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; 4) the end of the query period; or 5) the end of the clozapine exposure episode.

**Sensitivity Analysis:** To assess the impact of a longer clozapine washout period on ANC screening adherence metrics, we also evaluated ANC screening events in the [1, 182] days after index among clozapine episodes of at least one day in duration where only episodes without evidence of clozapine in the six months (183 days) prior to the index exposure were included. In each of the three time periods, members with qualifying exposure episodes were required to be continuously enrolled in the six months (183 days) prior to the index event through the earlier of the end of the ANC screening evaluation window or the end of the exposure episode.

**Events of Interest:** The event of interest was an ANC screening, defined using Revenue, Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System (HCPCS) procedure codes, as well as Revenue, CPT-4, and HCPCS laboratory codes. We evaluated ANC screenings during different windows relative to the clozapine exposure episode index date (day 0). The ANC screening evaluation window varied for each required minimum clozapine episode duration:

- For clozapine episodes at least one day in duration, the ANC screening evaluation windows were:
  - o [-30, 0] days of clozapine index ("Look 1"), and
  - o [1, 182] days of clozapine index ("Look 2").
- For clozapine episodes at least six months in duration, the ANC screening evaluation windows were:
  - o [1, 182] days of clozapine index ("Look 5") and
  - o [183, 364] days of clozapine index ("Look 3").
- For clozapine episodes at least one-year in duration, the ANC screening evaluation windows were:
  - o [183, 364] days of clozapine index ("Look 6") and
  - o [365, 729] days of clozapine index ("Look 6").
- For clozapine episodes at least two years in duration, the ANC screening evaluation window was [365, 729] days of clozapine index ("Look 7").

For Looks 2-7, we required additional continuous enrollment after clozapine index through the end of the ANC screening evaluation window, regardless of when clozapine follow-up ended. Please see Appendix D for the list of Revenue, CPT-4, and HCPCS procedure and laboratory codes used to define ANC screenings in this request.

**Adherence Criteria:** As mentioned above, we use three metrics to assess various aspects of adherence to the FDA REMS ANC screening recommendations for clozapine users. As in the recommendations, the adherence definitions in this query vary based on duration of clozapine treatment. We report descriptive statistics for each adherence metric, but rather than define clozapine episodes as "adherent" vs. "non-adherent," we additionally report the number of clozapine episodes by classification of each metric as follows:

- All gap lengths between ANC screenings:  $\leq 10$  days,  $\leq 17$  days, and  $\leq 33$  days
- Total number of ANC screenings during evaluation window: At least one and 36 or more
  - o Only reported for Looks 1, 5, 6, and 7 because minimum required clozapine duration ensures comparability across evaluation windows
  - o Further classified as 1-4, 5-7, 8-11, 12-14, 15-20, 25-27, 28-30, 31-35, and  $\geq 36$  for Looks 5-7
  - o Further classified as  $\geq 25$  for Look 5
  - o Further classified as  $\geq 12$  for Looks 6 and 7
- Monthly rate of ANC screenings during evaluation window:  $\geq 1$ ,  $\geq 2$ , and  $\geq 4$  per month
  - o Not reported for Look 1 since no recommendations exist for this evaluation window

**Baseline Characteristics:** We assessed recent drug utilization in the 30 days prior to and including the day of clozapine initiation. The specific drugs of interest were: lithium, atypical antipsychotics, typical antipsychotics, any antipsychotic, and antidepressants. We assessed the following clinical characteristics in patients' entire available enrollment history up to and including the day of clozapine initiation using the Chronic Conditions Warehouse (CCW) algorithms<sup>1</sup>: alcohol use disorders, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and other behavioral disorders, ADHD Only subset, bipolar disorders, depression, depressive disorders, drug use disorders, opioid use disorders (including sub-categories), personality disorders, schizophrenia, and schizophrenia and other psychotic disorders. We additionally calculated the Charlson/Elixhauser combined comorbidity score<sup>2</sup>, and health service utilization over patients' entire available enrollment history. Please see Appendices E and F for a list of generic and brand names of medical products, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), and HCPCS codes used to define baseline characteristics in this request.

**Please see Appendices G, H, I, J, and K for the specifications defining parameters and the design diagrams for this request.**

**Limitations:** Algorithms used to define primary events, secondary events, and baseline characteristics are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinel-system.org](mailto:info@sentinel-system.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinel-system.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).



## Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module\*

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

**Ambulatory Visit (AV)** - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

**Emergency Department (ED)** - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

**Inpatient Hospital Stay (IP)** - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

**Non-Acute Institutional Stay (IS)** - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

**Other Ambulatory Visit (OA)** - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

**Charlson/Elixhauser Combined Comorbidity Score** - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

**Code Days** - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

**Cohort Definition (drug/exposure)** - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

**Computed Start Marketing Date** - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

**Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Lookback Period** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Maximum Episode Duration** - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Member-Years** - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered.

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Monitoring Period** - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Switch Evaluation Step Value** - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

**Switch Gap Inclusion Indicator** - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

**Switch Pattern Cohort Inclusion Date** - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

**Switch Pattern Cohort Inclusion Strategy** - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

**Treatment Episode Truncation Indicator** - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

**Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

\*all terms may not be used in this report

## Table of Contents

<b><u>Glossary</u></b>	List of Terms Found in this Report and their Definitions
<b><u>Table 1A.a</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1)
<b><u>Table 1B.a</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic
<b><u>Table 1A.b</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)
<b><u>Table 1B.b</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1C.b</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1D.b</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1A.c</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3)
<b><u>Table 1B.c</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic
<b><u>Table 1C.c</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic
<b><u>Table 1D.c</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic
<b><u>Table 1A.d</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4)
<b><u>Table 1B.d</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic

## Table of Contents

<b><u>Table 1C.d</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic
<b><u>Table 1D.d</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic
<b><u>Table 1A.e</u></b>	Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)
<b><u>Table 1B.e</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1C.e</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1D.e</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
<b><u>Table 1A.f</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5)
<b><u>Table 1B.f</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic
<b><u>Table 1C.f</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic
<b><u>Table 1D.f</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic
<b><u>Table 1A.g</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6)

## Table of Contents

<b><u>Table 1B.g</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
<b><u>Table 1C.g</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
<b><u>Table 1D.g</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
<b><u>Table 1A.h</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7)
<b><u>Table 1B.h</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
<b><u>Table 1C.h</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
<b><u>Table 1D.h</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
<b><u>Table 1A.i</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1)
<b><u>Table 1B.i</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic
<b><u>Table 1C.i</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic
<b><u>Table 1D.i</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic
<b><u>Table 1A.j</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)

## Table of Contents

<b><u>Table 1B.j</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1C.j</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1D.j</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1A.k</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3)
<b><u>Table 1B.k</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic
<b><u>Table 1C.k</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic
<b><u>Table 1D.k</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic
<b><u>Table 1A.l</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4)
<b><u>Table 1B.l</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic
<b><u>Table 1C.l</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic
<b><u>Table 1D.l</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic
<b><u>Table 1A.m</u></b>	Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)



## Table of Contents

<b><u>Table 1B.m</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1C.m</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1D.m</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
<b><u>Table 1A.n</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5)
<b><u>Table 1B.n</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
<b><u>Table 1C.n</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
<b><u>Table 1D.n</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
<b><u>Table 1A.o</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6)
<b><u>Table 1B.o</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic
<b><u>Table 1C.o</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic
<b><u>Table 1D.o</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic
<b><u>Table 1A.p</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7)

## Table of Contents

<b><u>Table 1B.p</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
<b><u>Table 1C.p</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
<b><u>Table 1D.p</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
<b><u>Table 1A.q</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1)
<b><u>Table 1B.q</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic
<b><u>Table 1C.q</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic
<b><u>Table 1D.q</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic
<b><u>Table 1A.r</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2)
<b><u>Table 1B.r</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic
<b><u>Table 1C.r</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic
<b><u>Table 1D.r</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic
<b><u>Table 1A.s</u></b>	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3)



## Table of Contents

<b><u>Table 1B.s</u></b>	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic
<b><u>Table 1C.s</u></b>	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic
<b><u>Table 1D.s</u></b>	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic
<b><u>Summary Table 1a</u></b>	Summary of Clozapine Episodes that Met the REMS Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database (SDD), Gap between ANC Screenings
<b><u>Summary Table 1b</u></b>	Summary Statistics of the Gap Between Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)
<b><u>Summary Table 2a</u></b>	Summary of Clozapine Episodes that Met the REMS Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database (SDD), Number of ANC Screenings
<b><u>Summary Table 2b</u></b>	Summary Statistics of the Number of Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)
<b><u>Summary Table 3a</u></b>	Summary of Clozapine Episodes that Met the REMS Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database (SDD), Rate of ANC Screening Events per Month
<b><u>Summary Table 3b</u></b>	Summary Statistics of the Rate of Absolute Neutrophil Count (ANC) Screening during Clozapine Use in the Sentinel Distributed Database (SDD)
<b><u>Appendix A</u></b>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (August 15, 2022)
<b><u>Appendix B</u></b>	List of States and U.S. Territories per Census Bureau (CB) Region
<b><u>Appendix C</u></b>	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
<b><u>Appendix D</u></b>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), Revenue (RE) Codes Used to Define the Events of Interest in this Request
<b><u>Appendix E</u></b>	List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request
<b><u>Appendix F</u></b>	List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request
<b><u>Appendix G</u></b>	Specifications Defining Parameters for this Request
<b><u>Appendix H</u></b>	Specifications Defining Baseline Characteristics Parameters for this Request
<b><u>Appendix I</u></b>	Specifications Defining Medical Utilization and Comorbidity Score Parameters for this Request
<b><u>Appendix J</u></b>	Specifications Defining Stockpiling Parameters Used for this Request
<b><u>Appendix K</u></b>	Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)

**Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1)**

Characteristic <sup>1</sup>	Number	
Number of episodes	82,235	
Number of unique patients	54,707	
Demographics	Mean	Standard Deviation
Mean Age (years)	48.1	14.7
Age (years)	Number	Percent
12-18	912	1.1%
19-35	19,321	23.5%
36-50	26,010	31.6%
51-64	24,622	29.9%
65-74	7,913	9.6%
75+	3,457	4.2%
Sex		
Female	22,619	41.3%
Male	32,088	58.7%
Race		
Unknown	6,700	12.2%
American Indian or Alaska Native	523	1.0%
Asian	1,121	2.0%
Black or African American	7,536	13.8%
Native Hawaiian or Other Pacific Islander	26	<0.1%
White	38,801	70.9%
Ethnicity		
Not Hispanic	47,686	87.2%
Unknown	4,807	8.8%
Hispanic	2,214	4.0%
Year		
2010 Quarter 1	4,707	5.7%
2010 Quarter 2	3,680	4.5%
2010 Quarter 3	3,624	4.4%
2010 Quarter 4	3,455	4.2%
2011 Quarter 1	3,562	4.3%
2011 Quarter 2	3,396	4.1%
2011 Quarter 3	3,454	4.2%
2011 Quarter 4	3,234	3.9%
2012 Quarter 1	3,605	4.4%
2012 Quarter 2	3,293	4.0%
2012 Quarter 3	3,216	3.9%
2012 Quarter 4	3,171	3.9%
2013 Quarter 1	3,616	4.4%
2013 Quarter 2	3,306	4.0%
2013 Quarter 3	3,335	4.1%

**Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1)**

	Number	Percent
2013 Quarter 4	3,087	3.8%
2014 Quarter 1	3,686	4.5%
2014 Quarter 2	3,563	4.3%
2014 Quarter 3	3,685	4.5%
2014 Quarter 4	3,590	4.4%
2015 Quarter 1	4,127	5.0%
2015 Quarter 2	3,895	4.7%
2015 Quarter 3	3,948	4.8%
<b>Geographic Census Bureau Region</b>		
Invalid	55	0.1%
Midwest	23,063	28.0%
Missing	12	<0.1%
Northeast	19,736	24.0%
Other	104	0.1%
South	25,286	30.7%
West	13,979	17.0%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1
ADHD Only Subset	2,644	3.2%
ADHD and Other Behavior Disorders	11,349	13.8%
Alcohol Use Disorders	9,518	11.6%
Anxiety Disorders	31,449	38.2%
Bipolar Disorders	35,817	43.6%
Depression	46,530	56.6%
Depressive Disorders	33,995	41.3%
Drug Use Disorders	14,926	18.2%
Opioid Use Disorder (OUD) 1	2,915	3.5%
OUD 2	2,388	2.9%
OUD 3	2,051	2.5%
OUD 4	410	0.5%
Personality Disorders	11,332	13.8%
Schizophrenia	66,112	80.4%
Schizophrenia and Other Psychotic Disorders	69,717	84.8%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	10,247	12.5%
Atypical Antipsychotics	40,018	48.7%
Typical Antipsychotics	19,023	23.1%
Any Antipsychotic (Typical or Atypical)	48,020	58.4%
Antidepressants	38,555	46.9%

**Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	79.6	106.8
Mean number of emergency room encounters	3.5	8.4
Mean number of inpatient hospital encounters	1.6	3.1
Mean number of non-acute institutional encounters	2.3	3.9
Mean number of other ambulatory encounters	62.4	93.8
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.5	3.4
Mean number of generics	5.8	3.7
Mean number of filled prescriptions	7.0	5.1

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

**Table 1B.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Number of ANC Screenings		
				Quarter 1	Median	Quarter 3
Number of episodes	82,235					
Number of unique patients	54,707					
Demographics	Mean	Standard Deviation				
Mean Age (years)	48.1	14.7				
Age (years)	Number	Percent				
12-18	912	1.1%	1.8	1.2	1	2
19-35	19,321	23.5%	1.6	1.1	1	2
36-50	26,010	31.6%	1.6	1.1	1	2
51-64	24,622	29.9%	1.7	1.2	1	2
65-74	7,913	9.6%	1.8	1.3	1	2
75+	3,457	4.2%	1.8	1.3	1	2
Sex						
Female	22,619	41.3%	1.7	1.2	1	2
Male	32,088	58.7%	1.7	1.2	1	2
Race						
Unknown	6,700	12.2%	1.6	1.1	1	2
American Indian or Alaska Native	523	1.0%	1.7	1.2	1	2
Asian	1,121	2.0%	1.6	1.1	1	2
Black or African American	7,536	13.8%	1.8	1.2	1	2
Native Hawaiian or Other Pacific Islander	26	<0.1%	1.6	0.7	1	2
White	38,801	70.9%	1.7	1.2	1	2
Ethnicity						
Not Hispanic	47,686	87.2%	1.7	1.2	1	2
Unknown	4,807	8.8%	1.5	1.0	1	2
Hispanic	2,214	4.0%	1.7	1.2	1	2
Year						
2010 Quarter 1	4,707	5.7%	N/A*	N/A	N/A	N/A
2010 Quarter 2	3,680	4.5%	N/A	N/A	N/A	N/A

**Table 1B.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 3	3,624	4.4%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 4	3,455	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	3,562	4.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	3,396	4.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	3,454	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	3,234	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	3,605	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	3,293	4.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	3,216	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	3,171	3.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	3,616	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	3,306	4.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	3,335	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	3,087	3.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	3,686	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	3,563	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	3,685	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	3,590	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	4,127	5.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	3,895	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	3,948	4.8%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	55	0.1%	1.3	0.6	1	1	1
Midwest	23,063	28.0%	1.7	1.2	1	1	2
Missing	12	<0.1%	1.7	0.5	1	2	2
Northeast	19,736	24.0%	1.8	1.4	1	1	2
Other	104	0.1%	1.3	0.7	1	1	1
South	25,286	30.7%	1.7	1.1	1	1	2
West	13,979	17.0%	1.6	1.1	1	1	2

**Table 1B.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic**

			Number of ANC Screenings				
Evidence of Medical Comorbidities Any Time Through Index							
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1					
	Number	Percent					
ADHD Only Subset	2,644	3.2%	1.7	1.2	1	1	2
ADHD and Other Behavior Disorders	11,349	13.8%	1.9	1.4	1	1	2
Alcohol Use Disorders	9,518	11.6%	1.8	1.3	1	1	2
Anxiety Disorders	31,449	38.2%	1.8	1.3	1	1	2
Bipolar Disorders	35,817	43.6%	1.8	1.3	1	1	2
Depression	46,530	56.6%	1.8	1.3	1	1	2
Depressive Disorders	33,995	41.3%	1.8	1.3	1	1	2
Drug Use Disorders	14,926	18.2%	1.8	1.3	1	1	2
Opioid Use Disorder (OUD) 1	2,915	3.5%	1.9	1.4	1	1	2
OUD 2	2,388	2.9%	1.9	1.5	1	1	2
OUD 3	2,051	2.5%	1.9	1.5	1	1	2
OUD 4	410	0.5%	1.6	1.1	1	1	2
Personality Disorders	11,332	13.8%	1.9	1.4	1	1	2
Schizophrenia	66,112	80.4%	1.7	1.2	1	1	2
Schizophrenia and Other Psychotic Disorders	69,717	84.8%	1.7	1.2	1	1	2
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	10,247	12.5%	1.7	1.2	1	1	2
Atypical Antipsychotics	40,018	48.7%	1.7	1.1	1	1	2
Typical Antipsychotics	19,023	23.1%	1.7	1.2	1	1	2
Any Antipsychotic (Typical or Atypical)	48,020	58.4%	1.7	1.2	1	1	2
Antidepressants	38,555	46.9%	1.7	1.1	1	1	2
Healthcare Encounter Utilization at Any Time Through the							
Index Date	Mean	Standard Deviation					
Mean number of ambulatory encounters	79.6	106.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	3.5	8.4	N/A	N/A	N/A	N/A	N/A

**Table 1B.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of inpatient hospital encounters	1.6	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.3	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	62.4	93.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.5	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable



**Table 1A.b: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

Characteristic <sup>1</sup>	Number	
Number of episodes	82,235	
Number of unique patients	54,707	
Demographics	Mean	Standard Deviation
Mean Age (years)	48.1	14.7
Age (years)	Number	Percent
12-18	912	1.1%
19-35	19,321	23.5%
36-50	26,010	31.6%
51-64	24,622	29.9%
65-74	7,913	9.6%
75+	3,457	4.2%
Sex		
Female	22,619	41.3%
Male	32,088	58.7%
Race		
Unknown	6,700	12.2%
American Indian or Alaska Native	523	1.0%
Asian	1,121	2.0%
Black or African American	7,536	13.8%
Native Hawaiian or Other Pacific Islander	26	<0.1%
White	38,801	70.9%
Ethnicity		
Not Hispanic	47,686	87.2%
Unknown	4,807	8.8%
Hispanic	2,214	4.0%
Year		
2010 Quarter 1	4,707	5.7%
2010 Quarter 2	3,680	4.5%
2010 Quarter 3	3,624	4.4%
2010 Quarter 4	3,455	4.2%
2011 Quarter 1	3,562	4.3%
2011 Quarter 2	3,396	4.1%
2011 Quarter 3	3,454	4.2%
2011 Quarter 4	3,234	3.9%
2012 Quarter 1	3,605	4.4%
2012 Quarter 2	3,293	4.0%
2012 Quarter 3	3,216	3.9%
2012 Quarter 4	3,171	3.9%
2013 Quarter 1	3,616	4.4%
2013 Quarter 2	3,306	4.0%
2013 Quarter 3	3,335	4.1%

**Table 1A.b: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

	Number	Percent
2013 Quarter 4	3,087	3.8%
2014 Quarter 1	3,686	4.5%
2014 Quarter 2	3,563	4.3%
2014 Quarter 3	3,685	4.5%
2014 Quarter 4	3,590	4.4%
2015 Quarter 1	4,127	5.0%
2015 Quarter 2	3,895	4.7%
2015 Quarter 3	3,948	4.8%
<b>Geographic Census Bureau Region</b>		
Invalid	55	0.1%
Midwest	23,063	28.0%
Missing	12	<0.1%
Northeast	19,736	24.0%
Other	104	0.1%
South	25,286	30.7%
West	13,979	17.0%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1
ADHD Only Subset	2,644	3.2%
ADHD and Other Behavior Disorders	11,349	13.8%
Alcohol Use Disorders	9,518	11.6%
Anxiety Disorders	31,449	38.2%
Bipolar Disorders	35,817	43.6%
Depression	46,530	56.6%
Depressive Disorders	33,995	41.3%
Drug Use Disorders	14,926	18.2%
Opioid Use Disorder (OUD) 1	2,915	3.5%
OUD 2	2,388	2.9%
OUD 3	2,051	2.5%
OUD 4	410	0.5%
Personality Disorders	11,332	13.8%
Schizophrenia	66,112	80.4%
Schizophrenia and Other Psychotic Disorders	69,717	84.8%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	10,247	12.5%
Atypical Antipsychotics	40,018	48.7%
Typical Antipsychotics	19,023	23.1%
Any Antipsychotic (Typical or Atypical)	48,020	58.4%
Antidepressants	38,555	46.9%

**Table 1A.b: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	79.6	106.8
Mean number of emergency room encounters	3.5	8.4
Mean number of inpatient hospital encounters	1.6	3.1
Mean number of non-acute institutional encounters	2.3	3.9
Mean number of other ambulatory encounters	62.4	93.8
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.5	3.4
Mean number of generics	5.8	3.7
Mean number of filled prescriptions	7.0	5.1

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

**Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	82,235						
Number of unique patients	54,707						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.1	14.7					
Age (years)	Number	Percent					
12-18	912	1.1%	10.0	11.9	6	7	8
19-35	19,321	23.5%	10.7	12.1	7	7	10
36-50	26,010	31.6%	11.3	11.9	7	7	12
51-64	24,622	29.9%	11.1	11.6	6	7	13
65-74	7,913	9.6%	10.3	10.8	6	7	11
75+	3,457	4.2%	9.2	8.9	6	7	8
Sex							
Female	22,619	41.3%	10.6	11.3	6	7	11
Male	32,088	58.7%	11.1	11.9	7	7	12
Race							
Unknown	6,700	12.2%	11.8	13.7	7	7	13
American Indian or Alaska Native	523	1.0%	10.1	11.0	6	7	9
Asian	1,121	2.0%	11.7	13.3	7	7	13
Black or African American	7,536	13.8%	11.2	12.4	6	7	13
Native Hawaiian or Other Pacific Islander	26	<0.1%	14.8	16.2	7	7	15
White	38,801	70.9%	10.7	11.2	6	7	11
Ethnicity							
Not Hispanic	47,686	87.2%	10.8	11.4	6	7	11
Unknown	4,807	8.8%	12.1	14.0	7	7	13
Hispanic	2,214	4.0%	11.6	13.1	6	7	13
Year							
2010 Quarter 1	4,707	5.7%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	3,680	4.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	3,624	4.4%	N/A	N/A	N/A	N/A	N/A

**Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	3,455	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	3,562	4.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	3,396	4.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	3,454	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	3,234	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	3,605	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	3,293	4.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	3,216	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	3,171	3.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	3,616	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	3,306	4.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	3,335	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	3,087	3.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	3,686	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	3,563	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	3,685	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	3,590	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	4,127	5.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	3,895	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	3,948	4.8%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	55	0.1%	13.2	15.1	7	7	14
Midwest	23,063	28.0%	10.3	10.2	6	7	10
Missing	12	<0.1%	15.3	12.8	7	13	18
Northeast	19,736	24.0%	11.1	12.6	6	7	12
Other	104	0.1%	21.2	22.0	7	15	29
South	25,286	30.7%	11.4	12.0	6	7	13
West	13,979	17.0%	10.9	12.1	7	7	10

**Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1					
	Number	Percent					
ADHD Only Subset	2,644	3.2%	9.2	10.0	6	7	8
ADHD and Other Behavior Disorders	11,349	13.8%	9.1	10.1	6	7	8
Alcohol Use Disorders	9,518	11.6%	9.4	10.1	6	7	8
Anxiety Disorders	31,449	38.2%	9.4	9.9	6	7	8
Bipolar Disorders	35,817	43.6%	9.7	10.4	6	7	9
Depression	46,530	56.6%	9.9	10.4	6	7	9
Depressive Disorders	33,995	41.3%	9.6	10.1	6	7	8
Drug Use Disorders	14,926	18.2%	9.3	10.2	6	7	8
Opioid Use Disorder (OUD) 1	2,915	3.5%	9.2	9.9	6	7	8
OUD 2	2,388	2.9%	9.1	10.0	6	7	8
OUD 3	2,051	2.5%	9.2	10.0	6	7	8
OUD 4	410	0.5%	9.4	9.6	6	7	9
Personality Disorders	11,332	13.8%	9.0	9.8	6	7	8
Schizophrenia	66,112	80.4%	10.7	11.4	6	7	11
Schizophrenia and Other Psychotic Disorders	69,717	84.8%	10.6	11.3	6	7	10
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	10,247	12.5%	9.8	11.1	6	7	8
Atypical Antipsychotics	40,018	48.7%	9.1	9.8	6	7	8
Typical Antipsychotics	19,023	23.1%	9.2	10.3	6	7	8
Any Antipsychotic (Typical or Atypical)	48,020	58.4%	9.4	10.2	6	7	8
Antidepressants	38,555	46.9%	10.3	10.9	6	7	9
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	79.6	106.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	3.5	8.4	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.6	3.1	N/A	N/A	N/A	N/A	N/A

**Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.3	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	62.4	93.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.5	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1C.b: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	82,235						
Number of unique patients	54,707						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.1	14.7					
Age (years)	Number	Percent					
12-18	912	1.1%	11.0	9.2	3	8	19
19-35	19,321	23.5%	11.5	9.4	4	8	21
36-50	26,010	31.6%	11.2	9.3	4	7	19
51-64	24,622	29.9%	11.3	9.2	4	8	19
65-74	7,913	9.6%	11.6	9.5	4	8	20
75+	3,457	4.2%	12.2	10.0	4	9	21
Sex							
Female	22,619	41.3%	11.6	9.4	4	8	20
Male	32,088	58.7%	11.3	9.3	4	7	19
Race							
Unknown	6,700	12.2%	10.0	9.0	3	6	16
American Indian or Alaska Native	523	1.0%	12.3	9.6	4	8	23
Asian	1,121	2.0%	10.8	9.2	3	7	19
Black or African American	7,536	13.8%	10.5	9.0	3	7	17
Native Hawaiian or Other Pacific Islander	26	<0.1%	6.7	7.0	2	5	7
White	38,801	70.9%	11.8	9.4	4	8	21
Ethnicity							
Not Hispanic	47,686	87.2%	11.6	9.4	4	8	20
Unknown	4,807	8.8%	9.7	8.9	3	6	16
Hispanic	2,214	4.0%	10.5	9.1	3	7	17
Year							
2010 Quarter 1	4,707	5.7%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 2	3,680	4.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	3,624	4.4%	N/A	N/A	N/A	N/A	N/A



**Table 1C.b: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	3,455	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	3,562	4.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	3,396	4.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	3,454	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	3,234	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	3,605	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	3,293	4.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	3,216	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	3,171	3.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	3,616	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	3,306	4.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	3,335	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	3,087	3.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	3,686	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	3,563	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	3,685	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	3,590	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	4,127	5.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	3,895	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	3,948	4.8%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	55	0.1%	8.7	8.3	2	6	17
Midwest	23,063	28.0%	12.4	9.6	5	8	22
Missing	12	<0.1%	8.3	7.9	4	6	10
Northeast	19,736	24.0%	11.4	9.3	4	8	19
Other	104	0.1%	4.9	6.2	1	3	5
South	25,286	30.7%	10.4	9.0	3	7	17
West	13,979	17.0%	11.5	9.3	4	8	20

**Table 1C.b: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1					
	Number	Percent					
ADHD Only Subset	2,644	3.2%	12.6	10.0	4	9	22
ADHD and Other Behavior Disorders	11,349	13.8%	13.0	9.9	4	11	23
Alcohol Use Disorders	9,518	11.6%	12.2	9.5	4	9	21
Anxiety Disorders	31,449	38.2%	12.6	9.7	4	10	22
Bipolar Disorders	35,817	43.6%	12.2	9.7	4	9	21
Depression	46,530	56.6%	12.2	9.6	4	9	21
Depressive Disorders	33,995	41.3%	12.4	9.7	4	9	22
Drug Use Disorders	14,926	18.2%	12.3	9.7	4	9	22
Opioid Use Disorder (OUD) 1	2,915	3.5%	11.5	9.6	3	8	20
OUD 2	2,388	2.9%	11.3	9.6	3	8	20
OUD 3	2,051	2.5%	11.3	9.4	3	8	19
OUD 4	410	0.5%	10.6	9.6	2	7	18
Personality Disorders	11,332	13.8%	12.9	9.7	4	11	22
Schizophrenia	66,112	80.4%	11.6	9.4	4	8	20
Schizophrenia and Other Psychotic Disorders	69,717	84.8%	11.7	9.4	4	8	20
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,247	12.5%	12.6	9.8	4	9	22
Atypical Antipsychotics	40,018	48.7%	13.6	10.0	5	11	24
Typical Antipsychotics	19,023	23.1%	13.5	9.9	5	11	24
Any Antipsychotic (Typical or Atypical)	48,020	58.4%	13.2	9.9	4	10	23
Antidepressants	38,555	46.9%	12.0	9.6	4	8	21
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	79.6	106.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	3.5	8.4	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.6	3.1	N/A	N/A	N/A	N/A	N/A

**Table 1C.b: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.3	3.9	N/A*	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	62.4	93.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.5	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	82,235						
Number of unique patients	54,707						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.1	14.7					
Age (years)	Number	Percent					
12-18	912	1.1%	2.8	1.6	1	3.1	4
19-35	19,321	23.5%	2.6	1.7	1	2.5	4
36-50	26,010	31.6%	2.5	1.7	1	2.1	4
51-64	24,622	29.9%	2.6	1.8	1	2.2	4
65-74	7,913	9.6%	2.8	2.0	1	2.5	4
75+	3,457	4.2%	3.1	1.9	1	3.3	4
Sex							
Female	22,619	41.3%	2.7	1.8	1	2.5	4
Male	32,088	58.7%	2.6	1.8	1	2.2	4
Race							
Unknown	6,700	12.2%	2.4	1.7	1	2.0	4
American Indian or Alaska Native	523	1.0%	2.8	1.7	1	2.8	4
Asian	1,121	2.0%	2.4	1.9	1	2.0	4
Black or African American	7,536	13.8%	2.6	1.7	1	2.1	4
Native Hawaiian or Other Pacific Islander	26	<0.1%	2.0	1.4	1	1.5	3
White	38,801	70.9%	2.7	1.8	1	2.4	4
Ethnicity							
Not Hispanic	47,686	87.2%	2.7	1.8	1	2.3	4
Unknown	4,807	8.8%	2.3	1.7	1	1.8	4
Hispanic	2,214	4.0%	2.5	1.8	1	2.1	4
Year							
2010 Quarter 1	4,707	5.7%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	3,680	4.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	3,624	4.4%	N/A	N/A	N/A	N/A	N/A

**Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	3,455	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	3,562	4.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	3,396	4.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	3,454	4.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	3,234	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	3,605	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	3,293	4.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	3,216	3.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	3,171	3.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	3,616	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	3,306	4.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	3,335	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	3,087	3.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	3,686	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	3,563	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	3,685	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	3,590	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	4,127	5.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	3,895	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	3,948	4.8%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	55	0.1%	2.3	1.6	1	1.6	4
Midwest	23,063	28.0%	2.8	1.8	1	2.7	4
Missing	12	<0.1%	1.6	1.2	1	1.1	2
Northeast	19,736	24.0%	2.6	1.8	1	2.2	4
Other	104	0.1%	1.2	1.1	1	1.0	1
South	25,286	30.7%	2.5	1.7	1	2.1	4
West	13,979	17.0%	2.6	1.8	1	2.3	4

**Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.4	3.1					
	Number	Percent					
ADHD Only Subset	2,644	3.2%	3.1	1.7	1	3.3	4
ADHD and Other Behavior Disorders	11,349	13.8%	3.2	1.9	2	3.4	4
Alcohol Use Disorders	9,518	11.6%	3.0	1.8	2	3.2	4
Anxiety Disorders	31,449	38.2%	3.0	1.8	1	3.2	4
Bipolar Disorders	35,817	43.6%	2.9	1.8	1	3.0	4
Depression	46,530	56.6%	2.9	1.8	1	3.0	4
Depressive Disorders	33,995	41.3%	3.0	1.8	1	3.1	4
Drug Use Disorders	14,926	18.2%	3.1	1.8	2	3.2	4
Opioid Use Disorder (OUD) 1	2,915	3.5%	3.1	1.9	2	3.2	4
OUD 2	2,388	2.9%	3.1	1.9	2	3.2	4
OUD 3	2,051	2.5%	3.2	2.0	2	3.2	4
OUD 4	410	0.5%	2.9	1.6	1	3.0	4
Personality Disorders	11,332	13.8%	3.2	1.8	2	3.3	4
Schizophrenia	66,112	80.4%	2.7	1.8	1	2.3	4
Schizophrenia and Other Psychotic Disorders	69,717	84.8%	2.7	1.8	1	2.5	4
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,247	12.5%	2.9	1.8	1	3.1	4
Atypical Antipsychotics	40,018	48.7%	3.1	1.8	2	3.5	4
Typical Antipsychotics	19,023	23.1%	3.1	1.8	2	3.4	4
Any Antipsychotic (Typical or Atypical)	48,020	58.4%	3.1	1.8	1	3.3	4
Antidepressants	38,555	46.9%	2.8	1.8	1	2.7	4
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	79.6	106.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	3.5	8.4	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.6	3.1	N/A	N/A	N/A	N/A	N/A

**Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.3	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	62.4	93.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.5	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3)**

Characteristic <sup>1</sup>	Number	
Number of episodes	41,662	
Number of unique patients	34,960	
Demographics	Mean	Standard Deviation
Mean Age (years)	48.0	14.2
Age (years)	Number	Percent
12-18	306	0.7%
19-35	9,560	22.9%
36-50	13,757	33.0%
51-64	12,840	30.8%
65-74	3,769	9.0%
75+	1,430	3.4%
Sex		
Female	14,284	40.9%
Male	20,676	59.1%
Race		
Unknown	3,776	10.8%
American Indian or Alaska Native	330	0.9%
Asian	710	2.0%
Black or African American	4,400	12.6%
Native Hawaiian or Other Pacific Islander	11	<0.1%
White	25,733	73.6%
Ethnicity		
Not Hispanic	31,011	88.7%
Unknown	2,595	7.4%
Hispanic	1,354	3.9%
Year		
2010 Quarter 1	3,296	7.9%
2010 Quarter 2	2,098	5.0%
2010 Quarter 3	2,118	5.1%
2010 Quarter 4	1,970	4.7%
2011 Quarter 1	2,053	4.9%
2011 Quarter 2	1,901	4.6%
2011 Quarter 3	1,889	4.5%
2011 Quarter 4	1,712	4.1%
2012 Quarter 1	2,087	5.0%
2012 Quarter 2	1,822	4.4%
2012 Quarter 3	1,777	4.3%
2012 Quarter 4	1,715	4.1%
2013 Quarter 1	2,027	4.9%
2013 Quarter 2	1,843	4.4%
2013 Quarter 3	1,826	4.4%



**Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3)**

	Number	Percent
2013 Quarter 4	1,689	4.1%
2014 Quarter 1	2,006	4.8%
2014 Quarter 2	1,858	4.5%
2014 Quarter 3	1,952	4.7%
2014 Quarter 4	1,828	4.4%
2015 Quarter 1	2,195	5.3%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	0.1%
Midwest	12,473	29.9%
Missing	*****	<0.1%
Northeast	10,570	25.4%
Other	22	0.1%
South	11,633	27.9%
West	6,934	16.6%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9
ADHD Only Subset	1,090	2.6%
ADHD and Other Behavior Disorders	5,135	12.3%
Alcohol Use Disorders	4,024	9.7%
Anxiety Disorders	14,409	34.6%
Bipolar Disorders	16,506	39.6%
Depression	21,847	52.4%
Depressive Disorders	15,713	37.7%
Drug Use Disorders	6,350	15.2%
Opioid Use Disorder (OUD) 1	1,053	2.5%
OUD 2	817	2.0%
OUD 3	717	1.7%
OUD 4	126	0.3%
Personality Disorders	5,133	12.3%
Schizophrenia	33,852	81.3%
Schizophrenia and Other Psychotic Disorders	35,405	85.0%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,186	12.4%
Atypical Antipsychotics	20,323	48.8%
Typical Antipsychotics	9,902	23.8%
Any Antipsychotic (Typical or Atypical)	24,507	58.8%
Antidepressants	19,762	47.4%

**Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	72.8	101.8
Mean number of emergency room encounters	2.9	6.7
Mean number of inpatient hospital encounters	1.3	2.6
Mean number of non-acute institutional encounters	2.0	3.4
Mean number of other ambulatory encounters	55.4	84.0
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.4
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	13.4	13.8	7	9	15
19-35	9,560	22.9%	13.5	12.5	7	10	15
36-50	13,757	33.0%	13.9	12.4	7	11	16
51-64	12,840	30.8%	13.2	11.9	7	8	15
65-74	3,769	9.0%	12.1	11.4	7	7	14
75+	1,430	3.4%	10.6	9.7	7	7	14
Sex							
Female	14,284	40.9%	12.9	11.8	7	8	14
Male	20,676	59.1%	13.5	12.3	7	9	15
Race							
Unknown	3,776	10.8%	14.7	14.4	7	12	17
American Indian or Alaska Native	330	0.9%	12.9	12.0	7	8	14
Asian	710	2.0%	14.5	13.2	7	13	16
Black or African American	4,400	12.6%	13.1	12.4	7	8	15
Native Hawaiian or Other Pacific Islander	11	<0.1%	20.7	13.7	13	16	28
White	25,733	73.6%	13.1	11.7	7	9	15
Ethnicity							
Not Hispanic	31,011	88.7%	13.1	11.8	7	8	15
Unknown	2,595	7.4%	15.0	14.5	7	13	18
Hispanic	1,354	3.9%	14.4	14.2	7	11	16
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A

**Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	21.2	21.1	7	14	29
Midwest	12,473	29.9%	12.6	10.9	7	8	14
Missing	*****	<0.1%	18.1	12.3	9	15.5	26
Northeast	10,570	25.4%	13.6	12.9	7	10	15
Other	22	0.1%	16.6	23.3	7	7	17
South	11,633	27.9%	13.6	12.3	7	9	15
West	6,934	16.6%	13.5	12.6	7	9	15

**Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index							
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9					
	Number	Percent					
ADHD Only Subset	1,090	2.6%	11.9	10.7	7	8	14
ADHD and Other Behavior Disorders	5,135	12.3%	11.0	10.6	7	7	14
Alcohol Use Disorders	4,024	9.7%	11.9	11.0	7	8	14
Anxiety Disorders	14,409	34.6%	11.6	10.7	7	7	14
Bipolar Disorders	16,506	39.6%	12.0	11.0	7	7	14
Depression	21,847	52.4%	12.1	11.0	7	8	14
Depressive Disorders	15,713	37.7%	11.7	10.7	7	7	14
Drug Use Disorders	6,350	15.2%	11.8	10.9	7	8	14
Opioid Use Disorder (OUD) 1	1,053	2.5%	11.5	10.8	7	7	14
OUD 2	817	2.0%	11.4	10.6	7	7	14
OUD 3	717	1.7%	11.4	10.6	7	7	14
OUD 4	126	0.3%	11.0	9.8	7	7	14
Personality Disorders	5,133	12.3%	11.3	10.5	7	7	14
Schizophrenia	33,852	81.3%	13.1	11.8	7	9	15
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	12.9	11.7	7	8	14
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	5,186	12.4%	12.5	11.8	7	8	14
Atypical Antipsychotics	20,323	48.8%	11.6	10.5	7	7	14
Typical Antipsychotics	9,902	23.8%	11.5	10.8	7	7	14
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	11.8	10.8	7	8	14
Antidepressants	19,762	47.4%	12.7	11.5	7	8	14
Healthcare Encounter Utilization at Any Time Through the							
Index Date	Mean	Standard Deviation					
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A

**Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.c: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	9.6	7.2	4	7	14
19-35	9,560	22.9%	10.6	7.3	5	9	14
36-50	13,757	33.0%	10.5	7.2	6	8	14
51-64	12,840	30.8%	10.9	7.7	6	8	15
65-74	3,769	9.0%	11.6	8.2	6	9	16
75+	1,430	3.4%	13.1	8.9	6	12	19
Sex							
Female	14,284	40.9%	11.1	7.7	6	9	15
Male	20,676	59.1%	10.6	7.5	6	8	14
Race							
Unknown	3,776	10.8%	9.3	6.9	4	7	13
American Indian or Alaska Native	330	0.9%	11.5	7.4	6	10	16
Asian	710	2.0%	9.6	6.7	5	8	13
Black or African American	4,400	12.6%	10.8	7.8	5	8	15
Native Hawaiian or Other Pacific Islander	11	<0.1%	3.4	3.0	1	3	5
White	25,733	73.6%	11.1	7.6	6	9	15
Ethnicity							
Not Hispanic	31,011	88.7%	11.0	7.6	6	9	15
Unknown	2,595	7.4%	8.9	6.9	4	7	13
Hispanic	1,354	3.9%	9.8	7.0	5	7	14
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A

**Table 1C.c: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	6.3	4.9	2	6	7
Midwest	12,473	29.9%	11.4	7.8	6	9	15
Missing	*****	<0.1%	9.0	5.2	6	6	15
Northeast	10,570	25.4%	10.7	7.5	6	8	14
Other	22	0.1%	7.4	7.3	2	4	8
South	11,633	27.9%	10.4	7.4	5	8	14
West	6,934	16.6%	10.6	7.4	5	8	14



**Table 1C.c: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

Number of ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index							
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9					
	Number	Percent					
ADHD Only Subset	1,090	2.6%	11.5	7.8	5	11	16
ADHD and Other Behavior Disorders	5,135	12.3%	12.8	8.4	6	12	18
Alcohol Use Disorders	4,024	9.7%	11.7	7.6	6	11	16
Anxiety Disorders	14,409	34.6%	12.1	8.0	6	11	16
Bipolar Disorders	16,506	39.6%	11.8	7.9	6	10	16
Depression	21,847	52.4%	11.7	7.9	6	10	16
Depressive Disorders	15,713	37.7%	12.0	8.0	6	11	16
Drug Use Disorders	6,350	15.2%	11.8	7.6	6	11	16
Opioid Use Disorder (OUD) 1	1,053	2.5%	11.6	7.9	5	10	16
OUD 2	817	2.0%	11.6	7.8	5	11	16
OUD 3	717	1.7%	11.7	7.8	6	10.5	16
OUD 4	126	0.3%	11.9	8.6	5	10	17
Personality Disorders	5,133	12.3%	12.5	7.9	6	12	17
Schizophrenia	33,852	81.3%	11.0	7.6	6	9	15
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	11.1	7.6	6	9	15
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	5,186	12.4%	11.6	7.6	6	10	16
Atypical Antipsychotics	20,323	48.8%	12.6	7.9	6	12	17
Typical Antipsychotics	9,902	23.8%	12.6	7.9	6	12	17
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	12.3	7.8	6	12	16
Antidepressants	19,762	47.4%	11.3	7.7	6	9	15
Healthcare Encounter Utilization at Any Time Through the							
Index Date	Mean	Standard Deviation					
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A

**Table 1C.c: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	2.2	1.4	1	2.0	3
19-35	9,560	22.9%	2.1	1.4	1	1.9	3
36-50	13,757	33.0%	2.0	1.3	1	1.6	3
51-64	12,840	30.8%	2.1	1.4	1	1.8	3
65-74	3,769	9.0%	2.4	1.7	1	2.1	3
75+	1,430	3.4%	2.7	1.7	1	2.3	4
Sex							
Female	14,284	40.9%	2.2	1.5	1	2.0	3
Male	20,676	59.1%	2.1	1.4	1	1.8	3
Race							
Unknown	3,776	10.8%	1.9	1.3	1	1.5	2
American Indian or Alaska Native	330	0.9%	2.2	1.3	1	2.0	3
Asian	710	2.0%	1.9	1.1	1	1.6	2
Black or African American	4,400	12.6%	2.2	1.5	1	1.8	3
Native Hawaiian or Other Pacific Islander	11	<0.1%	1.3	1.1	1	0.8	2
White	25,733	73.6%	2.2	1.4	1	1.9	3
Ethnicity							
Not Hispanic	31,011	88.7%	2.2	1.4	1	1.8	3
Unknown	2,595	7.4%	1.8	1.2	1	1.5	2
Hispanic	1,354	3.9%	1.9	1.3	1	1.5	3
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A

**Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	1.3	1.0	1	1.0	2
Midwest	12,473	29.9%	2.2	1.4	1	2.0	3
Missing	*****	<0.1%	1.5	0.9	1	1.0	2
Northeast	10,570	25.4%	2.1	1.4	1	1.8	3
Other	22	0.1%	1.9	1.6	1	1.2	2
South	11,633	27.9%	2.1	1.4	1	1.6	3
West	6,934	16.6%	2.1	1.4	1	1.8	3

**Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Evidence of Medical Comorbidities Any Time Through Index Date			Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1 Median Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>			3.2	2.9			
	Number	Percent					
ADHD Only Subset	1,090	2.6%	2.4	1.4	1	2.1	3
ADHD and Other Behavior Disorders	5,135	12.3%	2.6	1.5	1	2.3	4
Alcohol Use Disorders	4,024	9.7%	2.4	1.4	1	2.1	3
Anxiety Disorders	14,409	34.6%	2.4	1.5	1	2.1	3
Bipolar Disorders	16,506	39.6%	2.4	1.5	1	2.1	3
Depression	21,847	52.4%	2.3	1.5	1	2.1	3
Depressive Disorders	15,713	37.7%	2.4	1.5	1	2.1	3
Drug Use Disorders	6,350	15.2%	2.4	1.4	1	2.1	3
Opioid Use Disorder (OUD) 1	1,053	2.5%	2.5	1.5	1	2.3	3
OUD 2	817	2.0%	2.5	1.5	1	2.3	3
OUD 3	717	1.7%	2.5	1.5	1	2.3	3
OUD 4	126	0.3%	2.4	1.3	1	2.2	3
Personality Disorders	5,133	12.3%	2.5	1.5	1	2.3	3
Schizophrenia	33,852	81.3%	2.2	1.4	1	1.9	3
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	2.2	1.4	1	2.0	3
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	5,186	12.4%	2.3	1.4	1	2.1	3
Atypical Antipsychotics	20,323	48.8%	2.5	1.5	1	2.3	3
Typical Antipsychotics	9,902	23.8%	2.5	1.4	1	2.3	3
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	2.4	1.5	1	2.1	3
Antidepressants	19,762	47.4%	2.2	1.4	1	2.0	3
Healthcare Encounter Utilization at Any Time Through the Index Date			Mean	Standard Deviation			
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A

**Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4)**

Characteristic <sup>1</sup>	Number	
Number of episodes	29,533	
Number of unique patients	27,009	
Demographics	Mean	Standard Deviation
Mean Age (years)	47.8	13.9
Age (years)	Number	Percent
12-18	162	0.5%
19-35	6,704	22.7%
36-50	10,160	34.4%
51-64	9,072	30.7%
65-74	2,534	8.6%
75+	901	3.1%
Sex		
Female	10,995	40.7%
Male	16,014	59.3%
Race		
Unknown	2,557	9.5%
American Indian or Alaska Native	*****	1.0%
Asian	548	2.0%
Black or African American	3,253	12.0%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	20,392	75.5%
Ethnicity		
Not Hispanic	24,348	90.1%
Unknown	1,648	6.1%
Hispanic	1,013	3.8%
Year		
2010 Quarter 1	2,804	9.5%
2010 Quarter 2	1,633	5.5%
2010 Quarter 3	1,701	5.8%
2010 Quarter 4	1,541	5.2%
2011 Quarter 1	1,619	5.5%
2011 Quarter 2	1,500	5.1%
2011 Quarter 3	1,477	5.0%
2011 Quarter 4	1,357	4.6%
2012 Quarter 1	1,644	5.6%
2012 Quarter 2	1,425	4.8%
2012 Quarter 3	1,426	4.8%
2012 Quarter 4	1,345	4.6%
2013 Quarter 1	1,550	5.2%
2013 Quarter 2	1,424	4.8%
2013 Quarter 3	1,425	4.8%

**Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4)**

	Number	Percent
2013 Quarter 4	1,312	4.4%
2014 Quarter 1	1,495	5.1%
2014 Quarter 2	1,347	4.6%
2014 Quarter 3	1,508	5.1%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	15	0.1%
Midwest	8,996	30.5%
Missing	*****	<0.1%
Northeast	7,748	26.2%
Other	****	<0.1%
South	7,933	26.9%
West	4,829	16.4%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8
ADHD Only Subset	694	2.3%
ADHD and Other Behavior Disorders	3,382	11.5%
Alcohol Use Disorders	2,689	9.1%
Anxiety Disorders	9,579	32.4%
Bipolar Disorders	11,122	37.7%
Depression	14,857	50.3%
Depressive Disorders	10,487	35.5%
Drug Use Disorders	4,192	14.2%
Opioid Use Disorder (OUD) 1	648	2.2%
OUD 2	493	1.7%
OUD 3	435	1.5%
OUD 4	72	0.2%
Personality Disorders	3,437	11.6%
Schizophrenia	23,913	81.0%
Schizophrenia and Other Psychotic Disorders	24,944	84.5%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	3,686	12.5%
Atypical Antipsychotics	14,588	49.4%
Typical Antipsychotics	7,053	23.9%
Any Antipsychotic (Typical or Atypical)	17,526	59.3%
Antidepressants	14,054	47.6%



**Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	66.7	91.5
Mean number of emergency room encounters	2.6	6.0
Mean number of inpatient hospital encounters	1.2	2.4
Mean number of non-acute institutional encounters	1.8	3.1
Mean number of other ambulatory encounters	49.0	75.1
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.d: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	18.6	17.9	7	14	28
19-35	6,704	22.7%	18.9	17.5	7	14	28
36-50	10,160	34.4%	18.4	16.1	7	14	28
51-64	9,072	30.7%	16.6	15.4	7	14	27
65-74	2,534	8.6%	14.7	15.0	7	10	21
75+	901	3.1%	13.0	13.7	7	7	14
Sex							
Female	10,995	40.7%	16.8	15.5	7	14	27
Male	16,014	59.3%	17.8	16.5	7	14	28
Race							
Unknown	2,557	9.5%	20.0	20.4	7	15	28
American Indian or Alaska Native	*****	1.0%	17.2	17.7	7	14	28
Asian	548	2.0%	19.7	18.2	8	15	28
Black or African American	3,253	12.0%	16.6	16.7	7	14	27
Native Hawaiian or Other Pacific Islander	*****	<0.1%	32.9	13.8	28	32.5	40
White	20,392	75.5%	17.2	15.4	7	14	28
Ethnicity							
Not Hispanic	24,348	90.1%	17.1	15.7	7	14	28
Unknown	1,648	6.1%	20.8	21.8	7	16	28
Hispanic	1,013	3.8%	19.3	18.7	7	14	28
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1B.d: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

Characteristic	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	32.1	27.5	25	28	31
Midwest	8,996	30.5%	16.6	13.8	7	14	28
Missing	*****	<0.1%	14.9	10.0	8	13.5	21
Northeast	7,748	26.2%	17.7	18.0	7	14	28
Other	****	<0.1%	25.5	30.1	7	19	28
South	7,933	26.9%	17.4	15.9	7	14	28
West	4,829	16.4%	18.2	17.2	7	14	28

**Table 1B.d: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date			Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1 Median Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>			3.0	2.8			
	Number	Percent					
ADHD Only Subset	694	2.3%	16.5	15.2	7	14	26
ADHD and Other Behavior Disorders	3,382	11.5%	14.7	15.1	7	10	21
Alcohol Use Disorders	2,689	9.1%	16.5	15.4	7	14	27
Anxiety Disorders	9,579	32.4%	15.6	14.5	7	13	24
Bipolar Disorders	11,122	37.7%	15.9	15.0	7	13	25
Depression	14,857	50.3%	15.9	15.0	7	13	25
Depressive Disorders	10,487	35.5%	15.4	14.6	7	13	23
Drug Use Disorders	4,192	14.2%	16.4	15.7	7	14	26
Opioid Use Disorder (OUD) 1	648	2.2%	15.6	15.9	7	13	22
OUD 2	493	1.7%	15.8	16.3	7	13	23
OUD 3	435	1.5%	15.4	16.5	7	13	21
OUD 4	72	0.2%	15.7	14.7	7	13	24
Personality Disorders	3,437	11.6%	15.4	15.1	7	13	23
Schizophrenia	23,913	81.0%	17.1	15.5	7	14	28
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	16.9	15.5	7	14	28
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	3,686	12.5%	17.0	16.9	7	14	27
Atypical Antipsychotics	14,588	49.4%	16.2	15.4	7	14	26
Typical Antipsychotics	7,053	23.9%	15.8	15.5	7	13	24
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	16.3	15.6	7	14	27
Antidepressants	14,054	47.6%	16.9	15.3	7	14	28
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A

**Table 1B.d: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.d: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	11.7	11.2	4	10	14
19-35	6,704	22.7%	14.4	11.0	8	13	17
36-50	10,160	34.4%	15.2	11.0	9	13	18
51-64	9,072	30.7%	16.4	12.5	9	14	20
65-74	2,534	8.6%	17.3	14.3	8	14	22
75+	901	3.1%	18.5	15.0	7	14	26
Sex							
Female	10,995	40.7%	16.1	12.3	8	13	20
Male	16,014	59.3%	15.3	11.8	8	13	18
Race							
Unknown	2,557	9.5%	12.5	10.5	5	11	15
American Indian or Alaska Native	*****	1.0%	16.1	12.7	9	13.5	19
Asian	548	2.0%	13.9	9.9	8	13	17
Black or African American	3,253	12.0%	16.0	12.8	8	13	20
Native Hawaiian or Other Pacific Islander	*****	<0.1%	9.0	1.4	8	9	10
White	20,392	75.5%	16.0	12.0	9	13	19
Ethnicity							
Not Hispanic	24,348	90.1%	16.0	12.1	9	13	19
Unknown	1,648	6.1%	11.6	10.3	5	10	14
Hispanic	1,013	3.8%	13.6	10.5	7	12	16
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1C.d: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	7.8	5.1	3	9	12
Midwest	8,996	30.5%	16.2	12.4	9	13	19
Missing	*****	<0.1%	5.0	2.6	2	6	7
Northeast	7,748	26.2%	15.7	11.9	8	13	19
Other	****	<0.1%	10.6	8.1	3	9	19
South	7,933	26.9%	15.3	12.0	8	13	18
West	4,829	16.4%	14.9	11.2	8	13	18

**Table 1C.d: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8					
	Number	Percent					
ADHD Only Subset	694	2.3%	15.1	12.6	7	13	19
ADHD and Other Behavior Disorders	3,382	11.5%	17.7	14.1	8	14	23
Alcohol Use Disorders	2,689	9.1%	15.5	11.8	8	13	20
Anxiety Disorders	9,579	32.4%	16.5	12.9	8	14	21
Bipolar Disorders	11,122	37.7%	16.3	12.7	8	14	20
Depression	14,857	50.3%	16.4	12.9	8	14	21
Depressive Disorders	10,487	35.5%	16.7	13.1	8	14	21
Drug Use Disorders	4,192	14.2%	15.5	11.9	7	13	20
Opioid Use Disorder (OUD) 1	648	2.2%	15.9	12.6	7	13	20
OUD 2	493	1.7%	15.3	12.6	6	13	20
OUD 3	435	1.5%	15.6	12.2	7	14	20
OUD 4	72	0.2%	14.7	13.3	6	11	19
Personality Disorders	3,437	11.6%	16.8	12.8	8	14	21
Schizophrenia	23,913	81.0%	15.9	12.1	9	13	19
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	16.0	12.2	9	13	19
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,686	12.5%	16.0	12.4	8	13	20
Atypical Antipsychotics	14,588	49.4%	16.8	12.6	9	14	21
Typical Antipsychotics	7,053	23.9%	17.2	12.8	9	14	22
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	16.6	12.5	9	14	21
Antidepressants	14,054	47.6%	16.0	12.2	9	13	19
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A



**Table 1C.d: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	1.6	1.3	1	1.1	2
19-35	6,704	22.7%	1.5	1.1	1	1.2	2
36-50	10,160	34.4%	1.6	1.2	1	1.2	2
51-64	9,072	30.7%	1.8	1.3	1	1.3	2
65-74	2,534	8.6%	2.0	1.5	1	1.5	2
75+	901	3.1%	2.3	1.5	1	1.9	3
Sex							
Female	10,995	40.7%	1.8	1.4	1	1.3	2
Male	16,014	59.3%	1.7	1.1	1	1.2	2
Race							
Unknown	2,557	9.5%	1.5	1.3	1	1.2	2
American Indian or Alaska Native	*****	1.0%	1.7	1.1	1	1.3	2
Asian	548	2.0%	1.5	0.9	1	1.2	2
Black or African American	3,253	12.0%	1.8	1.2	1	1.3	2
Native Hawaiian or Other Pacific Islander	*****	<0.1%	0.8	0.0	1	0.8	1
White	20,392	75.5%	1.7	1.2	1	1.3	2
Ethnicity							
Not Hispanic	24,348	90.1%	1.7	1.2	1	1.3	2
Unknown	1,648	6.1%	1.5	1.5	1	1.1	2
Hispanic	1,013	3.8%	1.5	1.0	1	1.2	2
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	0.8	0.4	1	1.0	1
Midwest	8,996	30.5%	1.8	1.2	1	1.3	2
Missing	*****	<0.1%	1.8	0.8	1	1.5	3
Northeast	7,748	26.2%	1.7	1.2	1	1.3	2
Other	****	<0.1%	1.0	0.6	1	1.1	2
South	7,933	26.9%	1.7	1.3	1	1.2	2
West	4,829	16.4%	1.6	1.3	1	1.2	2

**Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Evidence of Medical Comorbidities Any Time Through Index Date			Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1 Median Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>			3.0	2.8			
	Number	Percent					
ADHD Only Subset	694	2.3%	1.9	1.8	1	1.4	2
ADHD and Other Behavior Disorders	3,382	11.5%	2.1	1.6	1	1.6	3
Alcohol Use Disorders	2,689	9.1%	1.8	1.3	1	1.4	2
Anxiety Disorders	9,579	32.4%	1.9	1.4	1	1.5	2
Bipolar Disorders	11,122	37.7%	1.9	1.3	1	1.4	2
Depression	14,857	50.3%	1.9	1.3	1	1.4	2
Depressive Disorders	10,487	35.5%	1.9	1.4	1	1.5	2
Drug Use Disorders	4,192	14.2%	1.8	1.3	1	1.4	2
Opioid Use Disorder (OUD) 1	648	2.2%	1.9	1.3	1	1.5	2
OUD 2	493	1.7%	1.9	1.2	1	1.5	2
OUD 3	435	1.5%	2.0	1.3	1	1.6	2
OUD 4	72	0.2%	2.1	1.5	1	1.4	3
Personality Disorders	3,437	11.6%	1.9	1.3	1	1.5	2
Schizophrenia	23,913	81.0%	1.7	1.3	1	1.3	2
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	1.7	1.3	1	1.3	2
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	3,686	12.5%	1.7	1.3	1	1.3	2
Atypical Antipsychotics	14,588	49.4%	1.8	1.3	1	1.4	2
Typical Antipsychotics	7,053	23.9%	1.9	1.3	1	1.5	2
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	1.8	1.3	1	1.4	2
Antidepressants	14,054	47.6%	1.8	1.3	1	1.3	2
Healthcare Encounter Utilization at Any Time Through the Index Date			Mean	Standard Deviation			
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A

**Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

Characteristic <sup>1</sup>	Number	
Number of episodes	32,133	
Number of unique patients	30,218	
Demographics	Mean	Standard Deviation
Mean Age (years)	47.2	15.1
Age (years)	Number	Percent
12-18	464	1.4%
19-35	8,463	26.3%
36-50	10,026	31.2%
51-64	8,936	27.8%
65-74	2,747	8.5%
75+	1,497	4.7%
Sex		
Female	12,789	42.3%
Male	17,429	57.7%
Race		
Unknown	3,757	12.4%
American Indian or Alaska Native	*****	1.0%
Asian	617	2.0%
Black or African American	4,380	14.5%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	21,152	70.0%
Ethnicity		
Not Hispanic	26,251	86.9%
Unknown	2,785	9.2%
Hispanic	1,182	3.9%
Year		
2010 Quarter 1	104	0.3%
2010 Quarter 2	101	0.3%
2010 Quarter 3	1,491	4.6%
2010 Quarter 4	1,493	4.6%
2011 Quarter 1	1,581	4.9%
2011 Quarter 2	1,425	4.4%
2011 Quarter 3	1,550	4.8%
2011 Quarter 4	1,419	4.4%
2012 Quarter 1	1,570	4.9%
2012 Quarter 2	1,429	4.4%
2012 Quarter 3	1,440	4.5%
2012 Quarter 4	1,389	4.3%
2013 Quarter 1	1,544	4.8%
2013 Quarter 2	1,497	4.7%
2013 Quarter 3	1,511	4.7%

**Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

	Number	Percent
2013 Quarter 4	1,384	4.3%
2014 Quarter 1	1,422	4.4%
2014 Quarter 2	1,463	4.6%
2014 Quarter 3	1,697	5.3%
2014 Quarter 4	1,675	5.2%
2015 Quarter 1	1,654	5.1%
2015 Quarter 2	1,520	4.7%
2015 Quarter 3	1,774	5.5%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	<0.1%
Midwest	9,323	29.0%
Missing	*****	<0.1%
Northeast	7,657	23.8%
Other	16	<0.1%
South	9,519	29.6%
West	5,600	17.4%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.6	2.9
ADHD Only Subset	1,608	5.0%
ADHD and Other Behavior Disorders	6,358	19.8%
Alcohol Use Disorders	5,259	16.4%
Anxiety Disorders	15,880	49.4%
Bipolar Disorders	17,257	53.7%
Depression	21,431	66.7%
Depressive Disorders	16,174	50.3%
Drug Use Disorders	8,234	25.6%
Opioid Use Disorder (OUD) 1	1,667	5.2%
OUD 2	1,401	4.4%
OUD 3	1,163	3.6%
OUD 4	229	0.7%
Personality Disorders	6,245	19.4%
Schizophrenia	26,075	81.1%
Schizophrenia and Other Psychotic Disorders	28,203	87.8%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,030	15.7%
Atypical Antipsychotics	22,195	69.1%
Typical Antipsychotics	10,411	32.4%
Any Antipsychotic (Typical or Atypical)	25,159	78.3%
Antidepressants	16,516	51.4%

**Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	93.4	110.7
Mean number of emergency room encounters	5.1	10.4
Mean number of inpatient hospital encounters	1.8	3.5
Mean number of non-acute institutional encounters	2.9	4.2
Mean number of other ambulatory encounters	64.0	88.3
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	6.1	3.5
Mean number of generics	6.5	3.8
Mean number of filled prescriptions	8.1	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.



**Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	32,133						
Number of unique patients	30,218						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	15.1					
Age (years)	Number	Percent					
12-18	464	1.4%	8.7	9.9	6	7	8
19-35	8,463	26.3%	8.4	9.1	6	7	7
36-50	10,026	31.2%	8.3	8.7	6	7	7
51-64	8,936	27.8%	8.3	9.1	6	7	7
65-74	2,747	8.5%	7.8	8.1	6	7	7
75+	1,497	4.7%	7.4	6.5	6	7	7
Sex							
Female	12,789	42.3%	8.1	8.5	6	7	7
Male	17,429	57.7%	8.4	9.0	6	7	7
Race							
Unknown	3,757	12.4%	8.8	10.4	6	7	8
American Indian or Alaska Native	*****	1.0%	8.3	8.9	6	7	7
Asian	617	2.0%	9.0	10.5	7	7	7
Black or African American	4,380	14.5%	8.9	10.2	6	7	8
Native Hawaiian or Other Pacific Islander	*****	<0.1%	9.4	6.5	7	7	11
White	21,152	70.0%	8.1	8.2	6	7	7
Ethnicity							
Not Hispanic	26,251	86.9%	8.2	8.6	6	7	7
Unknown	2,785	9.2%	9.0	10.6	6	7	8
Hispanic	1,182	3.9%	8.6	10.0	6	7	7
Year							
2010 Quarter 1	104	0.3%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	101	0.3%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,491	4.6%	N/A	N/A	N/A	N/A	N/A

**Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Gaps between all ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,493	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,581	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,425	4.4%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,550	4.8%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,419	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,570	4.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,429	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,440	4.5%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,389	4.3%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,544	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,497	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,511	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,384	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,422	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,463	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,697	5.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,675	5.2%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	1,654	5.1%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	1,520	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	1,774	5.5%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	7.9	6.2	7	7	7
Midwest	9,323	29.0%	7.9	7.3	6	7	7
Missing	*****	<0.1%	9.2	4.7	6	7	13
Northeast	7,657	23.8%	8.5	10.0	6	7	7
Other	16	<0.1%	8.8	13.7	6	7	8
South	9,519	29.6%	8.5	9.0	6	7	8
West	5,600	17.4%	8.3	9.3	6	7	7

**Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.6	2.9					
	Number	Percent					
ADHD Only Subset	1,608	5.0%	8.0	8.3	6	7	7
ADHD and Other Behavior Disorders	6,358	19.8%	8.0	8.9	6	7	7
Alcohol Use Disorders	5,259	16.4%	8.1	8.5	6	7	7
Anxiety Disorders	15,880	49.4%	7.9	8.2	6	7	7
Bipolar Disorders	17,257	53.7%	8.1	8.6	6	7	7
Depression	21,431	66.7%	8.0	8.3	6	7	7
Depressive Disorders	16,174	50.3%	7.9	8.2	6	7	7
Drug Use Disorders	8,234	25.6%	8.1	8.6	6	7	7
Opioid Use Disorder (OUD) 1	1,667	5.2%	8.0	8.3	6	7	7
OUD 2	1,401	4.4%	8.0	8.3	6	7	7
OUD 3	1,163	3.6%	8.0	8.3	6	7	7
OUD 4	229	0.7%	8.0	7.5	5	7	8
Personality Disorders	6,245	19.4%	7.9	8.5	6	7	7
Schizophrenia	26,075	81.1%	8.3	8.8	6	7	7
Schizophrenia and Other Psychotic Disorders	28,203	87.8%	8.2	8.7	6	7	7
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	5,030	15.7%	8.1	8.9	6	7	7
Atypical Antipsychotics	22,195	69.1%	7.8	7.9	6	7	7
Typical Antipsychotics	10,411	32.4%	8.0	8.6	6	7	7
Any Antipsychotic (Typical or Atypical)	25,159	78.3%	7.9	8.1	6	7	7
Antidepressants	16,516	51.4%	7.9	7.9	6	7	7
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	93.4	110.7	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.1	10.4	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.8	3.5	N/A	N/A	N/A	N/A	N/A

**Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.9	4.2	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	64.0	88.3	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	6.1	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.1	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.e: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	32,133						
Number of unique patients	30,218						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	15.1					
Age (years)	Number	Percent					
12-18	464	1.4%	12.5	9.4	4	10	21
19-35	8,463	26.3%	14.6	9.9	5	14	25
36-50	10,026	31.2%	14.8	10.1	5	15	25
51-64	8,936	27.8%	14.3	10.2	5	13	25
65-74	2,747	8.5%	14.2	10.4	4	13	24
75+	1,497	4.7%	14.1	10.6	4	12	25
Sex							
Female	12,789	42.3%	14.5	10.2	4	14	25
Male	17,429	57.7%	14.5	10.1	5	14	25
Race							
Unknown	3,757	12.4%	13.4	9.9	4	11	24
American Indian or Alaska Native	*****	1.0%	14.8	10.0	5	14	25
Asian	617	2.0%	14.0	9.9	4	13.5	25
Black or African American	4,380	14.5%	12.8	9.9	4	10	23
Native Hawaiian or Other Pacific Islander	*****	<0.1%	9.5	10.1	2	4	20
White	21,152	70.0%	15.0	10.2	5	15	25
Ethnicity							
Not Hispanic	26,251	86.9%	14.7	10.2	5	14	25
Unknown	2,785	9.2%	13.1	9.7	4	11	23
Hispanic	1,182	3.9%	13.8	10.2	4	12	24
Year							
2010 Quarter 1	104	0.3%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	101	0.3%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,491	4.6%	N/A	N/A	N/A	N/A	N/A

**Table 1C.e: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,493	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,581	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,425	4.4%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,550	4.8%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,419	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,570	4.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,429	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,440	4.5%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,389	4.3%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,544	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,497	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,511	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,384	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,422	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,463	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,697	5.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,675	5.2%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	1,654	5.1%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	1,520	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	1,774	5.5%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	14.9	9.5	6	19.5	22
Midwest	9,323	29.0%	15.6	10.3	6	16	25
Missing	*****	<0.1%	12.0	12.1	1	10	25
Northeast	7,657	23.8%	14.4	10.1	5	13	25
Other	16	<0.1%	12.0	11.9	1	6.5	25
South	9,519	29.6%	13.5	9.9	4	12	23
West	5,600	17.4%	14.5	10.0	4	14	25

**Table 1C.e: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.6	2.9					
	Number	Percent					
ADHD Only Subset	1,608	5.0%	14.2	10.1	4	13	24
ADHD and Other Behavior Disorders	6,358	19.8%	14.4	10.2	4	14	24
Alcohol Use Disorders	5,259	16.4%	13.7	9.9	4	13	24
Anxiety Disorders	15,880	49.4%	14.6	10.1	5	14	25
Bipolar Disorders	17,257	53.7%	14.4	10.2	4	14	24
Depression	21,431	66.7%	14.6	10.1	5	14	25
Depressive Disorders	16,174	50.3%	14.6	10.1	5	14	25
Drug Use Disorders	8,234	25.6%	13.9	10.0	4	13	24
Opioid Use Disorder (OUD) 1	1,667	5.2%	12.8	10.0	3	10	23
OUD 2	1,401	4.4%	12.6	10.0	3	10	23
OUD 3	1,163	3.6%	12.5	9.8	3	9	22
OUD 4	229	0.7%	11.7	10.0	3	8.5	21
Personality Disorders	6,245	19.4%	14.4	10.1	4	14	24
Schizophrenia	26,075	81.1%	14.6	10.1	5	14	25
Schizophrenia and Other Psychotic Disorders	28,203	87.8%	14.6	10.1	5	14	25
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,030	15.7%	15.2	10.1	5	15	25
Atypical Antipsychotics	22,195	69.1%	15.6	10.2	5	17	25
Typical Antipsychotics	10,411	32.4%	15.3	10.2	5	16	25
Any Antipsychotic (Typical or Atypical)	25,159	78.3%	15.4	10.2	5	16	25
Antidepressants	16,516	51.4%	15.1	10.1	5	15	25
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	93.4	110.7	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.1	10.4	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.8	3.5	N/A	N/A	N/A	N/A	N/A

**Table 1C.e: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.9	4.2	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	64.0	88.3	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	6.1	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.1	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable



**Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	32,133						
Number of unique patients	30,218						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	15.1					
Age (years)	Number	Percent					
12-18	464	1.4%	3.2	1.4	2	3.6	4
19-35	8,463	26.3%	3.4	1.6	2	3.8	4
36-50	10,026	31.2%	3.4	1.6	2	3.8	4
51-64	8,936	27.8%	3.4	1.8	2	3.8	4
65-74	2,747	8.5%	3.7	2.0	3	4.0	4
75+	1,497	4.7%	3.8	1.6	3	4.1	4
Sex							
Female	12,789	42.3%	3.5	1.8	2	3.9	4
Male	17,429	57.7%	3.4	1.6	2	3.8	4
Race							
Unknown	3,757	12.4%	3.2	1.6	2	3.6	4
American Indian or Alaska Native	*****	1.0%	3.4	1.5	2	3.9	4
Asian	617	2.0%	3.2	2.0	2	3.6	4
Black or African American	4,380	14.5%	3.2	1.8	2	3.5	4
Native Hawaiian or Other Pacific Islander	*****	<0.1%	2.8	1.3	2	3.0	4
White	21,152	70.0%	3.5	1.7	2	4.0	4
Ethnicity							
Not Hispanic	26,251	86.9%	3.5	1.7	2	3.8	4
Unknown	2,785	9.2%	3.1	1.6	2	3.6	4
Hispanic	1,182	3.9%	3.3	1.8	2	3.7	4
Year							
2010 Quarter 1	104	0.3%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 2	101	0.3%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,491	4.6%	N/A	N/A	N/A	N/A	N/A

**Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,493	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,581	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,425	4.4%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,550	4.8%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,419	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,570	4.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,429	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,440	4.5%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,389	4.3%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,544	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,497	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,511	4.7%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,384	4.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,422	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,463	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,697	5.3%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,675	5.2%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	1,654	5.1%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	1,520	4.7%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	1,774	5.5%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	3.8	1.2	3	4.1	5
Midwest	9,323	29.0%	3.6	1.6	3	4.0	4
Missing	*****	<0.1%	2.4	1.6	1	2.0	4
Northeast	7,657	23.8%	3.4	1.8	2	3.8	4
Other	16	<0.1%	2.9	1.7	1	3.2	4
South	9,519	29.6%	3.3	1.7	2	3.6	4
West	5,600	17.4%	3.4	1.7	2	3.8	4

**Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

Rate of ANC Screening Events per Month									
Evidence of Medical Comorbidities Any Time Through Index Date			Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.6	2.9							
	Number	Percent							
ADHD Only Subset	1,608	5.0%	3.5	1.6	2	3.8	4		
ADHD and Other Behavior Disorders	6,358	19.8%	3.6	1.8	2	3.9	4		
Alcohol Use Disorders	5,259	16.4%	3.5	1.7	2	3.8	4		
Anxiety Disorders	15,880	49.4%	3.6	1.7	3	3.9	4		
Bipolar Disorders	17,257	53.7%	3.5	1.7	2	3.8	4		
Depression	21,431	66.7%	3.5	1.7	3	3.9	4		
Depressive Disorders	16,174	50.3%	3.6	1.7	3	3.9	4		
Drug Use Disorders	8,234	25.6%	3.5	1.7	2	3.8	4		
Opioid Use Disorder (OUD) 1	1,667	5.2%	3.5	1.7	2	3.8	4		
OUD 2	1,401	4.4%	3.5	1.7	2	3.7	4		
OUD 3	1,163	3.6%	3.6	1.8	2	3.7	4		
OUD 4	229	0.7%	3.3	1.4	2	3.6	4		
Personality Disorders	6,245	19.4%	3.6	1.8	3	3.9	4		
Schizophrenia	26,075	81.1%	3.4	1.7	2	3.8	4		
Schizophrenia and Other Psychotic Disorders	28,203	87.8%	3.5	1.7	2	3.8	4		
Evidence of Medical Product Use in the 30 Days Prior to or On Index									
Lithium	5,030	15.7%	3.5	1.7	2	3.9	4		
Atypical Antipsychotics	22,195	69.1%	3.7	1.6	3	4.0	4		
Typical Antipsychotics	10,411	32.4%	3.6	1.7	3	4.0	4		
Any Antipsychotic (Typical or Atypical)	25,159	78.3%	3.6	1.6	3	4.0	4		
Antidepressants	16,516	51.4%	3.6	1.6	3	4.0	4		
Healthcare Encounter Utilization at Any Time Through the Index Date									
	Mean	Standard Deviation							
Mean number of ambulatory encounters	93.4	110.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.1	10.4	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.8	3.5	N/A	N/A	N/A	N/A	N/A	N/A	N/A

**Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.9	4.2	N/A*	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	64.0	88.3	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	6.1	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.1	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5)**

Characteristic <sup>1</sup>	Number	
Number of episodes	41,662	
Number of unique patients	34,960	
Demographics	Mean	Standard Deviation
Mean Age (years)	48.0	14.2
Age (years)	Number	Percent
12-18	306	0.7%
19-35	9,560	22.9%
36-50	13,757	33.0%
51-64	12,840	30.8%
65-74	3,769	9.0%
75+	1,430	3.4%
Sex		
Female	14,284	40.9%
Male	20,676	59.1%
Race		
Unknown	3,776	10.8%
American Indian or Alaska Native	330	0.9%
Asian	710	2.0%
Black or African American	4,400	12.6%
Native Hawaiian or Other Pacific Islander	11	<0.1%
White	25,733	73.6%
Ethnicity		
Not Hispanic	31,011	88.7%
Unknown	2,595	7.4%
Hispanic	1,354	3.9%
Year		
2010 Quarter 1	3,296	7.9%
2010 Quarter 2	2,098	5.0%
2010 Quarter 3	2,118	5.1%
2010 Quarter 4	1,970	4.7%
2011 Quarter 1	2,053	4.9%
2011 Quarter 2	1,901	4.6%
2011 Quarter 3	1,889	4.5%
2011 Quarter 4	1,712	4.1%
2012 Quarter 1	2,087	5.0%
2012 Quarter 2	1,822	4.4%
2012 Quarter 3	1,777	4.3%
2012 Quarter 4	1,715	4.1%
2013 Quarter 1	2,027	4.9%
2013 Quarter 2	1,843	4.4%
2013 Quarter 3	1,826	4.4%

**Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5)**

	Number	Percent
2013 Quarter 4	1,689	4.1%
2014 Quarter 1	2,006	4.8%
2014 Quarter 2	1,858	4.5%
2014 Quarter 3	1,952	4.7%
2014 Quarter 4	1,828	4.4%
2015 Quarter 1	2,195	5.3%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	25	0.1%
Midwest	12,473	29.9%
Missing	*****	<0.1%
Northeast	10,570	25.4%
Other	*****	0.1%
South	11,633	27.9%
West	6,934	16.6%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9
ADHD Only Subset	1,090	2.6%
ADHD and Other Behavior Disorders	5,135	12.3%
Alcohol Use Disorders	4,024	9.7%
Anxiety Disorders	14,409	34.6%
Bipolar Disorders	16,506	39.6%
Depression	21,847	52.4%
Depressive Disorders	15,713	37.7%
Drug Use Disorders	6,350	15.2%
Opioid Use Disorder (OUD) 1	1,053	2.5%
OUD 2	817	2.0%
OUD 3	717	1.7%
OUD 4	126	0.3%
Personality Disorders	5,133	12.3%
Schizophrenia	33,852	81.3%
Schizophrenia and Other Psychotic Disorders	35,405	85.0%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,186	12.4%
Atypical Antipsychotics	20,323	48.8%
Typical Antipsychotics	9,902	23.8%
Any Antipsychotic (Typical or Atypical)	24,507	58.8%
Antidepressants	19,762	47.4%

**Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	72.8	101.8
Mean number of emergency room encounters	2.9	6.7
Mean number of inpatient hospital encounters	1.3	2.6
Mean number of non-acute institutional encounters	2.0	3.4
Mean number of other ambulatory encounters	55.4	84.0
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.4
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	10.2	12.2	7	7	8
19-35	9,560	22.9%	10.8	12.3	7	7	9
36-50	13,757	33.0%	11.5	12.1	7	7	13
51-64	12,840	30.8%	11.4	11.9	7	7	14
65-74	3,769	9.0%	10.7	11.2	7	7	12
75+	1,430	3.4%	9.4	9.0	6	7	8
Sex							
Female	14,284	40.9%	10.9	11.5	7	7	11
Male	20,676	59.1%	11.3	12.2	7	7	12
Race							
Unknown	3,776	10.8%	12.1	14.2	7	7	13
American Indian or Alaska Native	330	0.9%	10.3	10.9	7	7	9
Asian	710	2.0%	11.9	13.4	7	7	13
Black or African American	4,400	12.6%	11.5	12.7	7	7	13
Native Hawaiian or Other Pacific Islander	11	<0.1%	14.9	16.6	7	7	16
White	25,733	73.6%	11.0	11.4	7	7	11
Ethnicity							
Not Hispanic	31,011	88.7%	11.0	11.6	7	7	12
Unknown	2,595	7.4%	12.3	14.6	7	7	13
Hispanic	1,354	3.9%	11.9	13.5	7	7	13
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A



**Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Gaps between all ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	25	0.1%	16.1	17.3	7	7	27
Midwest	12,473	29.9%	10.5	10.4	7	7	10
Missing	*****	<0.1%	14.3	15.7	6	8	20
Northeast	10,570	25.4%	11.5	12.9	7	7	13
Other	*****	0.1%	15.1	19.8	7	7	19
South	11,633	27.9%	11.6	12.3	7	7	13
West	6,934	16.6%	11.0	12.4	7	7	10

**Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9					
	Number	Percent					
ADHD Only Subset	1,090	2.6%	9.4	10.3	6	7	8
ADHD and Other Behavior Disorders	5,135	12.3%	9.2	10.3	6	7	8
Alcohol Use Disorders	4,024	9.7%	9.6	10.3	7	7	8
Anxiety Disorders	14,409	34.6%	9.6	10.1	6	7	8
Bipolar Disorders	16,506	39.6%	9.9	10.6	6	7	8
Depression	21,847	52.4%	10.0	10.6	7	7	9
Depressive Disorders	15,713	37.7%	9.8	10.3	6	7	8
Drug Use Disorders	6,350	15.2%	9.5	10.5	6	7	8
Opioid Use Disorder (OUD) 1	1,053	2.5%	9.4	10.3	6	7	8
OUD 2	817	2.0%	9.3	10.4	6	7	8
OUD 3	717	1.7%	9.5	10.4	6	7	8
OUD 4	126	0.3%	9.5	9.5	6	7	8
Personality Disorders	5,133	12.3%	9.3	10.0	6	7	8
Schizophrenia	33,852	81.3%	11.0	11.6	7	7	11
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	10.8	11.5	7	7	11
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	5,186	12.4%	10.0	11.4	7	7	8
Atypical Antipsychotics	20,323	48.8%	9.2	9.9	7	7	8
Typical Antipsychotics	9,902	23.8%	9.4	10.4	7	7	8
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	9.5	10.4	7	7	8
Antidepressants	19,762	47.4%	10.6	11.1	7	7	10
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A

**Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	16.8	9.3	7	19	25
19-35	9,560	22.9%	15.7	9.4	6	16	25
36-50	13,757	33.0%	14.8	9.4	6	12	25
51-64	12,840	30.8%	14.9	9.4	7	12	24
65-74	3,769	9.0%	15.9	9.6	7	14	25
75+	1,430	3.4%	18.3	9.7	8	20.5	26
Sex							
Female	14,284	40.9%	15.6	9.5	7	14	25
Male	20,676	59.1%	15.0	9.4	6	13	25
Race							
Unknown	3,776	10.8%	14.0	9.5	6	11	24
American Indian or Alaska Native	330	0.9%	16.6	9.3	7	18	25
Asian	710	2.0%	14.2	9.3	6	11	24
Black or African American	4,400	12.6%	14.8	9.3	6	13	24
Native Hawaiian or Other Pacific Islander	11	<0.1%	11.2	9.3	4	6	23
White	25,733	73.6%	15.5	9.4	7	14	25
Ethnicity							
Not Hispanic	31,011	88.7%	15.4	9.4	7	14	25
Unknown	2,595	7.4%	13.8	9.5	6	10	24
Hispanic	1,354	3.9%	14.3	9.5	6	11	24
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A

**Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	25	0.1%	10.2	8.8	5	6	19
Midwest	12,473	29.9%	16.2	9.5	7	16	25
Missing	*****	<0.1%	11.7	11.6	4	6	25
Northeast	10,570	25.4%	14.8	9.4	6	12	24
Other	*****	0.1%	10.9	9.5	4	6	20
South	11,633	27.9%	14.6	9.2	6	12	24
West	6,934	16.6%	15.4	9.5	6	14	25

**Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9					
	Number	Percent					
ADHD Only Subset	1,090	2.6%	18.3	9.4	9	21	26
ADHD and Other Behavior Disorders	5,135	12.3%	18.7	9.1	10	22	26
Alcohol Use Disorders	4,024	9.7%	17.9	8.9	9	20	25
Anxiety Disorders	14,409	34.6%	17.9	9.2	8	20	26
Bipolar Disorders	16,506	39.6%	17.3	9.3	8	19	25
Depression	21,847	52.4%	17.1	9.3	8	18	25
Depressive Disorders	15,713	37.7%	17.5	9.2	8	19	26
Drug Use Disorders	6,350	15.2%	18.1	9.0	9	21	26
Opioid Use Disorder (OUD) 1	1,053	2.5%	18.2	9.1	9	20	26
OUD 2	817	2.0%	18.4	9.1	10	21	26
OUD 3	717	1.7%	18.0	9.1	9	20	26
OUD 4	126	0.3%	18.1	9.4	9	20.5	25
Personality Disorders	5,133	12.3%	18.5	8.9	10	21	26
Schizophrenia	33,852	81.3%	15.5	9.3	7	14	25
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	15.7	9.4	7	14	25
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,186	12.4%	17.1	9.5	7	19	26
Atypical Antipsychotics	20,323	48.8%	18.6	9.1	9	22	26
Typical Antipsychotics	9,902	23.8%	18.3	9.2	9	21	26
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	18.0	9.3	8	21	26
Antidepressants	19,762	47.4%	16.1	9.5	7	16	25
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A

**Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.f: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	41,662						
Number of unique patients	34,960						
Demographics	Mean	Standard Deviation					
Mean Age (years)	48.0	14.2					
Age (years)	Number	Percent					
12-18	306	0.7%	2.8	1.5	1	3.1	4
19-35	9,560	22.9%	2.6	1.5	1	2.6	4
36-50	13,757	33.0%	2.4	1.5	1	2.0	4
51-64	12,840	30.8%	2.4	1.5	1	2.0	4
65-74	3,769	9.0%	2.6	1.6	1	2.3	4
75+	1,430	3.4%	3.0	1.6	1	3.4	4
Sex							
Female	14,284	40.9%	2.6	1.6	1	2.3	4
Male	20,676	59.1%	2.5	1.5	1	2.1	4
Race							
Unknown	3,776	10.8%	2.3	1.6	1	1.8	4
American Indian or Alaska Native	330	0.9%	2.7	1.5	1	3.0	4
Asian	710	2.0%	2.3	1.5	1	1.8	4
Black or African American	4,400	12.6%	2.4	1.5	1	2.1	4
Native Hawaiian or Other Pacific Islander	11	<0.1%	1.8	1.5	1	1.0	4
White	25,733	73.6%	2.6	1.6	1	2.3	4
Ethnicity							
Not Hispanic	31,011	88.7%	2.5	1.6	1	2.3	4
Unknown	2,595	7.4%	2.3	1.6	1	1.6	4
Hispanic	1,354	3.9%	2.4	1.6	1	1.8	4
Year							
2010 Quarter 1	3,296	7.9%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	2,098	5.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	2,118	5.1%	N/A	N/A	N/A	N/A	N/A



**Table 1D.f: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,970	4.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	2,053	4.9%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,901	4.6%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,889	4.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,712	4.1%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	2,087	5.0%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,822	4.4%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,777	4.3%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,715	4.1%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	2,027	4.9%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,843	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,826	4.4%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,689	4.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	2,006	4.8%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,858	4.5%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,952	4.7%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	1,828	4.4%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	2,195	5.3%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	25	0.1%	1.7	1.4	1	1.0	3
Midwest	12,473	29.9%	2.7	1.6	1	2.6	4
Missing	*****	<0.1%	1.9	1.9	1	1.0	4
Northeast	10,570	25.4%	2.4	1.6	1	2.0	4
Other	*****	0.1%	1.8	1.6	1	1.0	3
South	11,633	27.9%	2.4	1.5	1	2.0	4
West	6,934	16.6%	2.5	1.6	1	2.3	4

**Table 1D.f: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

Rate of ANC Screening Events per Month									
Evidence of Medical Comorbidities Any Time Through Index Date			Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.2	2.9							
	Number	Percent							
ADHD Only Subset	1,090	2.6%	3.0	1.6	1	3.5	4		
ADHD and Other Behavior Disorders	5,135	12.3%	3.1	1.5	2	3.6	4		
Alcohol Use Disorders	4,024	9.7%	2.9	1.5	1	3.3	4		
Anxiety Disorders	14,409	34.6%	3.0	1.5	1	3.3	4		
Bipolar Disorders	16,506	39.6%	2.9	1.5	1	3.1	4		
Depression	21,847	52.4%	2.8	1.5	1	3.0	4		
Depressive Disorders	15,713	37.7%	2.9	1.5	1	3.1	4		
Drug Use Disorders	6,350	15.2%	3.0	1.5	1	3.5	4		
Opioid Use Disorder (OUD) 1	1,053	2.5%	3.0	1.5	1	3.3	4		
OUD 2	817	2.0%	3.0	1.5	2	3.5	4		
OUD 3	717	1.7%	3.0	1.5	1	3.3	4		
OUD 4	126	0.3%	3.0	1.5	1	3.4	4		
Personality Disorders	5,133	12.3%	3.1	1.5	2	3.5	4		
Schizophrenia	33,852	81.3%	2.6	1.5	1	2.3	4		
Schizophrenia and Other Psychotic Disorders	35,405	85.0%	2.6	1.5	1	2.3	4		
Evidence of Medical Product Use in the 30 Days Prior to or On Index									
Lithium	5,186	12.4%	2.8	1.6	1	3.1	4		
Atypical Antipsychotics	20,323	48.8%	3.1	1.5	1	3.6	4		
Typical Antipsychotics	9,902	23.8%	3.0	1.5	1	3.5	4		
Any Antipsychotic (Typical or Atypical)	24,507	58.8%	3.0	1.5	1	3.5	4		
Antidepressants	19,762	47.4%	2.7	1.6	1	2.6	4		
Healthcare Encounter Utilization at Any Time Through the Index Date									
	Mean	Standard Deviation							
Mean number of ambulatory encounters	72.8	101.8	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.9	6.7	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.3	2.6	N/A	N/A	N/A	N/A	N/A	N/A	N/A

**Table 1D.f: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	2.0	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	55.4	84.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6)**

Characteristic <sup>1</sup>	Number	
Number of episodes	29,533	
Number of unique patients	27,009	
Demographics	Mean	Standard Deviation
Mean Age (years)	47.8	13.9
Age (years)	Number	Percent
12-18	162	0.5%
19-35	6,704	22.7%
36-50	10,160	34.4%
51-64	9,072	30.7%
65-74	2,534	8.6%
75+	901	3.1%
Sex		
Female	10,995	40.7%
Male	16,014	59.3%
Race		
Unknown	2,557	9.5%
American Indian or Alaska Native	*****	1.0%
Asian	548	2.0%
Black or African American	3,253	12.0%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	20,392	75.5%
Ethnicity		
Not Hispanic	24,348	90.1%
Unknown	1,648	6.1%
Hispanic	1,013	3.8%
Year		
2010 Quarter 1	2,804	9.5%
2010 Quarter 2	1,633	5.5%
2010 Quarter 3	1,701	5.8%
2010 Quarter 4	1,541	5.2%
2011 Quarter 1	1,619	5.5%
2011 Quarter 2	1,500	5.1%
2011 Quarter 3	1,477	5.0%
2011 Quarter 4	1,357	4.6%
2012 Quarter 1	1,644	5.6%
2012 Quarter 2	1,425	4.8%
2012 Quarter 3	1,426	4.8%
2012 Quarter 4	1,345	4.6%
2013 Quarter 1	1,550	5.2%
2013 Quarter 2	1,424	4.8%
2013 Quarter 3	1,425	4.8%

**Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6)**

2013 Quarter 4	1,312	4.4%
2014 Quarter 1	1,495	5.1%
2014 Quarter 2	1,347	4.6%
2014 Quarter 3	1,508	5.1%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	15	0.1%
Midwest	8,996	30.5%
Missing	*****	<0.1%
Northeast	7,748	26.2%
Other	*****	<0.1%
South	7,933	26.9%
West	4,829	16.4%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8
ADHD Only Subset	694	2.3%
ADHD and Other Behavior Disorders	3,382	11.5%
Alcohol Use Disorders	2,689	9.1%
Anxiety Disorders	9,579	32.4%
Bipolar Disorders	11,122	37.7%
Depression	14,857	50.3%
Depressive Disorders	10,487	35.5%
Drug Use Disorders	4,192	14.2%
Opioid Use Disorder (OUD) 1	648	2.2%
OUD 2	493	1.7%
OUD 3	435	1.5%
OUD 4	72	0.2%
Personality Disorders	3,437	11.6%
Schizophrenia	23,913	81.0%
Schizophrenia and Other Psychotic Disorders	24,944	84.5%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	3,686	12.5%
Atypical Antipsychotics	14,588	49.4%
Typical Antipsychotics	7,053	23.9%
Any Antipsychotic (Typical or Atypical)	17,526	59.3%
Antidepressants	14,054	47.6%

**Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	66.7	91.5
Mean number of emergency room encounters	2.6	6.0
Mean number of inpatient hospital encounters	1.2	2.4
Mean number of non-acute institutional encounters	1.8	3.1
Mean number of other ambulatory encounters	49.0	75.1
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	13.9	13.9	7	10	15
19-35	6,704	22.7%	13.7	12.6	7	11	15
36-50	10,160	34.4%	14.0	12.4	7	11	16
51-64	9,072	30.7%	13.5	12.0	7	9	15
65-74	2,534	8.6%	12.3	11.4	7	7	14
75+	901	3.1%	10.7	9.7	7	7	14
Sex							
Female	10,995	40.7%	13.1	11.8	7	9	15
Male	16,014	59.3%	13.8	12.4	7	10	15
Race							
Unknown	2,557	9.5%	15.0	14.7	7	13	18
American Indian or Alaska Native	*****	1.0%	12.9	11.9	7	9	14
Asian	548	2.0%	14.8	13.4	7	13	17
Black or African American	3,253	12.0%	13.3	12.4	7	8	15
Native Hawaiian or Other Pacific Islander	*****	<0.1%	27.8	6.9	27	28	30
White	20,392	75.5%	13.3	11.8	7	9	15
Ethnicity							
Not Hispanic	24,348	90.1%	13.4	11.9	7	9	15
Unknown	1,648	6.1%	15.3	15.0	7	13	18
Hispanic	1,013	3.8%	14.7	14.3	7	12	17
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	23.8	23.1	13	16	31
Midwest	8,996	30.5%	12.9	10.9	7	8	14
Missing	*****	<0.1%	18.1	12.3	9	15.5	26
Northeast	7,748	26.2%	13.8	13.0	7	11	15
Other	*****	<0.1%	18.6	26.1	7	7	23
South	7,933	26.9%	13.8	12.4	7	10	16
West	4,829	16.4%	13.6	12.6	7	10	15



**Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8					
	Number	Percent					
ADHD Only Subset	694	2.3%	12.1	10.9	7	8	14
ADHD and Other Behavior Disorders	3,382	11.5%	11.2	10.7	7	7	14
Alcohol Use Disorders	2,689	9.1%	12.1	11.1	7	8	14
Anxiety Disorders	9,579	32.4%	11.9	10.7	7	8	14
Bipolar Disorders	11,122	37.7%	12.2	11.1	7	8	14
Depression	14,857	50.3%	12.3	11.1	7	8	14
Depressive Disorders	10,487	35.5%	12.0	10.8	7	8	14
Drug Use Disorders	4,192	14.2%	12.0	10.9	7	8	14
Opioid Use Disorder (OUD) 1	648	2.2%	11.6	10.6	7	7	14
OUD 2	493	1.7%	11.5	10.5	7	7	14
OUD 3	435	1.5%	11.6	10.6	7	7	14
OUD 4	72	0.2%	10.9	9.4	7	7	14
Personality Disorders	3,437	11.6%	11.5	10.6	7	7	14
Schizophrenia	23,913	81.0%	13.3	11.8	7	9	15
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	13.1	11.8	7	9	15
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	3,686	12.5%	12.7	11.9	7	8	14
Atypical Antipsychotics	14,588	49.4%	11.7	10.5	7	8	14
Typical Antipsychotics	7,053	23.9%	11.7	10.8	7	7	14
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	12.0	10.9	7	8	14
Antidepressants	14,054	47.6%	13.0	11.6	7	9	14
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A

**Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number of ANC Screenings						
	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	12.1	7.2	6	11.5	16
19-35	6,704	22.7%	12.2	7.2	6	12	16
36-50	10,160	34.4%	11.9	7.2	6	10	15
51-64	9,072	30.7%	12.5	7.6	7	10	16
65-74	2,534	8.6%	13.7	8.2	7	12	19
75+	901	3.1%	15.9	8.7	8	14	24
Sex							
Female	10,995	40.7%	12.8	7.6	7	12	17
Male	16,014	59.3%	12.1	7.4	6	10	16
Race							
Unknown	2,557	9.5%	11.1	7.1	6	9	15
American Indian or Alaska Native	*****	1.0%	13.0	7.3	7	13	17
Asian	548	2.0%	11.2	6.5	6	10	14
Black or African American	3,253	12.0%	12.7	7.9	7	11	17
Native Hawaiian or Other Pacific Islander	*****	<0.1%	5.5	0.7	5	5.5	6
White	20,392	75.5%	12.6	7.5	7	11	16
Ethnicity							
Not Hispanic	24,348	90.1%	12.6	7.5	7	11	16
Unknown	1,648	6.1%	10.8	7.1	6	9	14
Hispanic	1,013	3.8%	11.3	7.0	6	9	15
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	6.6	4.6	5	6	7
Midwest	8,996	30.5%	13.0	7.7	7	12	17
Missing	*****	<0.1%	9.0	5.2	6	6	15
Northeast	7,748	26.2%	12.1	7.4	7	11	15
Other	*****	<0.1%	8.8	7.6	4	7	11
South	7,933	26.9%	12.1	7.4	6	10	16
West	4,829	16.4%	12.3	7.4	6	11	16

**Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8					
	Number	Percent					
ADHD Only Subset	694	2.3%	13.9	7.6	8	13	18
ADHD and Other Behavior Disorders	3,382	11.5%	15.1	8.1	9	14	21
Alcohol Use Disorders	2,689	9.1%	13.9	7.4	8	13	18
Anxiety Disorders	9,579	32.4%	14.2	7.7	8	13	19
Bipolar Disorders	11,122	37.7%	13.9	7.7	7	13	19
Depression	14,857	50.3%	13.7	7.7	7	13	18
Depressive Disorders	10,487	35.5%	14.1	7.7	8	13	19
Drug Use Disorders	4,192	14.2%	14.1	7.4	8	13	19
Opioid Use Disorder (OUD) 1	648	2.2%	14.6	7.5	8	14	20
OUD 2	493	1.7%	14.7	7.4	9	14	20
OUD 3	435	1.5%	14.6	7.4	9	14	20
OUD 4	72	0.2%	15.6	8.3	9	14	25
Personality Disorders	3,437	11.6%	14.7	7.6	9	14	20
Schizophrenia	23,913	81.0%	12.6	7.5	7	11	16
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	12.8	7.5	7	12	17
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,686	12.5%	13.3	7.4	7	13	17
Atypical Antipsychotics	14,588	49.4%	14.4	7.6	8	13	19
Typical Antipsychotics	7,053	23.9%	14.5	7.7	8	14	19
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	14.1	7.6	8	13	18
Antidepressants	14,054	47.6%	13.0	7.6	7	12	17
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A

**Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	29,533						
Number of unique patients	27,009						
Demographics		Mean	Standard Deviation				
Mean Age (years)	47.8	13.9					
Age (years)	Number	Percent					
12-18	162	0.5%	2.0	1.2	1	1.9	3
19-35	6,704	22.7%	2.0	1.2	1	2.0	3
36-50	10,160	34.4%	2.0	1.2	1	1.6	2
51-64	9,072	30.7%	2.1	1.3	1	1.6	3
65-74	2,534	8.6%	2.3	1.4	1	2.0	3
75+	901	3.1%	2.6	1.4	1	2.3	4
Sex							
Female	10,995	40.7%	2.1	1.2	1	2.0	3
Male	16,014	59.3%	2.0	1.2	1	1.6	3
Race							
Unknown	2,557	9.5%	1.8	1.2	1	1.5	2
American Indian or Alaska Native	*****	1.0%	2.1	1.2	1	2.1	3
Asian	548	2.0%	1.9	1.1	1	1.6	2
Black or African American	3,253	12.0%	2.1	1.3	1	1.8	3
Native Hawaiian or Other Pacific Islander	*****	<0.1%	0.9	0.1	1	0.9	1
White	20,392	75.5%	2.1	1.2	1	1.8	3
Ethnicity							
Not Hispanic	24,348	90.1%	2.1	1.2	1	1.8	3
Unknown	1,648	6.1%	1.8	1.2	1	1.5	2
Hispanic	1,013	3.8%	1.9	1.2	1	1.5	2
Year							
2010 Quarter 1	2,804	9.5%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,633	5.5%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,701	5.8%	N/A	N/A	N/A	N/A	N/A

**Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,541	5.2%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,619	5.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,500	5.1%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,477	5.0%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	1,357	4.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,644	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	1,426	4.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	1,345	4.6%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,550	5.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	1,424	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,425	4.8%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	1,312	4.4%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	1,495	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	1,347	4.6%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	1,508	5.1%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	15	0.1%	1.1	0.8	1	1.0	1
Midwest	8,996	30.5%	2.1	1.3	1	2.0	3
Missing	*****	<0.1%	1.5	0.9	1	1.0	2
Northeast	7,748	26.2%	2.0	1.2	1	1.8	2
Other	*****	<0.1%	1.4	1.2	1	1.2	2
South	7,933	26.9%	2.0	1.2	1	1.6	3
West	4,829	16.4%	2.0	1.2	1	1.8	3



**Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

Rate of ANC Screening Events per Month							
Evidence of Medical Comorbidities Any Time Through Index							
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	3.0	2.8					
	Number	Percent					
ADHD Only Subset	694	2.3%	2.3	1.3	1	2.1	3
ADHD and Other Behavior Disorders	3,382	11.5%	2.5	1.3	1	2.3	3
Alcohol Use Disorders	2,689	9.1%	2.3	1.2	1	2.1	3
Anxiety Disorders	9,579	32.4%	2.3	1.3	1	2.1	3
Bipolar Disorders	11,122	37.7%	2.3	1.3	1	2.1	3
Depression	14,857	50.3%	2.3	1.3	1	2.1	3
Depressive Disorders	10,487	35.5%	2.3	1.3	1	2.1	3
Drug Use Disorders	4,192	14.2%	2.3	1.2	1	2.1	3
Opioid Use Disorder (OUD) 1	648	2.2%	2.4	1.2	1	2.3	3
OUD 2	493	1.7%	2.4	1.2	1	2.3	3
OUD 3	435	1.5%	2.4	1.2	1	2.3	3
OUD 4	72	0.2%	2.6	1.4	1	2.3	4
Personality Disorders	3,437	11.6%	2.4	1.2	1	2.3	3
Schizophrenia	23,913	81.0%	2.1	1.2	1	1.8	3
Schizophrenia and Other Psychotic Disorders	24,944	84.5%	2.1	1.2	1	2.0	3
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	3,686	12.5%	2.2	1.2	1	2.1	3
Atypical Antipsychotics	14,588	49.4%	2.4	1.3	1	2.1	3
Typical Antipsychotics	7,053	23.9%	2.4	1.3	1	2.3	3
Any Antipsychotic (Typical or Atypical)	17,526	59.3%	2.3	1.2	1	2.1	3
Antidepressants	14,054	47.6%	2.1	1.3	1	2.0	3
Healthcare Encounter Utilization at Any Time Through the							
Index Date	Mean	Standard Deviation					
Mean number of ambulatory encounters	66.7	91.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.6	6.0	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.2	2.4	N/A	N/A	N/A	N/A	N/A

**Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.8	3.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	49.0	75.1	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	5.0	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7)**

Characteristic <sup>1</sup>	Number	
Number of episodes	17,411	
Number of unique patients	17,164	
Demographics	Mean	Standard Deviation
Mean Age (years)	47.2	13.3
Age (years)	Number	Percent
12-18	58	0.3%
19-35	3,958	22.7%
36-50	6,373	36.6%
51-64	5,346	30.7%
65-74	1,287	7.4%
75+	389	2.2%
Sex		
Female	6,928	40.4%
Male	10,236	59.6%
Race		
Unknown	1,348	7.9%
American Indian or Alaska Native	*****	0.9%
Asian	356	2.1%
Black or African American	1,981	11.5%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	13,318	77.6%
Ethnicity		
Not Hispanic	15,762	91.8%
Unknown	798	4.6%
Hispanic	604	3.5%
Year		
2010 Quarter 1	2,235	12.8%
2010 Quarter 2	1,221	7.0%
2010 Quarter 3	1,249	7.2%
2010 Quarter 4	1,130	6.5%
2011 Quarter 1	1,170	6.7%
2011 Quarter 2	1,102	6.3%
2011 Quarter 3	1,091	6.3%
2011 Quarter 4	990	5.7%
2012 Quarter 1	1,187	6.8%
2012 Quarter 2	1,033	5.9%
2012 Quarter 3	975	5.6%
2012 Quarter 4	956	5.5%
2013 Quarter 1	1,078	6.2%
2013 Quarter 2	955	5.5%
2013 Quarter 3	1,039	6.0%

**Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7)**

2013 Quarter 4	0	0.0%
2014 Quarter 1	0	0.0%
2014 Quarter 2	0	0.0%
2014 Quarter 3	0	0.0%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	<0.1%
Midwest	5,248	30.1%
Missing	*****	<0.1%
Northeast	4,787	27.5%
Other	*****	<0.1%
South	4,527	26.0%
West	*****	16.3%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	2.7	2.6
ADHD Only Subset	328	1.9%
ADHD and Other Behavior Disorders	1,757	10.1%
Alcohol Use Disorders	1,405	8.1%
Anxiety Disorders	4,940	28.4%
Bipolar Disorders	5,905	33.9%
Depression	7,913	45.4%
Depressive Disorders	5,372	30.9%
Drug Use Disorders	2,137	12.3%
Opioid Use Disorder (OUD) 1	309	1.8%
OUD 2	229	1.3%
OUD 3	196	1.1%
OUD 4	29	0.2%
Personality Disorders	1,785	10.3%
Schizophrenia	14,066	80.8%
Schizophrenia and Other Psychotic Disorders	14,575	83.7%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	2,156	12.4%
Atypical Antipsychotics	8,643	49.6%
Typical Antipsychotics	4,146	23.8%
Any Antipsychotic (Typical or Atypical)	10,362	59.5%
Antidepressants	8,270	47.5%

**Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7)**

<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>	<b>Mean</b>	<b>Standard Deviation</b>
Mean number of ambulatory encounters	54.4	73.8
Mean number of emergency room encounters	2.2	5.5
Mean number of inpatient hospital encounters	0.9	2.0
Mean number of non-acute institutional encounters	1.5	2.6
Mean number of other ambulatory encounters	39.1	61.0
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.5
Mean number of filled prescriptions	7.1	4.8

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	17,411						
Number of unique patients	17,164						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	13.3					
Age (years)	Number	Percent					
12-18	58	0.3%	19.5	19.4	7	14	28
19-35	3,958	22.7%	19.3	17.7	7	14	28
36-50	6,373	36.6%	18.8	16.2	7	14	28
51-64	5,346	30.7%	17.1	15.8	7	14	28
65-74	1,287	7.4%	15.1	15.5	7	12	23
75+	389	2.2%	13.8	14.8	7	7	15
Sex							
Female	6,928	40.4%	17.3	15.9	7	14	28
Male	10,236	59.6%	18.3	16.7	7	14	28
Race							
Unknown	1,348	7.9%	20.5	21.2	7	15	28
American Indian or Alaska Native	*****	0.9%	17.4	18.0	7	14	28
Asian	356	2.1%	20.2	18.7	9	16	28
Black or African American	1,981	11.5%	17.4	17.3	7	14	28
Native Hawaiian or Other Pacific Islander	*****	<0.1%	33.1	13.9	29	34	38
White	13,318	77.6%	17.7	15.7	7	14	28
Ethnicity							
Not Hispanic	15,762	91.8%	17.7	16.0	7	14	28
Unknown	798	4.6%	21.2	22.8	7	16	28
Hispanic	604	3.5%	20.0	19.4	7	15	28
Year							
2010 Quarter 1	2,235	12.8%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,221	7.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,249	7.2%	N/A	N/A	N/A	N/A	N/A

**Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Gaps between all ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,130	6.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,170	6.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,102	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,091	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	990	5.7%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,187	6.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,033	5.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	975	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	956	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,078	6.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	955	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,039	6.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	30.3	22.7	24	28	31
Midwest	5,248	30.1%	17.2	14.0	7	14	28
Missing	*****	<0.1%					
Northeast	4,787	27.5%	18.1	18.4	7	14	28
Other	*****	<0.1%	23.5	30.0	7	14	28
South	4,527	26.0%	18.0	16.2	7	14	28
West	*****	16.3%	18.6	17.5	7	14	28

**Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

Gaps between all ANC Screenings							
Evidence of Medical Comorbidities Any Time Through Index Date							
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	2.7	2.6					
	Number	Percent					
ADHD Only Subset	328	1.9%	17.0	15.7	7	14	27
ADHD and Other Behavior Disorders	1,757	10.1%	15.0	15.2	7	11	22
Alcohol Use Disorders	1,405	8.1%	17.2	15.9	7	14	28
Anxiety Disorders	4,940	28.4%	16.0	14.7	7	14	26
Bipolar Disorders	5,905	33.9%	16.4	15.2	7	14	27
Depression	7,913	45.4%	16.4	15.4	7	14	27
Depressive Disorders	5,372	30.9%	15.9	15.0	7	14	25
Drug Use Disorders	2,137	12.3%	16.9	16.1	7	14	27
Opioid Use Disorder (OUD) 1	309	1.8%	16.2	16.3	7	14	24
OUD 2	229	1.3%	16.6	17.0	7	14	26
OUD 3	196	1.1%	16.0	17.2	7	14	22
OUD 4	29	0.2%	16.9	15.2	7	14	26
Personality Disorders	1,785	10.3%	16.0	15.5	7	14	25
Schizophrenia	14,066	80.8%	17.6	15.8	7	14	28
Schizophrenia and Other Psychotic Disorders	14,575	83.7%	17.5	15.8	7	14	28
Evidence of Medical Product Use in the 30 Days Prior to or On Index							
Lithium	2,156	12.4%	17.3	17.1	7	14	28
Atypical Antipsychotics	8,643	49.6%	16.7	15.8	7	14	27
Typical Antipsychotics	4,146	23.8%	16.3	15.8	7	14	26
Any Antipsychotic (Typical or Atypical)	10,362	59.5%	16.9	15.9	7	14	27
Antidepressants	8,270	47.5%	17.4	15.6	7	14	28
Healthcare Encounter Utilization at Any Time Through the Index Date							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	54.4	73.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.2	5.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	0.9	2.0	N/A	N/A	N/A	N/A	N/A



**Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.5	2.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	39.1	61.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	4.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	17,411						
Number of unique patients	17,164						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	13.3					
Age (years)	Number	Percent					
12-18	58	0.3%	17.7	13.0	11	13	19
19-35	3,958	22.7%	17.9	11.0	12	14	20
36-50	6,373	36.6%	18.4	11.0	13	15	21
51-64	5,346	30.7%	20.3	12.6	13	16	25
65-74	1,287	7.4%	23.1	15.3	13	17	28
75+	389	2.2%	25.5	15.5	14	20	33
Sex							
Female	6,928	40.4%	20.0	12.3	13	15	24
Male	10,236	59.6%	18.9	11.9	13	15	22
Race							
Unknown	1,348	7.9%	16.8	11.2	12	14	18
American Indian or Alaska Native	*****	0.9%	20.0	13.5	13	15	24
Asian	356	2.1%	17.0	9.5	12	14	19
Black or African American	1,981	11.5%	20.0	12.8	13	15	25
Native Hawaiian or Other Pacific Islander	*****	<0.1%	10.0	.	10	10	10
White	13,318	77.6%	19.6	12.1	13	15	23
Ethnicity							
Not Hispanic	15,762	91.8%	19.6	12.2	13	15	23
Unknown	798	4.6%	16.2	11.4	11	13	17
Hispanic	604	3.5%	17.2	10.5	12	14	19
Year							
2010 Quarter 1	2,235	12.8%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,221	7.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,249	7.2%	N/A	N/A	N/A	N/A	N/A

**Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,130	6.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,170	6.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,102	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,091	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	990	5.7%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,187	6.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,033	5.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	975	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	956	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,078	6.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	955	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,039	6.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	11.0	5.3	12	12	13
Midwest	5,248	30.1%	20.1	12.4	13	15	23
Missing	*****	<0.1%					
Northeast	4,787	27.5%	19.1	12.1	13	15	23
Other	*****	<0.1%	14.5	8.7	8	16	21
South	4,527	26.0%	19.2	12.1	12	15	22
West	*****	16.3%	18.6	11.5	12	14	22

**Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	2.7	2.6					
	Number	Percent					
ADHD Only Subset	328	1.9%	20.4	13.2	13	16	24
ADHD and Other Behavior Disorders	1,757	10.1%	23.2	14.5	14	18	29
Alcohol Use Disorders	1,405	8.1%	20.1	11.8	13	16	24
Anxiety Disorders	4,940	28.4%	21.7	13.0	13	17	26
Bipolar Disorders	5,905	33.9%	21.2	12.8	13	17	26
Depression	7,913	45.4%	21.2	13.1	13	16	26
Depressive Disorders	5,372	30.9%	21.9	13.4	13	17	27
Drug Use Disorders	2,137	12.3%	20.5	12.3	13	16	25
Opioid Use Disorder (OUD) 1	309	1.8%	21.5	12.7	13	17	26
OUD 2	229	1.3%	20.9	12.5	13	17	26
OUD 3	196	1.1%	21.7	12.6	14	18	27
OUD 4	29	0.2%	20.6	12.5	13	16	25
Personality Disorders	1,785	10.3%	21.8	13.0	14	17	26
Schizophrenia	14,066	80.8%	19.7	12.1	13	15	23
Schizophrenia and Other Psychotic Disorders	14,575	83.7%	19.8	12.2	13	15	24
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,156	12.4%	20.1	12.6	13	16	25
Atypical Antipsychotics	8,643	49.6%	20.8	12.6	13	16	25
Typical Antipsychotics	4,146	23.8%	21.3	12.7	13	17	26
Any Antipsychotic (Typical or Atypical)	10,362	59.5%	20.6	12.5	13	16	25
Antidepressants	8,270	47.5%	19.9	12.3	13	15	24
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	54.4	73.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.2	5.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	0.9	2.0	N/A	N/A	N/A	N/A	N/A

**Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.5	2.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	39.1	61.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	4.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	17,411						
Number of unique patients	17,164						
Demographics	Mean	Standard Deviation					
Mean Age (years)	47.2	13.3					
Age (years)	Number	Percent					
12-18	58	0.3%	1.5	1.1	1	1.1	2
19-35	3,958	22.7%	1.5	0.9	1	1.2	2
36-50	6,373	36.6%	1.5	0.9	1	1.2	2
51-64	5,346	30.7%	1.7	1.0	1	1.3	2
65-74	1,287	7.4%	1.9	1.3	1	1.4	2
75+	389	2.2%	2.1	1.3	1	1.6	3
Sex							
Female	6,928	40.4%	1.6	1.0	1	1.2	2
Male	10,236	59.6%	1.6	1.0	1	1.2	2
Race							
Unknown	1,348	7.9%	1.4	0.9	1	1.2	1
American Indian or Alaska Native	*****	0.9%	1.6	1.1	1	1.2	2
Asian	356	2.1%	1.4	0.8	1	1.2	2
Black or African American	1,981	11.5%	1.6	1.1	1	1.2	2
Native Hawaiian or Other Pacific Islander	*****	<0.1%	0.8	.	1	0.8	1
White	13,318	77.6%	1.6	1.0	1	1.2	2
Ethnicity							
Not Hispanic	15,762	91.8%	1.6	1.0	1	1.2	2
Unknown	798	4.6%	1.3	0.9	1	1.1	1
Hispanic	604	3.5%	1.4	0.9	1	1.2	2
Year							
2010 Quarter 1	2,235	12.8%	N/A*	N/A	N/A	N/A	N/A
2010 Quarter 2	1,221	7.0%	N/A	N/A	N/A	N/A	N/A
2010 Quarter 3	1,249	7.2%	N/A	N/A	N/A	N/A	N/A

**Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2010 Quarter 4	1,130	6.5%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 1	1,170	6.7%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 2	1,102	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 3	1,091	6.3%	N/A	N/A	N/A	N/A	N/A
2011 Quarter 4	990	5.7%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 1	1,187	6.8%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 2	1,033	5.9%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 3	975	5.6%	N/A	N/A	N/A	N/A	N/A
2012 Quarter 4	956	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 1	1,078	6.2%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 2	955	5.5%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 3	1,039	6.0%	N/A	N/A	N/A	N/A	N/A
2013 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2014 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2015 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	0.9	0.4	1	1.0	1
Midwest	5,248	30.1%	1.7	1.0	1	1.2	2
Missing	*****	<0.1%					
Northeast	4,787	27.5%	1.6	1.0	1	1.2	2
Other	*****	<0.1%	1.2	0.7	1	1.3	2
South	4,527	26.0%	1.6	1.0	1	1.2	2
West	*****	16.3%	1.5	0.9	1	1.2	2

**Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

Evidence of Medical Comorbidities Any Time Through Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	2.7	2.6					
	Number	Percent					
ADHD Only Subset	328	1.9%	1.7	1.1	1	1.3	2
ADHD and Other Behavior Disorders	1,757	10.1%	1.9	1.2	1	1.5	2
Alcohol Use Disorders	1,405	8.1%	1.7	1.0	1	1.3	2
Anxiety Disorders	4,940	28.4%	1.8	1.1	1	1.4	2
Bipolar Disorders	5,905	33.9%	1.7	1.1	1	1.4	2
Depression	7,913	45.4%	1.7	1.1	1	1.3	2
Depressive Disorders	5,372	30.9%	1.8	1.1	1	1.4	2
Drug Use Disorders	2,137	12.3%	1.7	1.0	1	1.3	2
Opioid Use Disorder (OUD) 1	309	1.8%	1.8	1.0	1	1.4	2
OUD 2	229	1.3%	1.7	1.0	1	1.4	2
OUD 3	196	1.1%	1.8	1.0	1	1.5	2
OUD 4	29	0.2%	1.7	1.0	1	1.3	2
Personality Disorders	1,785	10.3%	1.8	1.1	1	1.4	2
Schizophrenia	14,066	80.8%	1.6	1.0	1	1.2	2
Schizophrenia and Other Psychotic Disorders	14,575	83.7%	1.6	1.0	1	1.2	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,156	12.4%	1.6	1.0	1	1.3	2
Atypical Antipsychotics	8,643	49.6%	1.7	1.0	1	1.3	2
Typical Antipsychotics	4,146	23.8%	1.7	1.0	1	1.4	2
Any Antipsychotic (Typical or Atypical)	10,362	59.5%	1.7	1.0	1	1.3	2
Antidepressants	8,270	47.5%	1.6	1.0	1	1.2	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	54.4	73.8	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	2.2	5.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	0.9	2.0	N/A	N/A	N/A	N/A	N/A



**Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of non-acute institutional encounters	1.5	2.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	39.1	61.0	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.3	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.1	4.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.i: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1)**

Characteristic <sup>1</sup>	Number	
Number of episodes	75,063	
Number of unique patients	53,500	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.6	14.8
Age (years)	Number	Percent
12-18	2,718	3.6%
19-35	24,222	32.3%
36-50	19,584	26.1%
51-64	19,632	26.2%
65-74	6,679	8.9%
75+	2,228	3.0%
Sex		
Female	21,630	40.4%
Male	31,870	59.6%
Race		
Unknown	11,087	20.7%
American Indian or Alaska Native	675	1.3%
Asian	1,617	3.0%
Black or African American	7,987	14.9%
Native Hawaiian or Other Pacific Islander	91	0.2%
White	32,043	59.9%
Ethnicity		
Not Hispanic	42,104	78.7%
Unknown	7,601	14.2%
Hispanic	3,795	7.1%
Year		
2015 Quarter 4	3,891	5.2%
2016 Quarter 1	5,222	7.0%
2016 Quarter 2	4,798	6.4%
2016 Quarter 3	4,747	6.3%
2016 Quarter 4	4,802	6.4%
2017 Quarter 1	5,466	7.3%
2017 Quarter 2	5,092	6.8%
2017 Quarter 3	4,869	6.5%
2017 Quarter 4	4,905	6.5%
2018 Quarter 1	5,208	6.9%
2018 Quarter 2	4,791	6.4%
2018 Quarter 3	4,937	6.6%
2018 Quarter 4	4,734	6.3%
2019 Quarter 1	2,954	3.9%
2019 Quarter 2	2,954	3.9%

**Table 1A.i: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1)**

2019 Quarter 3	2,893	3.9%
2019 Quarter 4	2,800	3.7%
<b>Geographic Census Bureau Region</b>		
Invalid	74	0.1%
Midwest	18,990	25.3%
Missing	11	<0.1%
Northeast	18,956	25.3%
Other	100	0.1%
South	21,408	28.5%
West	15,524	20.7%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4
ADHD Only Subset	5,636	7.5%
ADHD and Other Behavior Disorders	17,425	23.2%
Alcohol Use Disorders	12,929	17.2%
Anxiety Disorders	41,565	55.4%
Bipolar Disorders	38,283	51.0%
Depression	47,485	63.3%
Depressive Disorders	37,396	49.8%
Drug Use Disorders	21,639	28.8%
Opioid Use Disorder (OUD) 1	5,158	6.9%
OUD 2	4,382	5.8%
OUD 3	3,628	4.8%
OUD 4	730	1.0%
Personality Disorders	15,015	20.0%
Schizophrenia	62,544	83.3%
Schizophrenia and Other Psychotic Disorders	66,213	88.2%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	10,699	14.3%
Atypical Antipsychotics	36,439	48.5%
Typical Antipsychotics	16,451	21.9%
Any Antipsychotic (Typical or Atypical)	43,519	58.0%
Antidepressants	35,374	47.1%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	146.0	173.6
Mean number of emergency room encounters	7.0	15.8
Mean number of inpatient hospital encounters	2.5	4.6
Mean number of non-acute institutional encounters	3.2	5.6
Mean number of other ambulatory encounters	121.9	176.4

**Table 1A.i: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.6	3.5
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

**Table 1B.i: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	75,063						
Number of unique patients	53,500						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.8					
Age (years)	Number	Percent					
12-18	2,718	3.6%	10.6	9.3	3	7	17
19-35	24,222	32.3%	11.6	10.0	3	8	21
36-50	19,584	26.1%	11.6	9.9	3	8	21
51-64	19,632	26.2%	11.1	9.7	3	7	19
65-74	6,679	8.9%	10.8	9.7	2	7	18
75+	2,228	3.0%	11.0	9.7	3	7	19
Sex							
Female	21,630	40.4%	11.2	9.8	3	7	20
Male	31,870	59.6%	11.4	9.9	3	8	20
Race							
Unknown	11,087	20.7%	11.7	10.0	3	8	21
American Indian or Alaska Native	675	1.3%	10.9	9.7	3	7	19
Asian	1,617	3.0%	11.7	10.0	3	8	21
Black or African American	7,987	14.9%	11.1	9.6	3	7	19
Native Hawaiian or Other Pacific Islander	91	0.2%	12.1	10.6	2	8	23
White	32,043	59.9%	11.3	9.9	3	7	20
Ethnicity							
Not Hispanic	42,104	78.7%	11.2	9.8	3	7	20
Unknown	7,601	14.2%	11.9	10.1	3	8	21
Hispanic	3,795	7.1%	11.4	9.9	3	8	20
Year							
2015 Quarter 4	3,891	5.2%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A	N/A

**Table 1B.i: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	12.2	9.8	4	8.5	22
Midwest	18,990	25.3%	11.2	9.9	2	7	20
Missing	11	<0.1%	15.0	6.7	10	15	21
Northeast	18,956	25.3%	11.3	9.8	3	7	20
Other	100	0.1%	14.0	10.8	3	12	26
South	21,408	28.5%	11.4	9.6	3	8	19
West	15,524	20.7%	11.4	10.1	2	7	21
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	Number	Percent					
ADHD Only Subset	5,636	7.5%	11.1	9.5	3	7	18
ADHD and Other Behavior Disorders	17,425	23.2%	10.5	9.4	3	7	17
Alcohol Use Disorders	12,929	17.2%	10.9	9.5	3	7	18

**Table 1B.i: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	11.0	9.6	3	7	18
Bipolar Disorders	38,283	51.0%	10.9	9.6	3	7	18
Depression	47,485	63.3%	11.0	9.6	3	7	19
Depressive Disorders	37,396	49.8%	10.9	9.5	3	7	18
Drug Use Disorders	21,639	28.8%	11.0	9.5	3	7	18
Opioid Use Disorder (OUD) 1	5,158	6.9%	10.6	9.4	3	7	17
OUD 2	4,382	5.8%	10.7	9.4	3	7	18
OUD 3	3,628	4.8%	10.3	9.3	2	7	17
OUD 4	730	1.0%	11.1	9.6	3	7	19
Personality Disorders	15,015	20.0%	10.5	9.4	3	7	17
Schizophrenia	62,544	83.3%	11.2	9.8	3	7	20
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	11.2	9.8	3	7	20
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	11.1	9.7	3	7	19
Atypical Antipsychotics	36,439	48.5%	11.3	9.8	3	7	20
Typical Antipsychotics	16,451	21.9%	11.0	9.7	3	7	19
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	11.2	9.8	3	7	19
Antidepressants	35,374	47.1%	11.3	9.8	3	8	20
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1B.i: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable



**Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Number of ANC Screenings		
				Quarter 1	Median	Quarter 3
Number of episodes	75,063					
Number of unique patients	53,500					
Demographics	Mean	Standard Deviation				
Mean Age (years)	44.6	14.8				
Age (years)	Number	Percent				
12-18	2,718	3.6%	1.8	1.3	1	2
19-35	24,222	32.3%	1.6	1.0	1	2
36-50	19,584	26.1%	1.6	1.0	1	2
51-64	19,632	26.2%	1.7	1.2	1	2
65-74	6,679	8.9%	1.8	1.4	1	2
75+	2,228	3.0%	1.7	1.2	1	2
Sex						
Female	21,630	40.4%	1.7	1.2	1	2
Male	31,870	59.6%	1.6	1.1	1	2
Race						
Unknown	11,087	20.7%	1.6	1.0	1	2
American Indian or Alaska Native	675	1.3%	1.7	1.4	1	2
Asian	1,617	3.0%	1.6	1.0	1	2
Black or African American	7,987	14.9%	1.7	1.2	1	2
Native Hawaiian or Other Pacific Islander	91	0.2%	1.5	0.9	1	2
White	32,043	59.9%	1.7	1.2	1	2
Ethnicity						
Not Hispanic	42,104	78.7%	1.7	1.2	1	2
Unknown	7,601	14.2%	1.5	1.0	1	2
Hispanic	3,795	7.1%	1.6	1.1	1	2
Year						
2015 Quarter 4	3,891	5.2%	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A

**Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	1.5	1.0	1	1	1
Midwest	18,990	25.3%	1.7	1.2	1	1	2
Missing	11	<0.1%	1.0	0.0	1	1	1
Northeast	18,956	25.3%	1.7	1.2	1	1	2
Other	100	0.1%	1.1	0.6	1	1	1
South	21,408	28.5%	1.6	1.1	1	1	2
West	15,524	20.7%	1.6	1.1	1	1	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	5,636	7.5%	1.7	1.1	1	1	2
ADHD and Other Behavior Disorders	17,425	23.2%	1.8	1.4	1	1	2
Alcohol Use Disorders	12,929	17.2%	1.7	1.2	1	1	2

**Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	1.7	1.2	1	1	2
Bipolar Disorders	38,283	51.0%	1.7	1.2	1	1	2
Depression	47,485	63.3%	1.7	1.2	1	1	2
Depressive Disorders	37,396	49.8%	1.8	1.3	1	1	2
Drug Use Disorders	21,639	28.8%	1.7	1.2	1	1	2
Opioid Use Disorder (OUD) 1	5,158	6.9%	1.8	1.4	1	1	2
OUD 2	4,382	5.8%	1.8	1.3	1	1	2
OUD 3	3,628	4.8%	1.9	1.5	1	1	2
OUD 4	730	1.0%	1.7	1.3	1	1	2
Personality Disorders	15,015	20.0%	1.9	1.4	1	1	2
Schizophrenia	62,544	83.3%	1.7	1.2	1	1	2
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	1.7	1.2	1	1	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	1.7	1.2	1	1	2
Atypical Antipsychotics	36,439	48.5%	1.7	1.1	1	1	2
Typical Antipsychotics	16,451	21.9%	1.7	1.2	1	1	2
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	1.7	1.1	1	1	2
Antidepressants	35,374	47.1%	1.6	1.1	1	1	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A*	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1D.i: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	75,063						
Number of unique patients	53,500						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.8					
Age (years)	Number	Percent					
12-18	2,718	3.6%	.	.	0	.	0
19-35	24,222	32.3%	.	.	0	.	0
36-50	19,584	26.1%	.	.	0	.	0
51-64	19,632	26.2%	.	.	0	.	0
65-74	6,679	8.9%	.	.	0	.	0
75+	2,228	3.0%	.	.	0	.	0
Sex							
Female	21,630	40.4%	.	.	0	.	0
Male	31,870	59.6%	.	.	0	.	0
Race							
Unknown	11,087	20.7%	.	.	0	.	0
American Indian or Alaska Native	675	1.3%	.	.	0	.	0
Asian	1,617	3.0%	.	.	0	.	0
Black or African American	7,987	14.9%	.	.	0	.	0
Native Hawaiian or Other Pacific Islander	91	0.2%	.	.	0	.	0
White	32,043	59.9%	.	.	0	.	0
Ethnicity							
Not Hispanic	42,104	78.7%	.	.	0	.	0
Unknown	7,601	14.2%	.	.	0	.	0
Hispanic	3,795	7.1%	.	.	0	.	0
Year							
2015 Quarter 4	3,891	5.2%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A	N/A

**Table 1D.i: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	.	.	0	.	0
Midwest	18,990	25.3%	.	.	0	.	0
Missing	11	<0.1%	.	.	0	.	0
Northeast	18,956	25.3%	.	.	0	.	0
Other	100	0.1%	.	.	0	.	0
South	21,408	28.5%	.	.	0	.	0
West	15,524	20.7%	.	.	0	.	0
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	5,636	7.5%	.	.	0	.	0
ADHD and Other Behavior Disorders	17,425	23.2%	.	.	0	.	0
Alcohol Use Disorders	12,929	17.2%	.	.	0	.	0

**Table 1D.i: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	.	.	0	.	0
Bipolar Disorders	38,283	51.0%	.	.	0	.	0
Depression	47,485	63.3%	.	.	0	.	0
Depressive Disorders	37,396	49.8%	.	.	0	.	0
Drug Use Disorders	21,639	28.8%	.	.	0	.	0
Opioid Use Disorder (OUD) 1	5,158	6.9%	.	.	0	.	0
OUD 2	4,382	5.8%	.	.	0	.	0
OUD 3	3,628	4.8%	.	.	0	.	0
OUD 4	730	1.0%	.	.	0	.	0
Personality Disorders	15,015	20.0%	.	.	0	.	0
Schizophrenia	62,544	83.3%	.	.	0	.	0
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	.	.	0	.	0
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	.	.	0	.	0
Atypical Antipsychotics	36,439	48.5%	.	.	0	.	0
Typical Antipsychotics	16,451	21.9%	.	.	0	.	0
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	.	.	0	.	0
Antidepressants	35,374	47.1%	.	.	0	.	0
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1D.i: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable



**Table 1A.j: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

Characteristic <sup>1</sup>	Number	
Number of episodes	75,063	
Number of unique patients	53,500	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.6	14.8
Age (years)	Number	Percent
12-18	2,718	3.6%
19-35	24,222	32.3%
36-50	19,584	26.1%
51-64	19,632	26.2%
65-74	6,679	8.9%
75+	2,228	3.0%
Sex		
Female	21,630	40.4%
Male	31,870	59.6%
Race		
Unknown	11,087	20.7%
American Indian or Alaska Native	675	1.3%
Asian	1,617	3.0%
Black or African American	7,987	14.9%
Native Hawaiian or Other Pacific Islander	91	0.2%
White	32,043	59.9%
Ethnicity		
Not Hispanic	42,104	78.7%
Unknown	7,601	14.2%
Hispanic	3,795	7.1%
Year		
2015 Quarter 4	3,891	5.2%
2016 Quarter 1	5,222	7.0%
2016 Quarter 2	4,798	6.4%
2016 Quarter 3	4,747	6.3%
2016 Quarter 4	4,802	6.4%
2017 Quarter 1	5,466	7.3%
2017 Quarter 2	5,092	6.8%
2017 Quarter 3	4,869	6.5%
2017 Quarter 4	4,905	6.5%
2018 Quarter 1	5,208	6.9%
2018 Quarter 2	4,791	6.4%
2018 Quarter 3	4,937	6.6%
2018 Quarter 4	4,734	6.3%
2019 Quarter 1	2,954	3.9%
2019 Quarter 2	2,954	3.9%

**Table 1A.j: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

2019 Quarter 3	2,893	3.9%
2019 Quarter 4	2,800	3.7%
<b>Geographic Census Bureau Region</b>		
Invalid	74	0.1%
Midwest	18,990	25.3%
Missing	11	<0.1%
Northeast	18,956	25.3%
Other	100	0.1%
South	21,408	28.5%
West	15,524	20.7%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4
ADHD Only Subset	5,636	7.5%
ADHD and Other Behavior Disorders	17,425	23.2%
Alcohol Use Disorders	12,929	17.2%
Anxiety Disorders	41,565	55.4%
Bipolar Disorders	38,283	51.0%
Depression	47,485	63.3%
Depressive Disorders	37,396	49.8%
Drug Use Disorders	21,639	28.8%
Opioid Use Disorder (OUD) 1	5,158	6.9%
OUD 2	4,382	5.8%
OUD 3	3,628	4.8%
OUD 4	730	1.0%
Personality Disorders	15,015	20.0%
Schizophrenia	62,544	83.3%
Schizophrenia and Other Psychotic Disorders	66,213	88.2%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	10,699	14.3%
Atypical Antipsychotics	36,439	48.5%
Typical Antipsychotics	16,451	21.9%
Any Antipsychotic (Typical or Atypical)	43,519	58.0%
Antidepressants	35,374	47.1%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	146.0	173.6
Mean number of emergency room encounters	7.0	15.8
Mean number of inpatient hospital encounters	2.5	4.6
Mean number of non-acute institutional encounters	3.2	5.6
Mean number of other ambulatory encounters	121.9	176.4

**Table 1A.j: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.6	3.5
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

**Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	75,063						
Number of unique patients	53,500						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.8					
Age (years)	Number	Percent					
12-18	2,718	3.6%	10.8	14.4	7	7	9
19-35	24,222	32.3%	11.4	13.5	7	7	11
36-50	19,584	26.1%	11.4	12.5	7	7	11
51-64	19,632	26.2%	11.5	12.6	7	7	13
65-74	6,679	8.9%	10.9	11.3	6	7	12
75+	2,228	3.0%	10.3	10.8	6	7	9
Sex							
Female	21,630	40.4%	11.1	12.5	7	7	11
Male	31,870	59.6%	11.5	12.9	7	7	12
Race							
Unknown	11,087	20.7%	12.0	14.2	7	7	13
American Indian or Alaska Native	675	1.3%	10.9	12.3	7	7	10
Asian	1,617	3.0%	12.1	13.9	7	7	13
Black or African American	7,987	14.9%	11.7	13.3	7	7	13
Native Hawaiian or Other Pacific Islander	91	0.2%	12.8	13.7	7	7	14
White	32,043	59.9%	11.0	12.2	7	7	11
Ethnicity							
Not Hispanic	42,104	78.7%	11.2	12.4	7	7	11
Unknown	7,601	14.2%	12.0	14.1	7	7	13
Hispanic	3,795	7.1%	12.0	14.3	7	7	13
Year							
2015 Quarter 4	3,891	5.2%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A	N/A

**Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	13.2	15.5	7	7	14
Midwest	18,990	25.3%	10.5	11.1	7	7	9
Missing	11	<0.1%	11.8	10.7	6	7.5	15
Northeast	18,956	25.3%	11.7	13.7	7	7	13
Other	100	0.1%	18.9	23.5	7	8.5	27
South	21,408	28.5%	12.1	13.6	7	7	14
West	15,524	20.7%	11.0	12.7	7	7	10
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	5,636	7.5%	10.0	11.7	6	7	8
ADHD and Other Behavior Disorders	17,425	23.2%	9.8	11.2	6	7	8
Alcohol Use Disorders	12,929	17.2%	10.0	11.0	6	7	9

**Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	10.2	11.2	6	7	9
Bipolar Disorders	38,283	51.0%	10.4	11.6	6	7	9
Depression	47,485	63.3%	10.5	11.5	6	7	9
Depressive Disorders	37,396	49.8%	10.3	11.2	6	7	9
Drug Use Disorders	21,639	28.8%	10.1	11.2	6	7	9
Opioid Use Disorder (OUD) 1	5,158	6.9%	9.9	10.9	6	7	9
OUD 2	4,382	5.8%	9.8	10.7	6	7	9
OUD 3	3,628	4.8%	9.8	10.9	6	7	9
OUD 4	730	1.0%	10.6	11.8	6	7	10
Personality Disorders	15,015	20.0%	9.7	10.8	6	7	8
Schizophrenia	62,544	83.3%	11.3	12.6	7	7	12
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	11.2	12.5	7	7	11
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	10.5	12.4	7	7	9
Atypical Antipsychotics	36,439	48.5%	9.4	10.5	6	7	8
Typical Antipsychotics	16,451	21.9%	9.5	11.0	6	7	8
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	9.7	10.9	7	7	8
Antidepressants	35,374	47.1%	10.6	11.8	7	7	9
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1C.j: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	75,063						
Number of unique patients	53,500						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.8					
Age (years)	Number	Percent					
12-18	2,718	3.6%	11.0	9.0	3	8	19
19-35	24,222	32.3%	10.5	9.0	3	7	19
36-50	19,584	26.1%	10.7	9.1	3	7	19
51-64	19,632	26.2%	10.7	8.9	4	7	18
65-74	6,679	8.9%	10.9	9.0	4	7	18
75+	2,228	3.0%	10.6	9.1	3	7	18
Sex							
Female	21,630	40.4%	10.8	9.1	3	7	19
Male	31,870	59.6%	10.6	9.0	3	7	18
Race							
Unknown	11,087	20.7%	9.9	8.7	3	6	16
American Indian or Alaska Native	675	1.3%	11.1	9.0	3	8	20
Asian	1,617	3.0%	9.9	8.6	3	6	17
Black or African American	7,987	14.9%	9.8	8.7	3	6	16
Native Hawaiian or Other Pacific Islander	91	0.2%	9.3	8.2	2	6	16
White	32,043	59.9%	11.1	9.2	4	7	19
Ethnicity							
Not Hispanic	42,104	78.7%	10.8	9.1	3	7	19
Unknown	7,601	14.2%	9.7	8.7	3	6	16
Hispanic	3,795	7.1%	10.1	8.7	3	7	17
Year							
2015 Quarter 4	3,891	5.2%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A	N/A



**Table 1C.j: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	9.4	8.2	3	6	15
Midwest	18,990	25.3%	11.7	9.3	4	8	21
Missing	11	<0.1%	6.2	5.1	4	5	5
Northeast	18,956	25.3%	10.4	9.0	3	7	18
Other	100	0.1%	6.3	7.6	1	4	7
South	21,408	28.5%	9.5	8.6	3	6	15
West	15,524	20.7%	11.2	9.0	4	7	19
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	5,636	7.5%	11.7	9.4	3	8	21
ADHD and Other Behavior Disorders	17,425	23.2%	12.0	9.5	4	9	21
Alcohol Use Disorders	12,929	17.2%	11.6	9.2	3	8	20

**Table 1C.j: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	11.6	9.3	3	8	20
Bipolar Disorders	38,283	51.0%	11.4	9.3	3	8	20
Depression	47,485	63.3%	11.3	9.2	3	8	20
Depressive Disorders	37,396	49.8%	11.5	9.3	3	8	20
Drug Use Disorders	21,639	28.8%	11.4	9.2	3	8	20
Opioid Use Disorder (OUD) 1	5,158	6.9%	10.9	9.1	3	8	19
OUD 2	4,382	5.8%	10.9	9.1	3	8	19
OUD 3	3,628	4.8%	10.7	9.2	3	7	18
OUD 4	730	1.0%	9.8	8.6	2	7	16
Personality Disorders	15,015	20.0%	11.9	9.5	4	9	21
Schizophrenia	62,544	83.3%	10.7	9.0	3	7	18
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	10.8	9.0	3	7	19
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	11.7	9.3	4	8	21
Atypical Antipsychotics	36,439	48.5%	13.0	9.6	4	11	23
Typical Antipsychotics	16,451	21.9%	13.0	9.7	4	11	23
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	12.6	9.6	4	10	23
Antidepressants	35,374	47.1%	11.4	9.3	4	8	20
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1C.j: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A*	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	75,063						
Number of unique patients	53,500						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.8					
Age (years)	Number	Percent					
12-18	2,718	3.6%	2.6	1.5	1	2.6	4
19-35	24,222	32.3%	2.4	1.6	1	2.2	4
36-50	19,584	26.1%	2.5	1.6	1	2.1	4
51-64	19,632	26.2%	2.5	1.7	1	2.1	4
65-74	6,679	8.9%	2.6	1.7	1	2.3	4
75+	2,228	3.0%	2.8	1.9	1	2.6	4
Sex							
Female	21,630	40.4%	2.5	1.7	1	2.3	4
Male	31,870	59.6%	2.5	1.6	1	2.1	4
Race							
Unknown	11,087	20.7%	2.3	1.6	1	2.1	4
American Indian or Alaska Native	675	1.3%	2.6	1.7	1	2.5	4
Asian	1,617	3.0%	2.3	1.6	1	2.0	4
Black or African American	7,987	14.9%	2.4	1.6	1	2.0	4
Native Hawaiian or Other Pacific Islander	91	0.2%	2.2	1.8	1	1.9	3
White	32,043	59.9%	2.6	1.7	1	2.3	4
Ethnicity							
Not Hispanic	42,104	78.7%	2.5	1.7	1	2.2	4
Unknown	7,601	14.2%	2.3	1.6	1	2.0	4
Hispanic	3,795	7.1%	2.4	1.6	1	2.1	4
Year							
2015 Quarter 4	3,891	5.2%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	5,222	7.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	4,798	6.4%	N/A	N/A	N/A	N/A	N/A

**Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	4,747	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	4,802	6.4%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	5,466	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	5,092	6.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	4,869	6.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	4,905	6.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	5,208	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	4,791	6.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	4,937	6.6%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	4,734	6.3%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	2,954	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	2,893	3.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	2,800	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	74	0.1%	2.4	1.6	1	2.1	4
Midwest	18,990	25.3%	2.7	1.7	1	2.6	4
Missing	11	<0.1%	4.3	3.0	2	3.5	6
Northeast	18,956	25.3%	2.4	1.6	1	2.1	4
Other	100	0.1%	1.4	1.3	1	1.0	2
South	21,408	28.5%	2.3	1.6	1	1.9	4
West	15,524	20.7%	2.6	1.7	1	2.4	4
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.4					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	5,636	7.5%	2.8	1.6	1	3.0	4
ADHD and Other Behavior Disorders	17,425	23.2%	2.9	1.7	1	3.0	4
Alcohol Use Disorders	12,929	17.2%	2.8	1.6	1	2.9	4

**Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	41,565	55.4%	2.8	1.7	1	2.8	4
Bipolar Disorders	38,283	51.0%	2.7	1.7	1	2.6	4
Depression	47,485	63.3%	2.7	1.7	1	2.6	4
Depressive Disorders	37,396	49.8%	2.7	1.7	1	2.7	4
Drug Use Disorders	21,639	28.8%	2.8	1.6	1	2.8	4
Opioid Use Disorder (OUD) 1	5,158	6.9%	2.8	1.7	1	2.9	4
OUD 2	4,382	5.8%	2.9	1.6	1	2.9	4
OUD 3	3,628	4.8%	2.9	1.8	1	2.8	4
OUD 4	730	1.0%	2.6	1.6	1	2.5	4
Personality Disorders	15,015	20.0%	2.9	1.7	1	3.0	4
Schizophrenia	62,544	83.3%	2.5	1.6	1	2.2	4
Schizophrenia and Other Psychotic Disorders	66,213	88.2%	2.5	1.7	1	2.3	4
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	10,699	14.3%	2.7	1.7	1	2.7	4
Atypical Antipsychotics	36,439	48.5%	3.0	1.6	1	3.3	4
Typical Antipsychotics	16,451	21.9%	3.0	1.6	1	3.3	4
Any Antipsychotic (Typical or Atypical)	43,519	58.0%	2.9	1.6	1	3.2	4
Antidepressants	35,374	47.1%	2.6	1.7	1	2.6	4
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	146.0	173.6	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	7.0	15.8	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.5	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.2	5.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	121.9	176.4	N/A	N/A	N/A	N/A	N/A

**Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.8	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.2	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*N/A = Not Applicable

**Table 1A.k: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3)**

Characteristic <sup>1</sup>	Number	
Number of episodes	35,106	
Number of unique patients	31,733	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.6	14.6
Age (years)	Number	Percent
12-18	1,216	3.5%
19-35	11,085	31.6%
36-50	9,290	26.5%
51-64	9,601	27.3%
65-74	3,069	8.7%
75+	845	2.4%
Sex		
Female	12,685	40.0%
Male	19,048	60.0%
Race		
Unknown	6,120	19.3%
American Indian or Alaska Native	385	1.2%
Asian	955	3.0%
Black or African American	4,386	13.8%
Native Hawaiian or Other Pacific Islander	60	0.2%
White	19,827	62.5%
Ethnicity		
Not Hispanic	25,454	80.2%
Unknown	4,048	12.8%
Hispanic	2,231	7.0%
Year		
2015 Quarter 4	1,960	5.6%
2016 Quarter 1	2,962	8.4%
2016 Quarter 2	2,576	7.3%
2016 Quarter 3	2,566	7.3%
2016 Quarter 4	2,501	7.1%
2017 Quarter 1	2,990	8.5%
2017 Quarter 2	2,735	7.8%
2017 Quarter 3	2,550	7.3%
2017 Quarter 4	2,620	7.5%
2018 Quarter 1	2,865	8.2%
2018 Quarter 2	2,575	7.3%
2018 Quarter 3	1,472	4.2%
2018 Quarter 4	1,417	4.0%
2019 Quarter 1	1,642	4.7%
2019 Quarter 2	1,643	4.7%



**Table 1A.k: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3)**

2019 Quarter 3	32	0.1%
2019 Quarter 4	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	0.1%
Midwest	9,518	27.1%
Missing	*****	<0.1%
Northeast	9,117	26.0%
Other	52	0.1%
South	8,906	25.4%
West	7,478	21.3%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3
ADHD Only Subset	2,454	7.0%
ADHD and Other Behavior Disorders	7,766	22.1%
Alcohol Use Disorders	5,556	15.8%
Anxiety Disorders	18,576	52.9%
Bipolar Disorders	17,158	48.9%
Depression	21,382	60.9%
Depressive Disorders	16,593	47.3%
Drug Use Disorders	9,091	25.9%
Opioid Use Disorder (OUD) 1	1,895	5.4%
OUD 2	1,593	4.5%
OUD 3	1,291	3.7%
OUD 4	222	0.6%
Personality Disorders	6,609	18.8%
Schizophrenia	29,237	83.3%
Schizophrenia and Other Psychotic Disorders	30,803	87.7%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,243	14.9%
Atypical Antipsychotics	17,567	50.0%
Typical Antipsychotics	8,143	23.2%
Any Antipsychotic (Typical or Atypical)	20,939	59.6%
Antidepressants	16,765	47.8%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	143.5	169.0
Mean number of emergency room encounters	6.2	13.5
Mean number of inpatient hospital encounters	2.2	4.0
Mean number of non-acute institutional encounters	2.9	5.0
Mean number of other ambulatory encounters	115.4	162.2

**Table 1A.k: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.8	3.6
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.5	5.7

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

		Gaps between all ANC Screenings					
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	14.9	16.2	7	13	15
19-35	11,085	31.6%	15.3	14.5	7	14	17
36-50	9,290	26.5%	14.9	13.3	7	13	17
51-64	9,601	27.3%	14.1	13.1	7	10	16
65-74	3,069	8.7%	12.9	12.1	7	8	14
75+	845	2.4%	12.7	11.9	7	8	14
Sex							
Female	12,685	40.0%	14.2	13.4	7	12	16
Male	19,048	60.0%	14.7	13.7	7	13	17
Race							
Unknown	6,120	19.3%	15.9	15.3	7	14	19
American Indian or Alaska Native	385	1.2%	14.4	14.4	7	12	16
Asian	955	3.0%	15.7	14.0	7	14	20
Black or African American	4,386	13.8%	14.7	14.2	7	12	17
Native Hawaiian or Other Pacific Islander	60	0.2%	16.9	16.8	7	14	21
White	19,827	62.5%	14.1	12.9	7	12	15
Ethnicity							
Not Hispanic	25,454	80.2%	14.2	13.2	7	12	16
Unknown	4,048	12.8%	16.2	15.2	7	14	20
Hispanic	2,231	7.0%	15.5	15.5	7	13	18
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A

**Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	16.3	14.3	6	13	27
Midwest	9,518	27.1%	13.6	11.8	7	11	15
Missing	*****	<0.1%	11.3	11.8	7	7.5	9
Northeast	9,117	26.0%	15.0	14.4	7	13	17
Other	52	0.1%	26.5	25.9	13	16	30
South	8,906	25.4%	14.9	14.3	7	12	18
West	7,478	21.3%	14.7	13.9	7	13	16
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	13.4	12.7	7	11	14
ADHD and Other Behavior Disorders	7,766	22.1%	12.6	12.3	7	9	14
Alcohol Use Disorders	5,556	15.8%	13.1	12.0	7	11	14

**Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	13.2	12.2	7	10	14
Bipolar Disorders	17,158	48.9%	13.3	12.4	7	10	14
Depression	21,382	60.9%	13.4	12.5	7	10	15
Depressive Disorders	16,593	47.3%	13.1	12.2	7	9	14
Drug Use Disorders	9,091	25.9%	13.2	12.1	7	11	14
Opioid Use Disorder (OUD) 1	1,895	5.4%	13.1	11.9	7	10	14
OUD 2	1,593	4.5%	13.0	11.8	7	10	14
OUD 3	1,291	3.7%	12.8	12.1	7	9	14
OUD 4	222	0.6%	14.5	13.9	7	12	16
Personality Disorders	6,609	18.8%	12.6	11.9	7	9	14
Schizophrenia	29,237	83.3%	14.3	13.3	7	12	16
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	14.2	13.2	7	12	16
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	13.8	13.2	7	12	15
Atypical Antipsychotics	17,567	50.0%	12.7	11.8	7	11	14
Typical Antipsychotics	8,143	23.2%	12.7	12.3	7	10	14
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	13.0	12.1	7	11	14
Antidepressants	16,765	47.8%	13.8	12.8	7	11	15
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.k: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	9.0	6.1	4	8	13
19-35	11,085	31.6%	9.0	6.1	4	7	13
36-50	9,290	26.5%	9.4	6.3	5	8	13
51-64	9,601	27.3%	9.9	7.0	5	8	14
65-74	3,069	8.7%	10.5	7.7	5	8	14
75+	845	2.4%	10.5	7.4	5	8	14
Sex							
Female	12,685	40.0%	9.8	6.8	5	8	14
Male	19,048	60.0%	9.4	6.5	5	7	13
Race							
Unknown	6,120	19.3%	8.5	6.0	4	7	13
American Indian or Alaska Native	385	1.2%	9.7	6.4	5	8	14
Asian	955	3.0%	8.9	6.0	5	7	13
Black or African American	4,386	13.8%	9.2	6.6	4	7	13
Native Hawaiian or Other Pacific Islander	60	0.2%	7.0	5.8	2	6	10
White	19,827	62.5%	9.9	6.8	5	8	14
Ethnicity							
Not Hispanic	25,454	80.2%	9.8	6.8	5	8	14
Unknown	4,048	12.8%	8.2	5.8	4	7	12
Hispanic	2,231	7.0%	8.9	6.3	4	7	13
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A

**Table 1C.k: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	8.2	7.7	5	6	11
Midwest	9,518	27.1%	10.2	6.9	5	8	14
Missing	*****	<0.1%	15.0	12.7	6	15	24
Northeast	9,117	26.0%	9.3	6.6	5	7	13
Other	52	0.1%	3.9	3.6	1	3	4
South	8,906	25.4%	9.1	6.6	4	7	13
West	7,478	21.3%	9.4	6.3	5	8	13
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	10.1	6.7	5	9	14
ADHD and Other Behavior Disorders	7,766	22.1%	10.9	7.3	5	10	15
Alcohol Use Disorders	5,556	15.8%	10.5	6.9	5	9	14



**Table 1C.k: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	10.4	7.0	5	9	14
Bipolar Disorders	17,158	48.9%	10.3	7.0	5	9	14
Depression	21,382	60.9%	10.3	7.0	5	9	14
Depressive Disorders	16,593	47.3%	10.5	7.1	5	9	14
Drug Use Disorders	9,091	25.9%	10.4	6.9	5	9	14
Opioid Use Disorder (OUD) 1	1,895	5.4%	10.1	6.8	5	9	14
OUD 2	1,593	4.5%	10.2	6.8	5	9	14
OUD 3	1,291	3.7%	10.1	7.1	4	9	14
OUD 4	222	0.6%	8.6	5.8	4	8	13
Personality Disorders	6,609	18.8%	11.0	7.2	6	10	15
Schizophrenia	29,237	83.3%	9.7	6.7	5	8	13
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	9.7	6.7	5	8	13
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	10.1	6.7	5	9	14
Atypical Antipsychotics	17,567	50.0%	11.0	6.9	6	11	15
Typical Antipsychotics	8,143	23.2%	11.0	7.1	6	11	15
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	10.8	6.9	6	10	14
Antidepressants	16,765	47.8%	10.1	6.9	5	8	14
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1C.k: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	1.9	1.7	1	1.8	2
19-35	11,085	31.6%	1.8	1.1	1	1.6	2
36-50	9,290	26.5%	1.9	1.2	1	1.6	2
51-64	9,601	27.3%	2.0	1.4	1	1.6	3
65-74	3,069	8.7%	2.2	1.3	1	1.8	3
75+	845	2.4%	2.2	1.3	1	2.0	3
Sex							
Female	12,685	40.0%	2.0	1.3	1	1.7	3
Male	19,048	60.0%	1.9	1.2	1	1.6	2
Race							
Unknown	6,120	19.3%	1.8	1.2	1	1.5	2
American Indian or Alaska Native	385	1.2%	1.9	1.1	1	1.8	3
Asian	955	3.0%	1.7	1.0	1	1.5	2
Black or African American	4,386	13.8%	1.9	1.3	1	1.6	2
Native Hawaiian or Other Pacific Islander	60	0.2%	1.6	1.0	1	1.5	2
White	19,827	62.5%	2.0	1.3	1	1.8	3
Ethnicity							
Not Hispanic	25,454	80.2%	2.0	1.3	1	1.7	2
Unknown	4,048	12.8%	1.7	1.3	1	1.4	2
Hispanic	2,231	7.0%	1.8	1.1	1	1.5	2
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A

**Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	1.7	1.5	1	1.2	2
Midwest	9,518	27.1%	2.1	1.3	1	1.9	3
Missing	*****	<0.1%	2.5	2.1	1	2.5	4
Northeast	9,117	26.0%	1.9	1.3	1	1.6	2
Other	52	0.1%	0.8	0.6	0	0.8	1
South	8,906	25.4%	1.9	1.3	1	1.5	2
West	7,478	21.3%	1.9	1.2	1	1.7	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	2.1	1.2	1	2.0	3
ADHD and Other Behavior Disorders	7,766	22.1%	2.2	1.3	1	2.1	3
Alcohol Use Disorders	5,556	15.8%	2.1	1.3	1	2.0	3

**Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	2.1	1.3	1	2.0	3
Bipolar Disorders	17,158	48.9%	2.1	1.3	1	2.0	3
Depression	21,382	60.9%	2.1	1.3	1	2.0	3
Depressive Disorders	16,593	47.3%	2.1	1.3	1	2.0	3
Drug Use Disorders	9,091	25.9%	2.1	1.3	1	2.0	3
Opioid Use Disorder (OUD) 1	1,895	5.4%	2.2	1.4	1	2.0	3
OUD 2	1,593	4.5%	2.2	1.5	1	2.0	3
OUD 3	1,291	3.7%	2.2	1.6	1	2.0	3
OUD 4	222	0.6%	2.1	1.7	1	1.8	2
Personality Disorders	6,609	18.8%	2.2	1.3	1	2.1	3
Schizophrenia	29,237	83.3%	1.9	1.2	1	1.6	2
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	1.9	1.3	1	1.7	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	2.0	1.3	1	2.0	3
Atypical Antipsychotics	17,567	50.0%	2.2	1.3	1	2.1	3
Typical Antipsychotics	8,143	23.2%	2.2	1.3	1	2.1	3
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	2.2	1.3	1	2.1	3
Antidepressants	16,765	47.8%	2.0	1.3	1	1.8	3
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.I: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4)**

Characteristic <sup>1</sup>	Number	
Number of episodes	22,697	
Number of unique patients	22,011	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.7	14.4
Age (years)	Number	Percent
12-18	703	3.1%
19-35	7,060	31.1%
36-50	6,220	27.4%
51-64	6,310	27.8%
65-74	1,913	8.4%
75+	491	2.2%
Sex		
Female	8,783	39.9%
Male	13,228	60.1%
Race		
Unknown	3,932	17.9%
American Indian or Alaska Native	274	1.2%
Asian	686	3.1%
Black or African American	2,980	13.5%
Native Hawaiian or Other Pacific Islander	39	0.2%
White	14,100	64.1%
Ethnicity		
Not Hispanic	17,983	81.7%
Unknown	2,510	11.4%
Hispanic	1,518	6.9%
Year		
2015 Quarter 4	1,519	6.7%
2016 Quarter 1	2,263	10.0%
2016 Quarter 2	1,997	8.8%
2016 Quarter 3	2,021	8.9%
2016 Quarter 4	1,937	8.5%
2017 Quarter 1	2,178	9.6%
2017 Quarter 2	2,053	9.0%
2017 Quarter 3	1,994	8.8%
2017 Quarter 4	2,048	9.0%
2018 Quarter 1	1,295	5.7%
2018 Quarter 2	1,182	5.2%
2018 Quarter 3	1,102	4.9%
2018 Quarter 4	1,108	4.9%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%

**Table 1A.I: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4)**

2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	0.1%
Midwest	6,168	27.2%
Missing	*****	<0.1%
Northeast	5,960	26.3%
Other	*****	<0.1%
South	5,589	24.6%
West	4,961	21.9%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3
ADHD Only Subset	1,480	6.5%
ADHD and Other Behavior Disorders	4,886	21.5%
Alcohol Use Disorders	3,507	15.5%
Anxiety Disorders	11,723	51.6%
Bipolar Disorders	10,862	47.9%
Depression	13,651	60.1%
Depressive Disorders	10,542	46.4%
Drug Use Disorders	5,655	24.9%
Opioid Use Disorder (OUD) 1	1,115	4.9%
OUD 2	940	4.1%
OUD 3	740	3.3%
OUD 4	113	0.5%
Personality Disorders	4,229	18.6%
Schizophrenia	18,970	83.6%
Schizophrenia and Other Psychotic Disorders	19,930	87.8%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	3,481	15.3%
Atypical Antipsychotics	11,640	51.3%
Typical Antipsychotics	5,433	23.9%
Any Antipsychotic (Typical or Atypical)	13,843	61.0%
Antidepressants	10,913	48.1%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	141.3	166.2
Mean number of emergency room encounters	6.0	13.6
Mean number of inpatient hospital encounters	2.1	3.8
Mean number of non-acute institutional encounters	2.8	4.8
Mean number of other ambulatory encounters	107.9	149.9



**Table 1A.I: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.8	3.5
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.6	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.I: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	23.9	27.2	12	20	28
19-35	7,060	31.1%	22.1	20.9	9	21	28
36-50	6,220	27.4%	20.8	18.6	8	19	28
51-64	6,310	27.8%	18.3	16.9	7	14	28
65-74	1,913	8.4%	16.1	16.2	7	12	27
75+	491	2.2%	15.6	14.9	7	12	25
Sex							
Female	8,783	39.9%	19.1	18.3	7	14	28
Male	13,228	60.1%	20.4	19.2	7	17	28
Race							
Unknown	3,932	17.9%	22.4	22.7	8	21	28
American Indian or Alaska Native	274	1.2%	20.7	18.5	7	19	28
Asian	686	3.1%	22.2	20.3	11	21	28
Black or African American	2,980	13.5%	19.5	19.1	7	14	28
Native Hawaiian or Other Pacific Islander	39	0.2%	22.4	24.0	10	19	28
White	14,100	64.1%	19.2	17.7	7	15	28
Ethnicity							
Not Hispanic	17,983	81.7%	19.4	18.0	7	15	28
Unknown	2,510	11.4%	23.2	23.3	10	23	29
Hispanic	1,518	6.9%	21.6	21.9	8	18	28
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1B.I: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	28.9	23.3	15	28	32
Midwest	6,168	27.2%	18.4	15.4	7	14	28
Missing	*****	<0.1%	11.6	10.7	7	7	13
Northeast	5,960	26.3%	20.3	20.6	7	16	28
Other	*****	<0.1%	25.4	11.1	20	28	33
South	5,589	24.6%	19.9	19.1	7	15	28
West	4,961	21.9%	21.2	20.5	8	19	28
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	20.0	18.9	8	15	28
ADHD and Other Behavior Disorders	4,886	21.5%	17.7	17.9	7	14	28
Alcohol Use Disorders	3,507	15.5%	18.6	16.8	7	14	28

**Table 1B.I: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	18.2	17.0	7	14	28
Bipolar Disorders	10,862	47.9%	18.3	17.3	7	14	28
Depression	13,651	60.1%	18.4	17.2	7	14	28
Depressive Disorders	10,542	46.4%	17.9	16.8	7	14	28
Drug Use Disorders	5,655	24.9%	18.6	17.6	7	14	28
Opioid Use Disorder (OUD) 1	1,115	4.9%	18.1	15.8	7	14	28
OUD 2	940	4.1%	18.0	15.6	7	14	28
OUD 3	740	3.3%	17.6	15.5	7	14	28
OUD 4	113	0.5%	19.7	18.0	7	15	28
Personality Disorders	4,229	18.6%	17.5	16.3	7	14	28
Schizophrenia	18,970	83.6%	19.5	18.2	7	15	28
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	19.5	18.2	7	15	28
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	19.8	19.3	7	15	28
Atypical Antipsychotics	11,640	51.3%	19.0	17.8	7	14	28
Typical Antipsychotics	5,433	23.9%	18.5	18.2	7	14	28
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	19.0	17.9	7	14	28
Antidepressants	10,913	48.1%	19.1	18.1	7	14	28
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A

**Table 1B.I: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.I: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	9.3	7.1	4	8	13
19-35	7,060	31.1%	11.1	8.1	5	11	14
36-50	6,220	27.4%	12.2	8.8	6	12	15
51-64	6,310	27.8%	13.8	10.9	7	12	16
65-74	1,913	8.4%	14.8	12.8	6	12	18
75+	491	2.2%	14.1	12.8	5	11	18
Sex							
Female	8,783	39.9%	13.0	10.4	6	12	16
Male	13,228	60.1%	12.2	9.4	6	12	15
Race							
Unknown	3,932	17.9%	10.4	8.0	4	10	14
American Indian or Alaska Native	274	1.2%	12.2	9.6	6	12	15
Asian	686	3.1%	11.4	7.7	5	11	15
Black or African American	2,980	13.5%	12.6	10.2	5	12	15
Native Hawaiian or Other Pacific Islander	39	0.2%	9.3	6.8	4	8	12
White	14,100	64.1%	13.1	10.2	6	12	16
Ethnicity							
Not Hispanic	17,983	81.7%	12.9	10.1	6	12	16
Unknown	2,510	11.4%	9.9	7.8	4	9	13
Hispanic	1,518	6.9%	11.3	8.3	5	11	14
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1C.I: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	6.1	4.5	3	4.5	12
Midwest	6,168	27.2%	13.4	10.2	6	12	16
Missing	*****	<0.1%	16.5	21.9	1	16.5	32
Northeast	5,960	26.3%	12.4	10.1	5	12	15
Other	*****	<0.1%	12.7	1.5	11	13	14
South	5,589	24.6%	12.4	10.1	5	11	15
West	4,961	21.9%	11.8	8.5	6	11	15
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	12.2	9.0	5	12	16
ADHD and Other Behavior Disorders	4,886	21.5%	13.9	11.0	6	12	17
Alcohol Use Disorders	3,507	15.5%	13.4	10.0	6	13	17

**Table 1C.I: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	13.5	10.7	6	12	16
Bipolar Disorders	10,862	47.9%	13.5	10.7	6	12	17
Depression	13,651	60.1%	13.4	10.7	6	12	16
Depressive Disorders	10,542	46.4%	13.8	11.1	6	12	17
Drug Use Disorders	5,655	24.9%	13.0	10.2	6	12	16
Opioid Use Disorder (OUD) 1	1,115	4.9%	13.2	10.2	6	12	17
OUD 2	940	4.1%	13.0	10.0	6	12	17
OUD 3	740	3.3%	13.5	10.4	6	12	17
OUD 4	113	0.5%	11.2	8.6	5	11	14
Personality Disorders	4,229	18.6%	14.2	11.0	7	13	17
Schizophrenia	18,970	83.6%	12.8	10.0	6	12	15
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	12.8	10.0	6	12	15
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	12.5	9.6	6	12	16
Atypical Antipsychotics	11,640	51.3%	13.2	9.9	6	12	16
Typical Antipsychotics	5,433	23.9%	13.6	10.5	6	12	17
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	13.2	10.0	6	12	16
Antidepressants	10,913	48.1%	13.0	10.2	6	12	16
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A



**Table 1C.I: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.I: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	1.2	0.9	1	1.1	1
19-35	7,060	31.1%	1.3	0.9	1	1.1	1
36-50	6,220	27.4%	1.4	0.8	1	1.2	2
51-64	6,310	27.8%	1.6	1.1	1	1.2	2
65-74	1,913	8.4%	1.8	1.2	1	1.3	2
75+	491	2.2%	1.8	1.2	1	1.4	2
Sex							
Female	8,783	39.9%	1.5	1.0	1	1.2	2
Male	13,228	60.1%	1.4	1.0	1	1.2	2
Race							
Unknown	3,932	17.9%	1.3	0.8	1	1.1	1
American Indian or Alaska Native	274	1.2%	1.4	0.9	1	1.2	2
Asian	686	3.1%	1.2	0.6	1	1.1	1
Black or African American	2,980	13.5%	1.5	1.2	1	1.2	2
Native Hawaiian or Other Pacific Islander	39	0.2%	1.2	0.6	1	1.1	1
White	14,100	64.1%	1.5	1.0	1	1.2	2
Ethnicity							
Not Hispanic	17,983	81.7%	1.5	1.0	1	1.2	2
Unknown	2,510	11.4%	1.2	0.8	1	1.1	1
Hispanic	1,518	6.9%	1.3	0.8	1	1.2	2
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1D.I: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	1.2	0.8	1	1.0	2
Midwest	6,168	27.2%	1.6	1.0	1	1.2	2
Missing	*****	<0.1%	1.7	1.4	1	1.7	3
Northeast	5,960	26.3%	1.4	1.1	1	1.2	2
Other	*****	<0.1%	1.1	0.2	1	1.2	1
South	5,589	24.6%	1.4	1.0	1	1.2	2
West	4,961	21.9%	1.4	0.9	1	1.2	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	1.5	0.9	1	1.2	2
ADHD and Other Behavior Disorders	4,886	21.5%	1.7	1.1	1	1.3	2
Alcohol Use Disorders	3,507	15.5%	1.6	1.0	1	1.2	2

**Table 1D.I: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	1.6	1.0	1	1.2	2
Bipolar Disorders	10,862	47.9%	1.6	1.0	1	1.2	2
Depression	13,651	60.1%	1.6	1.0	1	1.2	2
Depressive Disorders	10,542	46.4%	1.6	1.1	1	1.2	2
Drug Use Disorders	5,655	24.9%	1.6	1.0	1	1.2	2
Opioid Use Disorder (OUD) 1	1,115	4.9%	1.6	1.0	1	1.3	2
OUD 2	940	4.1%	1.6	1.0	1	1.3	2
OUD 3	740	3.3%	1.7	1.0	1	1.4	2
OUD 4	113	0.5%	1.5	1.1	1	1.2	2
Personality Disorders	4,229	18.6%	1.7	1.1	1	1.3	2
Schizophrenia	18,970	83.6%	1.5	1.0	1	1.2	2
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	1.5	1.0	1	1.2	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	1.5	1.0	1	1.2	2
Atypical Antipsychotics	11,640	51.3%	1.5	1.0	1	1.2	2
Typical Antipsychotics	5,433	23.9%	1.6	1.1	1	1.2	2
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	1.5	1.0	1	1.2	2
Antidepressants	10,913	48.1%	1.5	1.0	1	1.2	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A

**Table 1D.I: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

Characteristic <sup>1</sup>	Number	
Number of episodes	33,606	
Number of unique patients	32,018	
Demographics	Mean	Standard Deviation
Mean Age (years)	42.7	14.8
Age (years)	Number	Percent
12-18	1,666	5.0%
19-35	11,968	35.6%
36-50	8,843	26.3%
51-64	7,767	23.1%
65-74	2,375	7.1%
75+	987	2.9%
Sex		
Female	13,141	41.0%
Male	18,877	59.0%
Race		
Unknown	6,760	21.1%
American Indian or Alaska Native	460	1.4%
Asian	934	2.9%
Black or African American	4,770	14.9%
Native Hawaiian or Other Pacific Islander	52	0.2%
White	19,042	59.5%
Ethnicity		
Not Hispanic	25,101	78.4%
Unknown	4,619	14.4%
Hispanic	2,298	7.2%
Year		
2015 Quarter 4	1,715	5.1%
2016 Quarter 1	1,846	5.5%
2016 Quarter 2	1,682	5.0%
2016 Quarter 3	2,115	6.3%
2016 Quarter 4	2,216	6.6%
2017 Quarter 1	2,392	7.1%
2017 Quarter 2	2,355	7.0%
2017 Quarter 3	2,401	7.1%
2017 Quarter 4	2,505	7.5%
2018 Quarter 1	2,475	7.4%
2018 Quarter 2	2,321	6.9%
2018 Quarter 3	2,378	7.1%
2018 Quarter 4	2,277	6.8%
2019 Quarter 1	1,265	3.8%
2019 Quarter 2	1,158	3.4%

**Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

2019 Quarter 3	1,249	3.7%
2019 Quarter 4	1,256	3.7%
<b>Geographic Census Bureau Region</b>		
Invalid	35	0.1%
Midwest	8,757	26.1%
Missing	*****	<0.1%
Northeast	7,913	23.5%
Other	*****	<0.1%
South	9,321	27.7%
West	7,557	22.5%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.2
ADHD Only Subset	3,357	10.0%
ADHD and Other Behavior Disorders	9,703	28.9%
Alcohol Use Disorders	7,059	21.0%
Anxiety Disorders	21,270	63.3%
Bipolar Disorders	19,103	56.8%
Depression	23,323	69.4%
Depressive Disorders	18,689	55.6%
Drug Use Disorders	11,873	35.3%
Opioid Use Disorder (OUD) 1	2,905	8.6%
OUD 2	2,542	7.6%
OUD 3	2,047	6.1%
OUD 4	406	1.2%
Personality Disorders	8,173	24.3%
Schizophrenia	27,575	82.1%
Schizophrenia and Other Psychotic Disorders	29,859	88.9%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,724	17.0%
Atypical Antipsychotics	22,510	67.0%
Typical Antipsychotics	9,888	29.4%
Any Antipsychotic (Typical or Atypical)	25,390	75.6%
Antidepressants	17,151	51.0%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	149.6	173.2
Mean number of emergency room encounters	8.9	19.7
Mean number of inpatient hospital encounters	2.7	4.9
Mean number of non-acute institutional encounters	3.5	5.7
Mean number of other ambulatory encounters	114.2	162.0

**Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	6.1	3.6
Mean number of generics	6.5	3.9
Mean number of filled prescriptions	8.2	6.1

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.



**Table 1B.m: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	33,606						
Number of unique patients	32,018						
Demographics	Mean	Standard Deviation					
Mean Age (years)	42.7	14.8					
Age (years)	Number	Percent					
12-18	1,666	5.0%	9.6	12.8	7	7	8
19-35	11,968	35.6%	9.2	10.7	7	7	8
36-50	8,843	26.3%	8.6	9.4	6	7	8
51-64	7,767	23.1%	8.6	9.5	6	7	7
65-74	2,375	7.1%	8.1	8.2	6	7	7
75+	987	2.9%	7.7	7.3	6	7	7
Sex							
Female	13,141	41.0%	8.7	9.8	6	7	8
Male	18,877	59.0%	8.9	10.0	7	7	8
Race							
Unknown	6,760	21.1%	9.5	11.5	7	7	8
American Indian or Alaska Native	460	1.4%	8.7	9.5	6	7	8
Asian	934	2.9%	9.3	11.0	7	7	8
Black or African American	4,770	14.9%	9.2	10.8	6	7	8
Native Hawaiian or Other Pacific Islander	52	0.2%	9.8	10.5	7	7	10
White	19,042	59.5%	8.5	9.2	6	7	7
Ethnicity							
Not Hispanic	25,101	78.4%	8.6	9.6	6	7	7
Unknown	4,619	14.4%	9.4	11.3	7	7	8
Hispanic	2,298	7.2%	9.5	11.5	7	7	8
Year							
2015 Quarter 4	1,715	5.1%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,846	5.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,682	5.0%	N/A	N/A	N/A	N/A	N/A

**Table 1B.m: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,115	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,216	6.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,392	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,355	7.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,401	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,505	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,475	7.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,321	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	2,378	7.1%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	2,277	6.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,265	3.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,158	3.4%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	1,249	3.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	1,256	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	35	0.1%	10.2	14.4	6	7	8
Midwest	8,757	26.1%	8.2	8.1	6	7	7
Missing	*****	<0.1%	8.1	6.7	4	7	10
Northeast	7,913	23.5%	9.0	10.7	6	7	8
Other	*****	<0.1%	10.0	12.9	7	7	8
South	9,321	27.7%	9.2	10.6	6	7	8
West	7,557	22.5%	8.9	10.4	7	7	8
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	3,357	10.0%	8.5	9.4	6	7	8
ADHD and Other Behavior Disorders	9,703	28.9%	8.4	9.3	6	7	7
Alcohol Use Disorders	7,059	21.0%	8.4	8.9	6	7	7

**Table 1B.m: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Gaps between all ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	21,270	63.3%	8.4	8.9	6	7	7
Bipolar Disorders	19,103	56.8%	8.4	9.2	6	7	7
Depression	23,323	69.4%	8.4	9.0	6	7	7
Depressive Disorders	18,689	55.6%	8.3	8.8	6	7	7
Drug Use Disorders	11,873	35.3%	8.6	9.3	6	7	8
Opioid Use Disorder (OUD) 1	2,905	8.6%	8.4	8.6	6	7	8
OUD 2	2,542	7.6%	8.4	8.6	6	7	8
OUD 3	2,047	6.1%	8.4	8.8	6	7	8
OUD 4	406	1.2%	8.8	8.5	6	7	8
Personality Disorders	8,173	24.3%	8.3	8.8	6	7	7
Schizophrenia	27,575	82.1%	8.8	9.9	6	7	8
Schizophrenia and Other Psychotic Disorders	29,859	88.9%	8.8	9.8	6	7	8
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,724	17.0%	8.8	10.2	6	7	7
Atypical Antipsychotics	22,510	67.0%	8.1	8.6	6	7	7
Typical Antipsychotics	9,888	29.4%	8.3	9.1	6	7	7
Any Antipsychotic (Typical or Atypical)	25,390	75.6%	8.2	8.8	6	7	7
Antidepressants	17,151	51.0%	8.4	8.9	6	7	7
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	149.6	173.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	8.9	19.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.7	4.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.5	5.7	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	114.2	162.0	N/A	N/A	N/A	N/A	N/A

**Table 1B.m: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	6.1	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.2	6.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	33,606						
Number of unique patients	32,018						
Demographics	Mean	Standard Deviation					
Mean Age (years)	42.7	14.8					
Age (years)	Number	Percent					
12-18	1,666	5.0%	12.6	9.2	4	11	22
19-35	11,968	35.6%	13.2	9.6	4	12	23
36-50	8,843	26.3%	14.0	9.9	4	13	24
51-64	7,767	23.1%	13.8	9.9	4	13	24
65-74	2,375	7.1%	13.9	9.9	4	12	24
75+	987	2.9%	13.5	10.0	4	12	24
Sex							
Female	13,141	41.0%	13.6	9.9	4	12	24
Male	18,877	59.0%	13.6	9.7	4	12	24
Race							
Unknown	6,760	21.1%	12.4	9.4	4	10	22
American Indian or Alaska Native	460	1.4%	13.9	9.6	4	13	24
Asian	934	2.9%	12.7	9.4	4	11	23
Black or African American	4,770	14.9%	12.5	9.6	3	10	22
Native Hawaiian or Other Pacific Islander	52	0.2%	12.1	9.0	3	11.5	20
White	19,042	59.5%	14.3	9.9	5	14	24
Ethnicity							
Not Hispanic	25,101	78.4%	13.9	9.8	4	13	24
Unknown	4,619	14.4%	12.3	9.5	3	10	22
Hispanic	2,298	7.2%	12.8	9.4	4	11	22
Year							
2015 Quarter 4	1,715	5.1%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,846	5.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,682	5.0%	N/A	N/A	N/A	N/A	N/A

**Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	2,115	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,216	6.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,392	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,355	7.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,401	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,505	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,475	7.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,321	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	2,378	7.1%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	2,277	6.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,265	3.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,158	3.4%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	1,249	3.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	1,256	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	35	0.1%	11.6	9.4	3	7.5	22
Midwest	8,757	26.1%	15.0	9.9	5	15	25
Missing	*****	<0.1%	6.5	5.8	3	4.5	10
Northeast	7,913	23.5%	13.5	9.8	4	12	24
Other	*****	<0.1%	9.6	10.5	1	3.5	23
South	9,321	27.7%	12.2	9.6	3	10	22
West	7,557	22.5%	13.7	9.6	4	13	24
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	3,357	10.0%	14.1	9.8	4	14	24
ADHD and Other Behavior Disorders	9,703	28.9%	14.1	9.9	4	13	24
Alcohol Use Disorders	7,059	21.0%	13.6	9.7	4	13	24

**Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	21,270	63.3%	14.0	9.8	4	13	24
Bipolar Disorders	19,103	56.8%	13.9	9.8	4	13	24
Depression	23,323	69.4%	13.9	9.8	4	13	24
Depressive Disorders	18,689	55.6%	13.9	9.8	4	13	24
Drug Use Disorders	11,873	35.3%	13.4	9.7	4	12	23
Opioid Use Disorder (OUD) 1	2,905	8.6%	12.6	9.8	3	10	23
OUD 2	2,542	7.6%	12.5	9.8	3	10	23
OUD 3	2,047	6.1%	12.2	9.8	3	10	22
OUD 4	406	1.2%	11.7	9.2	3	9.5	20
Personality Disorders	8,173	24.3%	14.0	9.9	4	13	24
Schizophrenia	27,575	82.1%	13.6	9.8	4	12	24
Schizophrenia and Other Psychotic Disorders	29,859	88.9%	13.7	9.8	4	12	24
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,724	17.0%	14.1	9.8	4	13	24
Atypical Antipsychotics	22,510	67.0%	14.9	9.8	5	15	25
Typical Antipsychotics	9,888	29.4%	14.9	9.9	5	15	25
Any Antipsychotic (Typical or Atypical)	25,390	75.6%	14.7	9.8	5	15	25
Antidepressants	17,151	51.0%	14.3	9.8	4	14	24
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	149.6	173.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	8.9	19.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.7	4.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.5	5.7	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	114.2	162.0	N/A	N/A	N/A	N/A	N/A

**Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	6.1	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.2	6.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable



**Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	33,606						
Number of unique patients	32,018						
Demographics	Mean	Standard Deviation					
Mean Age (years)	42.7	14.8					
Age (years)	Number	Percent					
12-18	1,666	5.0%	2.9	1.5	2	3.3	4
19-35	11,968	35.6%	3.0	1.6	2	3.5	4
36-50	8,843	26.3%	3.2	1.6	2	3.6	4
51-64	7,767	23.1%	3.3	1.6	2	3.6	4
65-74	2,375	7.1%	3.5	1.6	2	3.8	4
75+	987	2.9%	3.6	1.6	3	4.0	4
Sex							
Female	13,141	41.0%	3.2	1.6	2	3.6	4
Male	18,877	59.0%	3.2	1.6	2	3.6	4
Race							
Unknown	6,760	21.1%	3.0	1.6	2	3.3	4
American Indian or Alaska Native	460	1.4%	3.2	1.4	2	3.6	4
Asian	934	2.9%	3.0	1.6	2	3.5	4
Black or African American	4,770	14.9%	3.0	1.6	2	3.3	4
Native Hawaiian or Other Pacific Islander	52	0.2%	2.8	1.3	2	3.0	4
White	19,042	59.5%	3.3	1.6	2	3.8	4
Ethnicity							
Not Hispanic	25,101	78.4%	3.2	1.6	2	3.6	4
Unknown	4,619	14.4%	3.0	1.6	2	3.4	4
Hispanic	2,298	7.2%	3.0	1.6	2	3.3	4
Year							
2015 Quarter 4	1,715	5.1%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,846	5.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,682	5.0%	N/A	N/A	N/A	N/A	N/A

**Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,115	6.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,216	6.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,392	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,355	7.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,401	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,505	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,475	7.4%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,321	6.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	2,378	7.1%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	2,277	6.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,265	3.8%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,158	3.4%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	1,249	3.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	1,256	3.7%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	35	0.1%	2.9	1.6	1	3.1	4
Midwest	8,757	26.1%	3.5	1.6	3	3.9	4
Missing	*****	<0.1%	5.1	2.7	3	4.8	7
Northeast	7,913	23.5%	3.1	1.6	2	3.5	4
Other	*****	<0.1%	2.6	1.6	1	2.3	4
South	9,321	27.7%	3.0	1.6	2	3.3	4
West	7,557	22.5%	3.2	1.6	2	3.6	4
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.3	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	3,357	10.0%	3.3	1.4	2	3.7	4
ADHD and Other Behavior Disorders	9,703	28.9%	3.3	1.6	2	3.8	4
Alcohol Use Disorders	7,059	21.0%	3.3	1.5	2	3.7	4

**Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	21,270	63.3%	3.3	1.6	2	3.8	4
Bipolar Disorders	19,103	56.8%	3.3	1.6	2	3.7	4
Depression	23,323	69.4%	3.3	1.5	2	3.7	4
Depressive Disorders	18,689	55.6%	3.4	1.6	2	3.8	4
Drug Use Disorders	11,873	35.3%	3.3	1.5	2	3.6	4
Opioid Use Disorder (OUD) 1	2,905	8.6%	3.3	1.6	2	3.6	4
OUD 2	2,542	7.6%	3.3	1.6	2	3.6	4
OUD 3	2,047	6.1%	3.3	1.7	2	3.6	4
OUD 4	406	1.2%	3.1	1.4	2	3.3	4
Personality Disorders	8,173	24.3%	3.4	1.6	2	3.8	4
Schizophrenia	27,575	82.1%	3.2	1.6	2	3.6	4
Schizophrenia and Other Psychotic Disorders	29,859	88.9%	3.2	1.6	2	3.6	4
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,724	17.0%	3.2	1.5	2	3.6	4
Atypical Antipsychotics	22,510	67.0%	3.4	1.5	3	3.8	4
Typical Antipsychotics	9,888	29.4%	3.4	1.5	2	3.8	4
Any Antipsychotic (Typical or Atypical)	25,390	75.6%	3.4	1.5	2	3.8	4
Antidepressants	17,151	51.0%	3.3	1.5	2	3.8	4
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	149.6	173.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	8.9	19.7	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.7	4.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	3.5	5.7	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	114.2	162.0	N/A	N/A	N/A	N/A	N/A

**Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	6.1	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.5	3.9	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	8.2	6.1	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5)**

Characteristic <sup>1</sup>	Number	
Number of episodes	35,106	
Number of unique patients	31,733	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.6	14.6
Age (years)	Number	Percent
12-18	1,216	3.5%
19-35	11,085	31.6%
36-50	9,290	26.5%
51-64	9,601	27.3%
65-74	3,069	8.7%
75+	845	2.4%
Sex		
Female	12,685	40.0%
Male	19,048	60.0%
Race		
Unknown	6,120	19.3%
American Indian or Alaska Native	385	1.2%
Asian	955	3.0%
Black or African American	4,386	13.8%
Native Hawaiian or Other Pacific Islander	60	0.2%
White	19,827	62.5%
Ethnicity		
Not Hispanic	25,454	80.2%
Unknown	4,048	12.8%
Hispanic	2,231	7.0%
Year		
2015 Quarter 4	1,960	5.6%
2016 Quarter 1	2,962	8.4%
2016 Quarter 2	2,576	7.3%
2016 Quarter 3	2,566	7.3%
2016 Quarter 4	2,501	7.1%
2017 Quarter 1	2,990	8.5%
2017 Quarter 2	2,735	7.8%
2017 Quarter 3	2,550	7.3%
2017 Quarter 4	2,620	7.5%
2018 Quarter 1	2,865	8.2%
2018 Quarter 2	2,575	7.3%
2018 Quarter 3	1,472	4.2%
2018 Quarter 4	1,417	4.0%
2019 Quarter 1	1,642	4.7%
2019 Quarter 2	1,643	4.7%

**Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5)**

2019 Quarter 3	32	0.1%
2019 Quarter 4	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	0.1%
Midwest	9,518	27.1%
Missing	*****	<0.1%
Northeast	9,117	26.0%
Other	52	0.1%
South	8,906	25.4%
West	7,478	21.3%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3
ADHD Only Subset	2,454	7.0%
ADHD and Other Behavior Disorders	7,766	22.1%
Alcohol Use Disorders	5,556	15.8%
Anxiety Disorders	18,576	52.9%
Bipolar Disorders	17,158	48.9%
Depression	21,382	60.9%
Depressive Disorders	16,593	47.3%
Drug Use Disorders	9,091	25.9%
Opioid Use Disorder (OUD) 1	1,895	5.4%
OUD 2	1,593	4.5%
OUD 3	1,291	3.7%
OUD 4	222	0.6%
Personality Disorders	6,609	18.8%
Schizophrenia	29,237	83.3%
Schizophrenia and Other Psychotic Disorders	30,803	87.7%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	5,243	14.9%
Atypical Antipsychotics	17,567	50.0%
Typical Antipsychotics	8,143	23.2%
Any Antipsychotic (Typical or Atypical)	20,939	59.6%
Antidepressants	16,765	47.8%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	143.5	169.0
Mean number of emergency room encounters	6.2	13.5
Mean number of inpatient hospital encounters	2.2	4.0
Mean number of non-acute institutional encounters	2.9	5.0
Mean number of other ambulatory encounters	115.4	162.2

**Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.8	3.6
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.5	5.7

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	10.8	15.0	7	7	8
19-35	11,085	31.6%	11.4	13.8	7	7	10
36-50	9,290	26.5%	11.4	12.7	7	7	11
51-64	9,601	27.3%	11.7	12.9	7	7	13
65-74	3,069	8.7%	11.1	11.6	7	7	12
75+	845	2.4%	10.7	11.3	7	7	10
Sex							
Female	12,685	40.0%	11.2	12.8	7	7	11
Male	19,048	60.0%	11.6	13.3	7	7	12
Race							
Unknown	6,120	19.3%	12.2	14.7	7	7	13
American Indian or Alaska Native	385	1.2%	11.0	12.7	7	7	10
Asian	955	3.0%	12.3	14.4	7	7	14
Black or African American	4,386	13.8%	11.8	13.7	7	7	13
Native Hawaiian or Other Pacific Islander	60	0.2%	12.7	13.9	7	7	14
White	19,827	62.5%	11.1	12.4	7	7	10
Ethnicity							
Not Hispanic	25,454	80.2%	11.3	12.7	7	7	11
Unknown	4,048	12.8%	12.2	14.6	7	7	13
Hispanic	2,231	7.0%	12.1	14.6	7	7	13
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A



**Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	14.9	15.9	7	7	23
Midwest	9,518	27.1%	10.7	11.3	7	7	9
Missing	*****	<0.1%	16.5	11.3	8	14	27
Northeast	9,117	26.0%	11.9	14.0	7	7	13
Other	52	0.1%	19.4	24.2	7	9	28
South	8,906	25.4%	12.1	13.9	7	7	13
West	7,478	21.3%	11.2	13.0	7	7	10
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	10.0	11.8	7	7	8
ADHD and Other Behavior Disorders	7,766	22.1%	9.8	11.4	7	7	8
Alcohol Use Disorders	5,556	15.8%	10.0	11.1	7	7	8

**Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Gaps between all ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	10.3	11.4	7	7	9
Bipolar Disorders	17,158	48.9%	10.5	11.8	7	7	9
Depression	21,382	60.9%	10.5	11.7	7	7	9
Depressive Disorders	16,593	47.3%	10.3	11.4	7	7	9
Drug Use Disorders	9,091	25.9%	10.1	11.4	7	7	8
Opioid Use Disorder (OUD) 1	1,895	5.4%	10.0	10.9	7	7	9
OUD 2	1,593	4.5%	9.8	10.5	7	7	9
OUD 3	1,291	3.7%	9.9	10.9	6	7	9
OUD 4	222	0.6%	10.6	12.0	7	7	9
Personality Disorders	6,609	18.8%	9.8	10.9	7	7	8
Schizophrenia	29,237	83.3%	11.4	12.8	7	7	11
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	11.3	12.7	7	7	11
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	10.6	12.7	7	7	8
Atypical Antipsychotics	17,567	50.0%	9.4	10.6	7	7	8
Typical Antipsychotics	8,143	23.2%	9.5	11.2	7	7	8
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	9.7	11.1	7	7	8
Antidepressants	16,765	47.8%	10.7	12.0	7	7	9
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Gaps between all ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	15.8	9.2	6	18	25
19-35	11,085	31.6%	14.8	9.2	6	14	24
36-50	9,290	26.5%	14.9	9.2	6	13	24
51-64	9,601	27.3%	14.5	9.1	6	12	24
65-74	3,069	8.7%	15.3	9.2	7	13	25
75+	845	2.4%	16.0	9.2	7	15	25
Sex							
Female	12,685	40.0%	15.1	9.2	6	14	24
Male	19,048	60.0%	14.6	9.2	6	13	24
Race							
Unknown	6,120	19.3%	13.9	9.1	6	12	23
American Indian or Alaska Native	385	1.2%	15.5	9.0	7	16	25
Asian	955	3.0%	13.7	9.0	6	11	23
Black or African American	4,386	13.8%	14.4	9.0	6	12	24
Native Hawaiian or Other Pacific Islander	60	0.2%	13.3	8.0	6	12	21
White	19,827	62.5%	15.2	9.3	6	14	25
Ethnicity							
Not Hispanic	25,454	80.2%	15.1	9.2	6	14	24
Unknown	4,048	12.8%	13.8	9.2	6	11	24
Hispanic	2,231	7.0%	13.9	9.0	6	12	23
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A

**Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	11.2	8.7	6	7	21
Midwest	9,518	27.1%	15.9	9.3	7	16	25
Missing	*****	<0.1%	10.0	7.1	5	10	15
Northeast	9,117	26.0%	14.3	9.2	6	12	24
Other	52	0.1%	8.3	8.1	4	6	7
South	8,906	25.4%	13.9	9.0	6	11	23
West	7,478	21.3%	15.2	9.1	6	15	24
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	17.2	9.1	8	20	25
ADHD and Other Behavior Disorders	7,766	22.1%	17.4	9.0	8	20	25
Alcohol Use Disorders	5,556	15.8%	17.0	8.8	8	19	25

**Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Number of ANC Screenings		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	16.6	9.0	7	18	25
Bipolar Disorders	17,158	48.9%	16.3	9.1	7	18	25
Depression	21,382	60.9%	16.2	9.1	7	17	25
Depressive Disorders	16,593	47.3%	16.5	9.0	7	18	25
Drug Use Disorders	9,091	25.9%	16.9	8.8	8	19	25
Opioid Use Disorder (OUD) 1	1,895	5.4%	17.2	8.6	9	19	25
OUD 2	1,593	4.5%	17.5	8.4	10	19	25
OUD 3	1,291	3.7%	17.2	8.6	9	19	25
OUD 4	222	0.6%	16.1	8.7	8	17	24
Personality Disorders	6,609	18.8%	17.5	9.0	8	20	25
Schizophrenia	29,237	83.3%	14.9	9.1	6	13	24
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	15.1	9.1	6	14	24
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	16.1	9.2	7	18	25
Atypical Antipsychotics	17,567	50.0%	18.3	8.8	9	22	26
Typical Antipsychotics	8,143	23.2%	18.0	9.0	9	21	26
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	17.7	9.0	8	21	25
Antidepressants	16,765	47.8%	15.9	9.2	7	17	25
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	35,106						
Number of unique patients	31,733						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.6	14.6					
Age (years)	Number	Percent					
12-18	1,216	3.5%	2.6	1.5	1	3.0	4
19-35	11,085	31.6%	2.4	1.5	1	2.3	4
36-50	9,290	26.5%	2.4	1.5	1	2.1	4
51-64	9,601	27.3%	2.4	1.5	1	2.0	4
65-74	3,069	8.7%	2.5	1.5	1	2.1	4
75+	845	2.4%	2.6	1.5	1	2.5	4
Sex							
Female	12,685	40.0%	2.5	1.5	1	2.3	4
Male	19,048	60.0%	2.4	1.5	1	2.1	4
Race							
Unknown	6,120	19.3%	2.3	1.5	1	2.0	4
American Indian or Alaska Native	385	1.2%	2.6	1.5	1	2.6	4
Asian	955	3.0%	2.3	1.5	1	1.8	4
Black or African American	4,386	13.8%	2.4	1.5	1	2.0	4
Native Hawaiian or Other Pacific Islander	60	0.2%	2.2	1.3	1	2.0	3
White	19,827	62.5%	2.5	1.5	1	2.3	4
Ethnicity							
Not Hispanic	25,454	80.2%	2.5	1.5	1	2.3	4
Unknown	4,048	12.8%	2.3	1.5	1	1.8	4
Hispanic	2,231	7.0%	2.3	1.5	1	2.0	4
Year							
2015 Quarter 4	1,960	5.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,962	8.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	2,576	7.3%	N/A	N/A	N/A	N/A	N/A



**Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
2016 Quarter 3	2,566	7.3%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	2,501	7.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,990	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,735	7.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	2,550	7.3%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,620	7.5%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	2,865	8.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	2,575	7.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,472	4.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,417	4.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	1,642	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	1,643	4.7%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	32	0.1%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	1.8	1.4	1	1.2	3
Midwest	9,518	27.1%	2.6	1.5	1	2.6	4
Missing	*****	<0.1%	1.6	1.2	1	1.6	2
Northeast	9,117	26.0%	2.4	1.5	1	2.0	4
Other	52	0.1%	1.4	1.3	1	1.0	1
South	8,906	25.4%	2.3	1.5	1	1.8	4
West	7,478	21.3%	2.5	1.5	1	2.5	4
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.2	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	2,454	7.0%	2.8	1.5	1	3.3	4
ADHD and Other Behavior Disorders	7,766	22.1%	2.9	1.5	1	3.3	4
Alcohol Use Disorders	5,556	15.8%	2.8	1.4	1	3.1	4

**Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	18,576	52.9%	2.7	1.5	1	3.0	4
Bipolar Disorders	17,158	48.9%	2.7	1.5	1	3.0	4
Depression	21,382	60.9%	2.7	1.5	1	2.8	4
Depressive Disorders	16,593	47.3%	2.7	1.5	1	3.0	4
Drug Use Disorders	9,091	25.9%	2.8	1.5	1	3.1	4
Opioid Use Disorder (OUD) 1	1,895	5.4%	2.8	1.4	1	3.1	4
OUD 2	1,593	4.5%	2.9	1.4	2	3.1	4
OUD 3	1,291	3.7%	2.8	1.4	1	3.1	4
OUD 4	222	0.6%	2.7	1.4	1	2.8	4
Personality Disorders	6,609	18.8%	2.9	1.5	1	3.3	4
Schizophrenia	29,237	83.3%	2.5	1.5	1	2.1	4
Schizophrenia and Other Psychotic Disorders	30,803	87.7%	2.5	1.5	1	2.3	4
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	5,243	14.9%	2.7	1.5	1	3.0	4
Atypical Antipsychotics	17,567	50.0%	3.0	1.5	1	3.6	4
Typical Antipsychotics	8,143	23.2%	3.0	1.5	1	3.5	4
Any Antipsychotic (Typical or Atypical)	20,939	59.6%	2.9	1.5	1	3.5	4
Antidepressants	16,765	47.8%	2.6	1.5	1	2.8	4
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	143.5	169.0	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.2	13.5	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.2	4.0	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	5.0	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	115.4	162.2	N/A	N/A	N/A	N/A	N/A

**Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.5	5.7	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6)**

Characteristic <sup>1</sup>	Number	
Number of episodes	22,697	
Number of unique patients	22,011	
Demographics	Mean	Standard Deviation
Mean Age (years)	44.7	14.4
Age (years)	Number	Percent
12-18	703	3.1%
19-35	7,060	31.1%
36-50	6,220	27.4%
51-64	6,310	27.8%
65-74	1,913	8.4%
75+	491	2.2%
Sex		
Female	8,783	39.9%
Male	13,228	60.1%
Race		
Unknown	3,932	17.9%
American Indian or Alaska Native	274	1.2%
Asian	686	3.1%
Black or African American	2,980	13.5%
Native Hawaiian or Other Pacific Islander	39	0.2%
White	14,100	64.1%
Ethnicity		
Not Hispanic	17,983	81.7%
Unknown	2,510	11.4%
Hispanic	1,518	6.9%
Year		
2015 Quarter 4	1,519	6.7%
2016 Quarter 1	2,263	10.0%
2016 Quarter 2	1,997	8.8%
2016 Quarter 3	2,021	8.9%
2016 Quarter 4	1,937	8.5%
2017 Quarter 1	2,178	9.6%
2017 Quarter 2	2,053	9.0%
2017 Quarter 3	1,994	8.8%
2017 Quarter 4	2,048	9.0%
2018 Quarter 1	1,295	5.7%
2018 Quarter 2	1,182	5.2%
2018 Quarter 3	1,102	4.9%
2018 Quarter 4	1,108	4.9%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%

**Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6)**

2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	0.1%
Midwest	6,168	27.2%
Missing	*****	<0.1%
Northeast	5,960	26.3%
Other	*****	<0.1%
South	5,589	24.6%
West	4,961	21.9%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3
ADHD Only Subset	1,480	6.5%
ADHD and Other Behavior Disorders	4,886	21.5%
Alcohol Use Disorders	3,507	15.5%
Anxiety Disorders	11,723	51.6%
Bipolar Disorders	10,862	47.9%
Depression	13,651	60.1%
Depressive Disorders	10,542	46.4%
Drug Use Disorders	5,655	24.9%
Opioid Use Disorder (OUD) 1	1,115	4.9%
OUD 2	940	4.1%
OUD 3	740	3.3%
OUD 4	113	0.5%
Personality Disorders	4,229	18.6%
Schizophrenia	18,970	83.6%
Schizophrenia and Other Psychotic Disorders	19,930	87.8%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	3,481	15.3%
Atypical Antipsychotics	11,640	51.3%
Typical Antipsychotics	5,433	23.9%
Any Antipsychotic (Typical or Atypical)	13,843	61.0%
Antidepressants	10,913	48.1%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	141.3	166.2
Mean number of emergency room encounters	6.0	13.6
Mean number of inpatient hospital encounters	2.1	3.8
Mean number of non-acute institutional encounters	2.8	4.8
Mean number of other ambulatory encounters	107.9	149.9

**Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.8	3.5
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.6	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	15.3	16.6	7	13	15
19-35	7,060	31.1%	15.4	14.7	7	14	17
36-50	6,220	27.4%	15.0	13.4	7	14	17
51-64	6,310	27.8%	14.3	13.2	7	11	17
65-74	1,913	8.4%	13.1	12.3	7	8	14
75+	491	2.2%	12.9	11.9	7	8	14
Sex							
Female	8,783	39.9%	14.4	13.5	7	12	16
Male	13,228	60.1%	14.9	13.8	7	13	17
Race							
Unknown	3,932	17.9%	16.1	15.6	7	14	20
American Indian or Alaska Native	274	1.2%	15.0	14.6	7	13	16
Asian	686	3.1%	16.1	14.3	7	14	21
Black or African American	2,980	13.5%	14.9	14.4	7	13	17
Native Hawaiian or Other Pacific Islander	39	0.2%	17.3	17.9	7	14	21
White	14,100	64.1%	14.3	13.0	7	13	15
Ethnicity							
Not Hispanic	17,983	81.7%	14.4	13.3	7	13	16
Unknown	2,510	11.4%	16.5	15.5	7	14	21
Hispanic	1,518	6.9%	15.7	15.7	7	14	18
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	19.4	15.8	9	14	28
Midwest	6,168	27.2%	13.7	11.8	7	12	15
Missing	*****	<0.1%	11.3	11.8	7	7.5	9
Northeast	5,960	26.3%	15.2	14.5	7	13	18
Other	*****	<0.1%	16.5	9.5	14	14	15
South	5,589	24.6%	15.2	14.5	7	13	19
West	4,961	21.9%	15.0	14.1	7	13	16
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	13.5	12.8	7	12	14
ADHD and Other Behavior Disorders	4,886	21.5%	12.7	12.4	7	9	14
Alcohol Use Disorders	3,507	15.5%	13.3	12.0	7	11	14



**Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	13.3	12.3	7	11	14
Bipolar Disorders	10,862	47.9%	13.5	12.5	7	11	15
Depression	13,651	60.1%	13.6	12.5	7	11	15
Depressive Disorders	10,542	46.4%	13.3	12.3	7	10	14
Drug Use Disorders	5,655	24.9%	13.3	12.2	7	11	14
Opioid Use Disorder (OUD) 1	1,115	4.9%	13.3	11.8	7	11	14
OUD 2	940	4.1%	13.1	11.7	7	11	14
OUD 3	740	3.3%	13.0	11.9	7	10	14
OUD 4	113	0.5%	14.6	13.9	7	13	16
Personality Disorders	4,229	18.6%	12.8	12.0	7	10	14
Schizophrenia	18,970	83.6%	14.5	13.3	7	13	16
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	14.4	13.3	7	13	16
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	14.0	13.4	7	13	15
Atypical Antipsychotics	11,640	51.3%	12.9	11.8	7	12	14
Typical Antipsychotics	5,433	23.9%	12.8	12.3	7	11	14
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	13.1	12.1	7	12	14
Antidepressants	10,913	48.1%	14.0	12.9	7	12	15
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A

**Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	10.9	6.1	6	11	14
19-35	7,060	31.1%	10.7	6.1	6	10	14
36-50	6,220	27.4%	11.1	6.2	6	10	14
51-64	6,310	27.8%	11.6	7.0	6	9	15
65-74	1,913	8.4%	12.8	7.8	7	12	17
75+	491	2.2%	13.0	7.4	7	12	17
Sex							
Female	8,783	39.9%	11.6	6.8	6	10	15
Male	13,228	60.1%	11.1	6.5	6	10	14
Race							
Unknown	3,932	17.9%	10.2	6.1	6	9	14
American Indian or Alaska Native	274	1.2%	11.1	6.3	6	10	14
Asian	686	3.1%	10.3	5.9	6	8	13
Black or African American	2,980	13.5%	11.2	6.7	6	10	14
Native Hawaiian or Other Pacific Islander	39	0.2%	9.4	6.1	6	7.5	13
White	14,100	64.1%	11.7	6.7	6	11	15
Ethnicity							
Not Hispanic	17,983	81.7%	11.6	6.7	6	10	15
Unknown	2,510	11.4%	10.0	5.8	6	8	13
Hispanic	1,518	6.9%	10.6	6.3	6	9	14
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	8.3	5.3	6	7	13
Midwest	6,168	27.2%	12.2	6.8	7	12	15
Missing	*****	<0.1%	15.0	12.7	6	15	24
Northeast	5,960	26.3%	10.9	6.6	6	9	14
Other	*****	<0.1%	10.0	5.3	4	12	14
South	5,589	24.6%	10.9	6.7	6	9	14
West	4,961	21.9%	11.1	6.2	6	10	14
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	12.4	6.4	7	13	16
ADHD and Other Behavior Disorders	4,886	21.5%	13.2	7.0	8	13	17
Alcohol Use Disorders	3,507	15.5%	12.7	6.7	7	12	16

**Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	12.6	6.9	7	12	16
Bipolar Disorders	10,862	47.9%	12.4	6.9	7	12	16
Depression	13,651	60.1%	12.3	6.9	7	12	16
Depressive Disorders	10,542	46.4%	12.6	7.0	7	12	16
Drug Use Disorders	5,655	24.9%	12.6	6.7	7	12	16
Opioid Use Disorder (OUD) 1	1,115	4.9%	12.7	6.5	8	12	16
OUD 2	940	4.1%	12.8	6.4	8	12	16
OUD 3	740	3.3%	13.0	6.7	8	12	17
OUD 4	113	0.5%	11.4	5.6	6	12	15
Personality Disorders	4,229	18.6%	13.2	7.0	8	13	17
Schizophrenia	18,970	83.6%	11.5	6.6	6	10	15
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	11.5	6.7	6	11	15
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	11.9	6.6	7	12	15
Atypical Antipsychotics	11,640	51.3%	13.0	6.5	8	13	16
Typical Antipsychotics	5,433	23.9%	13.1	6.8	8	13	16
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	12.8	6.6	7	13	16
Antidepressants	10,913	48.1%	12.0	6.8	7	11	15
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A

**Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	22,697						
Number of unique patients	22,011						
Demographics	Mean	Standard Deviation					
Mean Age (years)	44.7	14.4					
Age (years)	Number	Percent					
12-18	703	3.1%	1.8	1.0	1	1.8	2
19-35	7,060	31.1%	1.8	1.0	1	1.6	2
36-50	6,220	27.4%	1.8	1.0	1	1.6	2
51-64	6,310	27.8%	1.9	1.2	1	1.5	2
65-74	1,913	8.4%	2.1	1.3	1	2.0	3
75+	491	2.2%	2.1	1.2	1	2.0	3
Sex							
Female	8,783	39.9%	1.9	1.1	1	1.6	2
Male	13,228	60.1%	1.8	1.1	1	1.6	2
Race							
Unknown	3,932	17.9%	1.7	1.0	1	1.5	2
American Indian or Alaska Native	274	1.2%	1.8	1.0	1	1.6	2
Asian	686	3.1%	1.7	1.0	1	1.3	2
Black or African American	2,980	13.5%	1.8	1.1	1	1.6	2
Native Hawaiian or Other Pacific Islander	39	0.2%	1.6	1.0	1	1.2	2
White	14,100	64.1%	1.9	1.1	1	1.8	2
Ethnicity							
Not Hispanic	17,983	81.7%	1.9	1.1	1	1.6	2
Unknown	2,510	11.4%	1.6	1.0	1	1.3	2
Hispanic	1,518	6.9%	1.7	1.0	1	1.5	2
Year							
2015 Quarter 4	1,519	6.7%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	2,263	10.0%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,997	8.8%	N/A	N/A	N/A	N/A	N/A

**Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	2,021	8.9%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,937	8.5%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	2,178	9.6%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	2,053	9.0%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	1,994	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	2,048	9.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	1,295	5.7%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	1,182	5.2%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	1,102	4.9%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	1,108	4.9%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	0.1%	1.4	0.9	1	1.2	2
Midwest	6,168	27.2%	2.0	1.1	1	2.0	2
Missing	*****	<0.1%	2.5	2.1	1	2.5	4
Northeast	5,960	26.3%	1.8	1.1	1	1.5	2
Other	*****	<0.1%	1.6	0.9	1	2.0	2
South	5,589	24.6%	1.8	1.1	1	1.5	2
West	4,961	21.9%	1.8	1.0	1	1.6	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.1	3.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,480	6.5%	2.0	1.1	1	2.1	3
ADHD and Other Behavior Disorders	4,886	21.5%	2.2	1.2	1	2.1	3
Alcohol Use Disorders	3,507	15.5%	2.1	1.1	1	2.0	3



**Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	11,723	51.6%	2.1	1.1	1	2.0	3
Bipolar Disorders	10,862	47.9%	2.1	1.1	1	2.0	3
Depression	13,651	60.1%	2.0	1.1	1	2.0	3
Depressive Disorders	10,542	46.4%	2.1	1.2	1	2.0	3
Drug Use Disorders	5,655	24.9%	2.1	1.1	1	2.0	3
Opioid Use Disorder (OUD) 1	1,115	4.9%	2.1	1.1	1	2.0	3
OUD 2	940	4.1%	2.1	1.0	1	2.0	3
OUD 3	740	3.3%	2.1	1.1	1	2.0	3
OUD 4	113	0.5%	1.9	0.9	1	2.0	2
Personality Disorders	4,229	18.6%	2.2	1.1	1	2.1	3
Schizophrenia	18,970	83.6%	1.9	1.1	1	1.6	2
Schizophrenia and Other Psychotic Disorders	19,930	87.8%	1.9	1.1	1	1.8	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	3,481	15.3%	2.0	1.1	1	2.0	2
Atypical Antipsychotics	11,640	51.3%	2.1	1.1	1	2.1	3
Typical Antipsychotics	5,433	23.9%	2.2	1.1	1	2.1	3
Any Antipsychotic (Typical or Atypical)	13,843	61.0%	2.1	1.1	1	2.1	3
Antidepressants	10,913	48.1%	2.0	1.1	1	1.8	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	141.3	166.2	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	6.0	13.6	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	2.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.8	4.8	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	107.9	149.9	N/A	N/A	N/A	N/A	N/A

**Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.8	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.1	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.6	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7)**

Characteristic <sup>1</sup>	Number	
Number of episodes	10,341	
Number of unique patients	10,341	
Demographics	Mean	Standard Deviation
Mean Age (years)	45.1	14.0
Age (years)	Number	Percent
12-18	220	2.1%
19-35	3,093	29.9%
36-50	3,032	29.3%
51-64	3,017	29.2%
65-74	805	7.8%
75+	174	1.7%
Sex		
Female	4,098	39.6%
Male	6,243	60.4%
Race		
Unknown	1,485	14.4%
American Indian or Alaska Native	*****	*****
Asian	326	3.2%
Black or African American	1,347	13.0%
Native Hawaiian or Other Pacific Islander	*****	*****
White	7,032	68.0%
Ethnicity		
Not Hispanic	8,813	85.2%
Unknown	883	8.5%
Hispanic	645	6.2%
Year		
2015 Quarter 4	1,093	10.6%
2016 Quarter 1	1,600	15.5%
2016 Quarter 2	1,401	13.5%
2016 Quarter 3	1,389	13.4%
2016 Quarter 4	1,333	12.9%
2017 Quarter 1	919	8.9%
2017 Quarter 2	907	8.8%
2017 Quarter 3	842	8.1%
2017 Quarter 4	857	8.3%
2018 Quarter 1	0	0.0%
2018 Quarter 2	0	0.0%
2018 Quarter 3	0	0.0%
2018 Quarter 4	0	0.0%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%

**Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7)**

2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%
<b>Geographic Census Bureau Region</b>		
Invalid	*****	*****
Midwest	2,817	27.2%
Missing	*****	*****
Northeast	2,807	27.1%
Other	*****	*****
South	2,463	23.8%
West	*****	*****
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.0	3.2
ADHD Only Subset	610	5.9%
ADHD and Other Behavior Disorders	2,173	21.0%
Alcohol Use Disorders	1,613	15.6%
Anxiety Disorders	5,287	51.1%
Bipolar Disorders	4,986	48.2%
Depression	6,272	60.7%
Depressive Disorders	4,843	46.8%
Drug Use Disorders	2,491	24.1%
Opioid Use Disorder (OUD) 1	491	4.7%
OUD 2	406	3.9%
OUD 3	325	3.1%
OUD 4	40	0.4%
Personality Disorders	1,903	18.4%
Schizophrenia	8,769	84.8%
Schizophrenia and Other Psychotic Disorders	9,137	88.4%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	1,564	15.1%
Atypical Antipsychotics	5,456	52.8%
Typical Antipsychotics	2,541	24.6%
Any Antipsychotic (Typical or Atypical)	6,451	62.4%
Antidepressants	5,072	49.0%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	Mean	Standard Deviation
Mean number of emergency room encounters	140.3	159.1
Mean number of inpatient hospital encounters	5.9	13.9
Mean number of non-acute institutional encounters	1.9	3.5
Mean number of other ambulatory encounters	2.9	4.6
	98.8	133.4

**Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7)**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation
Mean number of unique drug classes	5.9	3.5
Mean number of generics	6.2	3.8
Mean number of filled prescriptions	7.7	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	10,341						
Number of unique patients	10,341						
Demographics	Mean	Standard Deviation					
Mean Age (years)	45.1	14.0					
Age (years)	Number	Percent					
12-18	220	2.1%	25.6	29.6	13	22	29
19-35	3,093	29.9%	22.6	21.7	10	23	28
36-50	3,032	29.3%	21.0	18.9	8	20	28
51-64	3,017	29.2%	18.7	17.3	7	14	28
65-74	805	7.8%	16.5	16.5	7	12	27
75+	174	1.7%	15.5	15.9	7	10	24
Sex							
Female	4,098	39.6%	19.4	18.5	7	15	28
Male	6,243	60.4%	20.8	19.8	7	19	28
Race							
Unknown	1,485	14.4%	23.4	24.6	10	23	28
American Indian or Alaska Native	*****	*****	21.3	17.3	8	22	28
Asian	326	3.2%	22.2	21.3	10	22	28
Black or African American	1,347	13.0%	20.0	19.5	7	15	28
Native Hawaiian or Other Pacific Islander	*****	*****	27.8	31.8	14	23	28
White	7,032	68.0%	19.6	18.0	7	15	28
Ethnicity							
Not Hispanic	8,813	85.2%	19.8	18.4	7	16	28
Unknown	883	8.5%	23.9	25.5	11	24	29
Hispanic	645	6.2%	22.9	23.3	10	21	28
Year							
2015 Quarter 4	1,093	10.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,600	15.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,401	13.5%	N/A	N/A	N/A	N/A	N/A

**Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	1,389	13.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,333	12.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	919	8.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	907	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	842	8.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	857	8.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	28.0	8.4	28	30	31
Midwest	2,817	27.2%	18.9	15.5	7	15	28
Missing	*****	*****	11.0	10.6	7	7	10
Northeast	2,807	27.1%	20.6	21.3	7	17	28
Other	*****	*****	27.0	11.8	24	29	35
South	2,463	23.8%	20.1	19.0	7	16	28
West	*****	*****	21.7	21.5	8	20	28
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.0	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	610	5.9%	20.0	19.5	8	15	28
ADHD and Other Behavior Disorders	2,173	21.0%	18.1	18.3	7	14	28
Alcohol Use Disorders	1,613	15.6%	19.0	16.9	7	15	28

**Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	5,287	51.1%	18.6	17.1	7	14	28
Bipolar Disorders	4,986	48.2%	18.6	17.5	7	14	28
Depression	6,272	60.7%	18.8	17.4	7	14	28
Depressive Disorders	4,843	46.8%	18.2	17.1	7	14	28
Drug Use Disorders	2,491	24.1%	19.2	18.2	7	14	28
Opioid Use Disorder (OUD) 1	491	4.7%	18.4	15.7	7	14	28
OUD 2	406	3.9%	18.5	15.7	7	14	28
OUD 3	325	3.1%	17.9	15.7	7	14	28
OUD 4	40	0.4%	21.2	18.6	8	20	28
Personality Disorders	1,903	18.4%	17.8	16.6	7	14	28
Schizophrenia	8,769	84.8%	19.9	18.6	7	16	28
Schizophrenia and Other Psychotic Disorders	9,137	88.4%	19.8	18.6	7	16	28
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,564	15.1%	20.4	20.0	7	16	28
Atypical Antipsychotics	5,456	52.8%	19.4	18.1	7	15	28
Typical Antipsychotics	2,541	24.6%	18.7	18.5	7	14	28
Any Antipsychotic (Typical or Atypical)	6,451	62.4%	19.4	18.3	7	15	28
Antidepressants	5,072	49.0%	19.5	18.6	7	15	28
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	140.3	159.1	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.9	13.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	98.8	133.4	N/A	N/A	N/A	N/A	N/A



**Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

Gaps between all ANC Screenings							
Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.2	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.7	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	10,341						
Number of unique patients	10,341						
Demographics	Mean	Standard Deviation					
Mean Age (years)	45.1	14.0					
Age (years)	Number	Percent					
12-18	220	2.1%	13.2	7.4	9	13	16
19-35	3,093	29.9%	15.1	8.2	12	13	17
36-50	3,032	29.3%	16.3	9.0	12	14	18
51-64	3,017	29.2%	18.4	11.3	13	15	20
65-74	805	7.8%	21.1	14.1	13	16	25
75+	174	1.7%	22.4	14.3	13	17	28
Sex							
Female	4,098	39.6%	17.8	10.9	12	14	19
Male	6,243	60.4%	16.5	9.8	12	14	18
Race							
Unknown	1,485	14.4%	14.6	8.4	11	13	16
American Indian or Alaska Native	*****	*****	16.1	9.6	12	14	16
Asian	326	3.2%	15.4	7.5	12	14	17
Black or African American	1,347	13.0%	17.2	10.6	12	14	18
Native Hawaiian or Other Pacific Islander	*****	*****	12.1	4.8	10	12	15
White	7,032	68.0%	17.6	10.6	12	14	19
Ethnicity							
Not Hispanic	8,813	85.2%	17.4	10.5	12	14	19
Unknown	883	8.5%	14.2	8.4	11	13	16
Hispanic	645	6.2%	14.9	8.2	11	14	17
Year							
2015 Quarter 4	1,093	10.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,600	15.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,401	13.5%	N/A	N/A	N/A	N/A	N/A

**Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	1,389	13.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,333	12.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	919	8.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	907	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	842	8.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	857	8.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	12.0	.	12	12	12
Midwest	2,817	27.2%	18.2	10.3	13	15	20
Missing	*****	*****	32.0	.	32	32	32
Northeast	2,807	27.1%	16.6	11.0	12	14	18
Other	*****	*****	12.5	2.1	11	12.5	14
South	2,463	23.8%	17.1	10.5	12	14	18
West	*****	*****	15.8	8.7	12	14	17
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.0	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	610	5.9%	17.2	9.5	12	15	20
ADHD and Other Behavior Disorders	2,173	21.0%	19.1	11.6	13	15	22
Alcohol Use Disorders	1,613	15.6%	18.1	10.0	13	15	20

**Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Anxiety Disorders	5,287	51.1%	18.6	11.2	13	15	21
Bipolar Disorders	4,986	48.2%	18.5	11.1	13	15	21
Depression	6,272	60.7%	18.4	11.2	13	15	20
Depressive Disorders	4,843	46.8%	19.0	11.7	13	15	21
Drug Use Disorders	2,491	24.1%	17.9	10.7	13	15	20
Opioid Use Disorder (OUD) 1	491	4.7%	18.8	10.6	13	15	21
OUD 2	406	3.9%	18.7	10.1	13	15	21
OUD 3	325	3.1%	19.3	11.0	13	16	22
OUD 4	40	0.4%	16.2	7.9	11	14	19
Personality Disorders	1,903	18.4%	19.5	11.5	13	16	22
Schizophrenia	8,769	84.8%	17.3	10.3	12	14	19
Schizophrenia and Other Psychotic Disorders	9,137	88.4%	17.4	10.4	12	14	19
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,564	15.1%	16.8	10.0	12	14	18
Atypical Antipsychotics	5,456	52.8%	17.7	10.1	13	15	20
Typical Antipsychotics	2,541	24.6%	18.4	11.1	13	15	21
Any Antipsychotic (Typical or Atypical)	6,451	62.4%	17.8	10.3	13	15	19
Antidepressants	5,072	49.0%	17.6	10.8	12	15	19
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	140.3	159.1	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.9	13.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	98.8	133.4	N/A	N/A	N/A	N/A	N/A

**Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Number of ANC Screenings						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.2	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.7	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	10,341						
Number of unique patients	10,341						
Demographics	Mean	Standard Deviation					
Mean Age (years)	45.1	14.0					
Age (years)	Number	Percent					
12-18	220	2.1%	1.1	0.6	1	1.1	1
19-35	3,093	29.9%	1.2	0.7	1	1.1	1
36-50	3,032	29.3%	1.3	0.7	1	1.2	1
51-64	3,017	29.2%	1.5	0.9	1	1.2	2
65-74	805	7.8%	1.7	1.2	1	1.3	2
75+	174	1.7%	1.8	1.2	1	1.4	2
Sex							
Female	4,098	39.6%	1.5	0.9	1	1.2	2
Male	6,243	60.4%	1.4	0.8	1	1.2	1
Race							
Unknown	1,485	14.4%	1.2	0.7	1	1.1	1
American Indian or Alaska Native	*****	*****	1.3	0.8	1	1.2	1
Asian	326	3.2%	1.3	0.6	1	1.2	1
Black or African American	1,347	13.0%	1.4	0.9	1	1.2	1
Native Hawaiian or Other Pacific Islander	*****	*****	1.0	0.4	1	1.0	1
White	7,032	68.0%	1.4	0.9	1	1.2	2
Ethnicity							
Not Hispanic	8,813	85.2%	1.4	0.9	1	1.2	2
Unknown	883	8.5%	1.2	0.7	1	1.1	1
Hispanic	645	6.2%	1.2	0.7	1	1.2	1
Year							
2015 Quarter 4	1,093	10.6%	N/A*	N/A	N/A	N/A	N/A
2016 Quarter 1	1,600	15.5%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 2	1,401	13.5%	N/A	N/A	N/A	N/A	N/A

**Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2016 Quarter 3	1,389	13.4%	N/A	N/A	N/A	N/A	N/A
2016 Quarter 4	1,333	12.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 1	919	8.9%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 2	907	8.8%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 3	842	8.1%	N/A	N/A	N/A	N/A	N/A
2017 Quarter 4	857	8.3%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2018 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 1	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 2	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2019 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	1.0	.	1	1.0	1
Midwest	2,817	27.2%	1.5	0.8	1	1.2	2
Missing	*****	*****	2.6	.	3	2.6	3
Northeast	2,807	27.1%	1.4	0.9	1	1.2	1
Other	*****	*****	1.0	0.2	1	1.0	1
South	2,463	23.8%	1.4	0.9	1	1.2	1
West	*****	*****	1.3	0.7	1	1.2	1
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	4.0	3.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	610	5.9%	1.4	0.8	1	1.2	2
ADHD and Other Behavior Disorders	2,173	21.0%	1.6	1.0	1	1.2	2
Alcohol Use Disorders	1,613	15.6%	1.5	0.8	1	1.2	2

**Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

	Number	Percent	Mean	Standard Deviation	Rate of ANC Screening Events per Month		
					Quarter 1	Median	Quarter 3
Anxiety Disorders	5,287	51.1%	1.5	0.9	1	1.2	2
Bipolar Disorders	4,986	48.2%	1.5	0.9	1	1.2	2
Depression	6,272	60.7%	1.5	0.9	1	1.2	2
Depressive Disorders	4,843	46.8%	1.6	1.0	1	1.2	2
Drug Use Disorders	2,491	24.1%	1.5	0.9	1	1.2	2
Opioid Use Disorder (OUD) 1	491	4.7%	1.5	0.9	1	1.2	2
OUD 2	406	3.9%	1.5	0.8	1	1.2	2
OUD 3	325	3.1%	1.6	0.9	1	1.3	2
OUD 4	40	0.4%	1.3	0.7	1	1.2	2
Personality Disorders	1,903	18.4%	1.6	0.9	1	1.3	2
Schizophrenia	8,769	84.8%	1.4	0.8	1	1.2	2
Schizophrenia and Other Psychotic Disorders	9,137	88.4%	1.4	0.9	1	1.2	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,564	15.1%	1.4	0.8	1	1.2	1
Atypical Antipsychotics	5,456	52.8%	1.5	0.8	1	1.2	2
Typical Antipsychotics	2,541	24.6%	1.5	0.9	1	1.2	2
Any Antipsychotic (Typical or Atypical)	6,451	62.4%	1.5	0.8	1	1.2	2
Antidepressants	5,072	49.0%	1.4	0.9	1	1.2	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	140.3	159.1	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	5.9	13.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	1.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	2.9	4.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	98.8	133.4	N/A	N/A	N/A	N/A	N/A



**Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic**

Medical Product Utilization Metrics From 30 Days Prior Through the Index Date	Rate of ANC Screening Events per Month						
	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Mean number of unique drug classes	5.9	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	6.2	3.8	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.7	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.q: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1)**

Characteristic <sup>1</sup>	Number	
Number of episodes	20,266	
Number of unique patients	15,582	
Demographics	Mean	Standard Deviation
Mean Age (years)	50.2	15.6
Age (years)	Number	Percent
12-18	110	0.5%
19-35	4,613	22.8%
36-50	5,493	27.1%
51-64	5,789	28.6%
65-74	3,219	15.9%
75+	1,042	5.1%
Sex		
Female	6,380	40.9%
Male	9,202	59.1%
Race		
Unknown	2,888	18.5%
American Indian or Alaska Native	*****	1.1%
Asian	378	2.4%
Black or African American	1,963	12.6%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	10,172	65.3%
Ethnicity		
Not Hispanic	12,463	80.0%
Unknown	2,520	16.2%
Hispanic	599	3.8%
Year		
2020 Quarter 1	3,058	15.1%
2020 Quarter 2	2,568	12.7%
2020 Quarter 3	2,845	14.0%
2020 Quarter 4	2,727	13.5%
2021 Quarter 1	2,843	14.0%
2021 Quarter 2	2,722	13.4%
2021 Quarter 3	2,625	13.0%
2021 Quarter 4	878	4.3%
Geographic Census Bureau Region		
Invalid	*****	<0.1%
Midwest	5,482	27.1%
Missing	*****	<0.1%
Northeast	4,895	24.2%
Other	*****	<0.1%
South	6,027	29.7%

**Table 1A.q: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1)**

	Number	Percent
West	3,850	19.0%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3
ADHD Only Subset	1,829	9.0%
ADHD and Other Behavior Disorders	5,838	28.8%
Alcohol Use Disorders	4,341	21.4%
Anxiety Disorders	14,281	70.5%
Bipolar Disorders	12,071	59.6%
Depression	15,295	75.5%
Depressive Disorders	12,716	62.7%
Drug Use Disorders	7,149	35.3%
Opioid Use Disorder (OUD) 1	1,830	9.0%
OUD 2	1,560	7.7%
OUD 3	1,216	6.0%
OUD 4	314	1.5%
Personality Disorders	5,188	25.6%
Schizophrenia	17,324	85.5%
Schizophrenia and Other Psychotic Disorders	18,261	90.1%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	2,757	13.6%
Atypical Antipsychotics	9,639	47.6%
Typical Antipsychotics	4,046	20.0%
Any Antipsychotic (Typical or Atypical)	11,416	56.3%
Antidepressants	10,460	51.6%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	219.4	242.5
Mean number of emergency room encounters	10.6	20.9
Mean number of inpatient hospital encounters	3.4	5.9
Mean number of non-acute institutional encounters	4.9	7.6
Mean number of other ambulatory encounters	167.1	224.7
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.4	3.4
Mean number of generics	5.6	3.6
Mean number of filled prescriptions	7.0	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.q: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

		Gaps between all ANC Screenings					
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	20,266						
Number of unique patients	15,582						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.2	15.6					
Age (years)	Number	Percent					
12-18	110	0.5%	11.0	9.3	3	7	17
19-35	4,613	22.8%	11.9	9.8	3	9	21
36-50	5,493	27.1%	11.7	9.8	3	8	21
51-64	5,789	28.6%	11.3	9.7	3	8	19
65-74	3,219	15.9%	10.9	9.6	3	7	18
75+	1,042	5.1%	11.0	9.5	3	7	19
Sex							
Female	6,380	40.9%	11.3	9.6	3	7	19
Male	9,202	59.1%	11.6	9.8	3	8	20
Race							
Unknown	2,888	18.5%	12.1	10.0	3	9	21
American Indian or Alaska Native	*****	1.1%	11.8	9.9	3	9	20
Asian	378	2.4%	11.9	9.8	3	8	21
Black or African American	1,963	12.6%	11.3	9.4	3	8	19
Native Hawaiian or Other Pacific Islander	*****	<0.1%	13.8	12.1	2	10	26
White	10,172	65.3%	11.4	9.7	3	7	20
Ethnicity							
Not Hispanic	12,463	80.0%	11.3	9.7	3	8	19
Unknown	2,520	16.2%	12.2	10.0	3	9	22
Hispanic	599	3.8%	11.5	9.7	3	8	19
Year							
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A	N/A

**Table 1B.q: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	11.5	11.7	2	6	25
Midwest	5,482	27.1%	11.5	9.9	3	8	20
Missing	*****	<0.1%	15.0	17.0	3	15	27
Northeast	4,895	24.2%	10.9	9.5	3	7	19
Other	*****	<0.1%	10.0	10.6	2	6	22
South	6,027	29.7%	11.7	9.6	3	8	20
West	3,850	19.0%	11.9	9.9	3	8	21
Date	Mean	Standard Deviation	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	Number	Percent					
ADHD Only Subset	1,829	9.0%	11.2	9.6	3	8	19
ADHD and Other Behavior Disorders	5,838	28.8%	10.7	9.4	3	7	17
Alcohol Use Disorders	4,341	21.4%	11.1	9.4	3	8	18
Anxiety Disorders	14,281	70.5%	11.1	9.5	3	7	19
Bipolar Disorders	12,071	59.6%	11.1	9.5	3	7	19
Depression	15,295	75.5%	11.2	9.6	3	8	19
Depressive Disorders	12,716	62.7%	11.1	9.5	3	7	19
Drug Use Disorders	7,149	35.3%	11.0	9.4	3	7	18
Opioid Use Disorder (OUD) 1	1,830	9.0%	10.8	9.4	3	7	17
OUD 2	1,560	7.7%	10.9	9.4	3	7	18
OUD 3	1,216	6.0%	10.6	9.2	3	7	17
OUD 4	314	1.5%	11.3	9.7	3	8	20

**Table 1B.q: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	10.7	9.4	3	7	17
Schizophrenia	17,324	85.5%	11.4	9.7	3	8	20
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	11.4	9.7	3	8	20
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	11.3	9.5	3	8	19
Atypical Antipsychotics	9,639	47.6%	11.3	9.7	3	8	19
Typical Antipsychotics	4,046	20.0%	11.1	9.5	3	8	19
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	11.3	9.6	3	8	19
Antidepressants	10,460	51.6%	11.4	9.7	3	8	20
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.q: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Number of ANC Screenings		
				Quarter 1	Median	Quarter 3
Number of episodes	20,266					
Number of unique patients	15,582					
Demographics	Mean	Standard Deviation				
Mean Age (years)	50.2	15.6				
Age (years)	Number	Percent				
12-18	110	0.5%	1.7	1.1	1	2
19-35	4,613	22.8%	1.5	1.0	1	2
36-50	5,493	27.1%	1.6	1.1	1	2
51-64	5,789	28.6%	1.7	1.1	1	2
65-74	3,219	15.9%	1.7	1.2	1	2
75+	1,042	5.1%	1.7	1.1	1	2
Sex						
Female	6,380	40.9%	1.7	1.1	1	2
Male	9,202	59.1%	1.6	1.1	1	2
Race						
Unknown	2,888	18.5%	1.5	0.9	1	2
American Indian or Alaska Native	*****	1.1%	1.5	0.9	1	2
Asian	378	2.4%	1.5	1.0	1	2
Black or African American	1,963	12.6%	1.7	1.2	1	2
Native Hawaiian or Other Pacific Islander	*****	<0.1%	1.2	0.4	1	1
White	10,172	65.3%	1.6	1.1	1	2
Ethnicity						
Not Hispanic	12,463	80.0%	1.6	1.1	1	2
Unknown	2,520	16.2%	1.5	0.9	1	2
Hispanic	599	3.8%	1.6	1.1	1	2
Year						
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A

**Table 1C.q: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

Characteristic	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	1.6	0.5	1	2	2
Midwest	5,482	27.1%	1.6	1.1	1	1	2
Missing	*****	<0.1%	1.0	.	1	1	1
Northeast	4,895	24.2%	1.8	1.3	1	1	2
Other	*****	<0.1%	2.0	.	2	2	2
South	6,027	29.7%	1.6	1.0	1	1	2
West	3,850	19.0%	1.5	1.0	1	1	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,829	9.0%	1.7	1.2	1	1	2
ADHD and Other Behavior Disorders	5,838	28.8%	1.8	1.3	1	1	2
Alcohol Use Disorders	4,341	21.4%	1.7	1.2	1	1	2
Anxiety Disorders	14,281	70.5%	1.7	1.2	1	1	2
Bipolar Disorders	12,071	59.6%	1.7	1.2	1	1	2
Depression	15,295	75.5%	1.7	1.1	1	1	2
Depressive Disorders	12,716	62.7%	1.7	1.2	1	1	2
Drug Use Disorders	7,149	35.3%	1.7	1.2	1	1	2
Opioid Use Disorder (OUD) 1	1,830	9.0%	1.8	1.3	1	1	2
OUD 2	1,560	7.7%	1.8	1.3	1	1	2
OUD 3	1,216	6.0%	1.8	1.4	1	1	2
OUD 4	314	1.5%	1.6	1.2	1	1	2



**Table 1C.q: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	1.8	1.3	1	1	2
Schizophrenia	17,324	85.5%	1.6	1.1	1	1	2
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	1.6	1.1	1	1	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	1.7	1.2	1	1	2
Atypical Antipsychotics	9,639	47.6%	1.7	1.1	1	1	2
Typical Antipsychotics	4,046	20.0%	1.7	1.1	1	1	2
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	1.7	1.1	1	1	2
Antidepressants	10,460	51.6%	1.6	1.1	1	1	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.q: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	20,266						
Number of unique patients	15,582						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.2	15.6					
Age (years)	Number	Percent					
12-18	110	0.5%	.	.	0	.	0
19-35	4,613	22.8%	.	.	0	.	0
36-50	5,493	27.1%	.	.	0	.	0
51-64	5,789	28.6%	.	.	0	.	0
65-74	3,219	15.9%	.	.	0	.	0
75+	1,042	5.1%	.	.	0	.	0
Sex							
Female	6,380	40.9%	.	.	0	.	0
Male	9,202	59.1%	.	.	0	.	0
Race							
Unknown	2,888	18.5%	.	.	0	.	0
American Indian or Alaska Native	*****	1.1%	.	.	0	.	0
Asian	378	2.4%	.	.	0	.	0
Black or African American	1,963	12.6%	.	.	0	.	0
Native Hawaiian or Other Pacific Islander	*****	<0.1%	.	.	0	.	0
White	10,172	65.3%	.	.	0	.	0
Ethnicity							
Not Hispanic	12,463	80.0%	.	.	0	.	0
Unknown	2,520	16.2%	.	.	0	.	0
Hispanic	599	3.8%	.	.	0	.	0
Year							
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A	N/A

**Table 1D.q: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	.	.	0	.	0
Midwest	5,482	27.1%	.	.	0	.	0
Missing	*****	<0.1%	.	.	0	.	0
Northeast	4,895	24.2%	.	.	0	.	0
Other	*****	<0.1%	.	.	0	.	0
South	6,027	29.7%	.	.	0	.	0
West	3,850	19.0%	.	.	0	.	0
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,829	9.0%	.	.	0	.	0
ADHD and Other Behavior Disorders	5,838	28.8%	.	.	0	.	0
Alcohol Use Disorders	4,341	21.4%	.	.	0	.	0
Anxiety Disorders	14,281	70.5%	.	.	0	.	0
Bipolar Disorders	12,071	59.6%	.	.	0	.	0
Depression	15,295	75.5%	.	.	0	.	0
Depressive Disorders	12,716	62.7%	.	.	0	.	0
Drug Use Disorders	7,149	35.3%	.	.	0	.	0
Opioid Use Disorder (OUD) 1	1,830	9.0%	.	.	0	.	0
OUD 2	1,560	7.7%	.	.	0	.	0
OUD 3	1,216	6.0%	.	.	0	.	0
OUD 4	314	1.5%	.	.	0	.	0

**Table 1D.q: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 1), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	.	.	0	.	0
Schizophrenia	17,324	85.5%	.	.	0	.	0
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	.	.	0	.	0
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	.	.	0	.	0
Atypical Antipsychotics	9,639	47.6%	.	.	0	.	0
Typical Antipsychotics	4,046	20.0%	.	.	0	.	0
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	.	.	0	.	0
Antidepressants	10,460	51.6%	.	.	0	.	0
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.r: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2)**

Characteristic <sup>1</sup>	Number	
Number of episodes	20,266	
Number of unique patients	15,582	
Demographics	Mean	Standard Deviation
Mean Age (years)	50.2	15.6
Age (years)	Number	Percent
12-18	110	0.5%
19-35	4,613	22.8%
36-50	5,493	27.1%
51-64	5,789	28.6%
65-74	3,219	15.9%
75+	1,042	5.1%
Sex		
Female	6,380	40.9%
Male	9,202	59.1%
Race		
Unknown	2,888	18.5%
American Indian or Alaska Native	*****	1.1%
Asian	378	2.4%
Black or African American	1,963	12.6%
Native Hawaiian or Other Pacific Islander	*****	<0.1%
White	10,172	65.3%
Ethnicity		
Not Hispanic	12,463	80.0%
Unknown	2,520	16.2%
Hispanic	599	3.8%
Year		
2020 Quarter 1	3,058	15.1%
2020 Quarter 2	2,568	12.7%
2020 Quarter 3	2,845	14.0%
2020 Quarter 4	2,727	13.5%
2021 Quarter 1	2,843	14.0%
2021 Quarter 2	2,722	13.4%
2021 Quarter 3	2,625	13.0%
2021 Quarter 4	878	4.3%
Geographic Census Bureau Region		
Invalid	*****	<0.1%
Midwest	5,482	27.1%
Missing	*****	<0.1%
Northeast	4,895	24.2%
Other	*****	<0.1%
South	6,027	29.7%

**Table 1A.r: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2)**

	Number	Percent
West	3,850	19.0%
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3
ADHD Only Subset	1,829	9.0%
ADHD and Other Behavior Disorders	5,838	28.8%
Alcohol Use Disorders	4,341	21.4%
Anxiety Disorders	14,281	70.5%
Bipolar Disorders	12,071	59.6%
Depression	15,295	75.5%
Depressive Disorders	12,716	62.7%
Drug Use Disorders	7,149	35.3%
Opioid Use Disorder (OUD) 1	1,830	9.0%
OUD 2	1,560	7.7%
OUD 3	1,216	6.0%
OUD 4	314	1.5%
Personality Disorders	5,188	25.6%
Schizophrenia	17,324	85.5%
Schizophrenia and Other Psychotic Disorders	18,261	90.1%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	2,757	13.6%
Atypical Antipsychotics	9,639	47.6%
Typical Antipsychotics	4,046	20.0%
Any Antipsychotic (Typical or Atypical)	11,416	56.3%
Antidepressants	10,460	51.6%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	219.4	242.5
Mean number of emergency room encounters	10.6	20.9
Mean number of inpatient hospital encounters	3.4	5.9
Mean number of non-acute institutional encounters	4.9	7.6
Mean number of other ambulatory encounters	167.1	224.7
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.4	3.4
Mean number of generics	5.6	3.6
Mean number of filled prescriptions	7.0	5.6

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.r: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
Characteristic <sup>1</sup>	Number	Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	20,266						
Number of unique patients	15,582						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.2	15.6					
Age (years)	Number	Percent					
12-18	110	0.5%	11.1	13.8	7	7	9
19-35	4,613	22.8%	12.9	15.8	7	7	14
36-50	5,493	27.1%	12.8	14.9	7	7	14
51-64	5,789	28.6%	12.8	14.5	7	7	14
65-74	3,219	15.9%	12.2	13.7	7	7	14
75+	1,042	5.1%	10.9	11.8	6	7	11
Sex							
Female	6,380	40.9%	12.3	14.1	7	7	14
Male	9,202	59.1%	12.8	15.0	7	7	14
Race							
Unknown	2,888	18.5%	13.8	16.3	7	7	15
American Indian or Alaska Native	*****	1.1%	11.6	13.1	7	7	12
Asian	378	2.4%	14.4	16.3	7	7	18
Black or African American	1,963	12.6%	13.3	15.9	6	7	14
Native Hawaiian or Other Pacific Islander	*****	<0.1%	18.5	12.5	7	18.5	29
White	10,172	65.3%	12.2	14.0	7	7	14
Ethnicity							
Not Hispanic	12,463	80.0%	12.4	14.3	7	7	14
Unknown	2,520	16.2%	14.1	16.6	7	7	15
Hispanic	599	3.8%	12.8	15.2	7	7	14
Year							
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A	N/A

**Table 1B.r: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	13.3	13.7	7	7	16
Midwest	5,482	27.1%	11.5	12.7	7	7	12
Missing	*****	<0.1%	36.2	33.7	26	27	32
Northeast	4,895	24.2%	12.7	15.0	7	7	14
Other	*****	<0.1%	13.0	17.6	3	6	24
South	6,027	29.7%	13.4	15.4	7	7	15
West	3,850	19.0%	13.3	15.8	7	7	14
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,829	9.0%	11.5	13.7	7	7	11
ADHD and Other Behavior Disorders	5,838	28.8%	11.4	13.5	6	7	11
Alcohol Use Disorders	4,341	21.4%	11.9	14.2	7	7	13
Anxiety Disorders	14,281	70.5%	11.8	13.8	7	7	13
Bipolar Disorders	12,071	59.6%	11.9	13.9	7	7	13
Depression	15,295	75.5%	12.0	13.9	7	7	13
Depressive Disorders	12,716	62.7%	11.7	13.7	7	7	13
Drug Use Disorders	7,149	35.3%	11.7	14.2	7	7	12
Opioid Use Disorder (OUD) 1	1,830	9.0%	11.5	13.8	6	7	12
OUD 2	1,560	7.7%	11.5	13.8	6	7	12
OUD 3	1,216	6.0%	11.3	13.5	6	7	12
OUD 4	314	1.5%	11.1	12.5	6	7	11



**Table 1B.r: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

	Gaps between all ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	11.2	13.3	6	7	11
Schizophrenia	17,324	85.5%	12.7	14.7	7	7	14
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	12.5	14.5	7	7	14
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	11.9	14.4	7	7	12
Atypical Antipsychotics	9,639	47.6%	10.5	12.7	6	7	9
Typical Antipsychotics	4,046	20.0%	10.7	13.0	7	7	9
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	10.8	13.0	7	7	9
Antidepressants	10,460	51.6%	11.8	13.8	7	7	12
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.r: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	20,266						
Number of unique patients	15,582						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.2	15.6					
Age (years)	Number	Percent					
12-18	110	0.5%	10.2	8.6	3	6	18
19-35	4,613	22.8%	8.7	8.2	2	6	13
36-50	5,493	27.1%	8.8	8.2	2	6	13
51-64	5,789	28.6%	8.8	8.1	3	6	13
65-74	3,219	15.9%	9.0	8.1	3	6	13
75+	1,042	5.1%	9.4	8.5	3	6	15
Sex							
Female	6,380	40.9%	9.0	8.2	3	6	14
Male	9,202	59.1%	8.7	8.1	2	6	13
Race							
Unknown	2,888	18.5%	7.9	7.6	2	5	11
American Indian or Alaska Native	*****	1.1%	10.6	8.8	4	7	17
Asian	378	2.4%	7.6	7.1	2	6	10
Black or African American	1,963	12.6%	8.0	7.9	2	5	11
Native Hawaiian or Other Pacific Islander	*****	<0.1%	6.1	2.0	5	6	7
White	10,172	65.3%	9.3	8.4	3	6	14
Ethnicity							
Not Hispanic	12,463	80.0%	9.1	8.3	3	6	14
Unknown	2,520	16.2%	7.7	7.4	2	5	10
Hispanic	599	3.8%	8.7	8.0	2	6	13
Year							
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A	N/A

**Table 1C.r: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

Characteristic	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	5.4	5.9	1	5	6
Midwest	5,482	27.1%	9.9	8.6	3	6	16
Missing	*****	<0.1%	4.0	.	4	4	4
Northeast	4,895	24.2%	9.0	8.2	3	6	13
Other	*****	<0.1%	1.0	0.0	1	1	1
South	6,027	29.7%	8.0	7.8	2	5	11
West	3,850	19.0%	8.4	7.8	2	6	12
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,829	9.0%	9.7	8.6	2	6	16
ADHD and Other Behavior Disorders	5,838	28.8%	9.7	8.5	3	6	15
Alcohol Use Disorders	4,341	21.4%	9.1	8.2	2	6	14
Anxiety Disorders	14,281	70.5%	9.4	8.4	3	6	15
Bipolar Disorders	12,071	59.6%	9.3	8.4	3	6	14
Depression	15,295	75.5%	9.3	8.4	3	6	14
Depressive Disorders	12,716	62.7%	9.4	8.4	3	6	15
Drug Use Disorders	7,149	35.3%	9.2	8.3	2	6	14
Opioid Use Disorder (OUD) 1	1,830	9.0%	9.0	8.2	2	6	14
OUD 2	1,560	7.7%	9.1	8.3	2	6	14
OUD 3	1,216	6.0%	9.1	8.3	2	6	14
OUD 4	314	1.5%	8.9	8.5	2	6	14

**Table 1C.r: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	9.9	8.6	3	7	16
Schizophrenia	17,324	85.5%	8.8	8.1	2	6	13
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	8.9	8.2	2	6	13
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	9.5	8.4	3	6	15
Atypical Antipsychotics	9,639	47.6%	10.7	9.0	3	7	19
Typical Antipsychotics	4,046	20.0%	10.5	8.8	3	7	18
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	10.4	8.9	3	7	18
Antidepressants	10,460	51.6%	9.5	8.5	3	6	15
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.r: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

Characteristic <sup>1</sup>	Number	Rate of ANC Screening Events per Month					
		Mean	Standard Deviation	Quarter 1	Median	Quarter 3	
Number of episodes	20,266						
Number of unique patients	15,582						
Demographics		Mean	Standard Deviation				
Mean Age (years)	50.2	15.6					
Age (years)	Number	Percent					
12-18	110	0.5%	2.5	1.5	1	2.7	4
19-35	4,613	22.8%	2.2	1.6	1	1.7	4
36-50	5,493	27.1%	2.2	1.6	1	1.6	4
51-64	5,789	28.6%	2.2	1.6	1	1.6	3
65-74	3,219	15.9%	2.4	1.8	1	1.9	4
75+	1,042	5.1%	2.6	1.6	1	2.3	4
Sex							
Female	6,380	40.9%	2.3	1.6	1	1.8	4
Male	9,202	59.1%	2.2	1.6	1	1.6	4
Race							
Unknown	2,888	18.5%	2.0	1.5	1	1.4	3
American Indian or Alaska Native	*****	1.1%	2.3	1.5	1	2.0	4
Asian	378	2.4%	1.9	1.4	1	1.3	3
Black or African American	1,963	12.6%	2.1	1.6	1	1.6	3
Native Hawaiian or Other Pacific Islander	*****	<0.1%	1.7	1.2	1	1.2	2
White	10,172	65.3%	2.3	1.6	1	1.8	4
Ethnicity							
Not Hispanic	12,463	80.0%	2.3	1.6	1	1.8	4
Unknown	2,520	16.2%	2.0	1.7	1	1.3	3
Hispanic	599	3.8%	2.2	1.6	1	1.7	4
Year							
2020 Quarter 1	3,058	15.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	2,568	12.7%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	2,845	14.0%	N/A	N/A	N/A	N/A	N/A

**Table 1D.r: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	2,727	13.5%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	2,843	14.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	2,722	13.4%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	2,625	13.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	878	4.3%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	<0.1%	2.0	1.5	1	1.5	4
Midwest	5,482	27.1%	2.5	1.7	1	2.1	4
Missing	*****	<0.1%	0.7	.	1	0.7	1
Northeast	4,895	24.2%	2.2	1.6	1	1.7	4
Other	*****	<0.1%	2.8	3.1	1	2.8	5
South	6,027	29.7%	2.1	1.6	1	1.4	3
West	3,850	19.0%	2.1	1.6	1	1.6	3
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	6.0	4.3					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	1,829	9.0%	2.4	1.6	1	2.1	4
ADHD and Other Behavior Disorders	5,838	28.8%	2.5	1.7	1	2.2	4
Alcohol Use Disorders	4,341	21.4%	2.4	1.6	1	2.1	4
Anxiety Disorders	14,281	70.5%	2.4	1.6	1	2.1	4
Bipolar Disorders	12,071	59.6%	2.4	1.7	1	2.0	4
Depression	15,295	75.5%	2.4	1.6	1	2.0	4
Depressive Disorders	12,716	62.7%	2.4	1.7	1	2.1	4
Drug Use Disorders	7,149	35.3%	2.4	1.6	1	2.1	4
Opioid Use Disorder (OUD) 1	1,830	9.0%	2.4	1.7	1	2.1	4
OUD 2	1,560	7.7%	2.4	1.6	1	2.1	4
OUD 3	1,216	6.0%	2.5	1.7	1	2.1	4
OUD 4	314	1.5%	2.3	1.5	1	1.9	4

**Table 1D.r: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 2), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	5,188	25.6%	2.5	1.7	1	2.3	4
Schizophrenia	17,324	85.5%	2.2	1.6	1	1.6	4
Schizophrenia and Other Psychotic Disorders	18,261	90.1%	2.2	1.6	1	1.8	4
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	2,757	13.6%	2.4	1.6	1	2.1	4
Atypical Antipsychotics	9,639	47.6%	2.7	1.6	1	2.7	4
Typical Antipsychotics	4,046	20.0%	2.6	1.7	1	2.6	4
Any Antipsychotic (Typical or Atypical)	11,416	56.3%	2.6	1.6	1	2.6	4
Antidepressants	10,460	51.6%	2.4	1.7	1	2.1	4
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	219.4	242.5	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	10.6	20.9	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.4	5.9	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.9	7.6	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	167.1	224.7	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.4	3.4	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.6	3.6	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.0	5.6	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1A.s: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3)**

Characteristic <sup>1</sup>	Number	
Number of episodes	7,733	
Number of unique patients	7,543	
Demographics	Mean	Standard Deviation
Mean Age (years)	50.0	15.4
Age (years)	Number	Percent
12-18	40	0.5%
19-35	1,718	22.2%
36-50	2,143	27.7%
51-64	2,289	29.6%
65-74	1,219	15.8%
75+	324	4.2%
Sex		
Female	3,058	40.5%
Male	4,485	59.5%
Race		
Unknown	1,259	16.7%
American Indian or Alaska Native	*****	*****
Asian	179	2.4%
Black or African American	878	11.6%
Native Hawaiian or Other Pacific Islander	*****	*****
White	5,131	68.0%
Ethnicity		
Not Hispanic	6,197	82.2%
Unknown	1,050	13.9%
Hispanic	296	3.9%
Year		
2020 Quarter 1	1,631	21.1%
2020 Quarter 2	1,323	17.1%
2020 Quarter 3	1,395	18.0%
2020 Quarter 4	1,297	16.8%
2021 Quarter 1	1,572	20.3%
2021 Quarter 2	515	6.7%
2021 Quarter 3	0	0.0%
2021 Quarter 4	0	0.0%
Geographic Census Bureau Region		
Invalid	*****	*****
Midwest	2,172	28.1%
Missing	*****	*****
Northeast	1,953	25.3%
Other	0	0.0%
South	2,124	27.5%



**Table 1A.s: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3)**

	Number	Percent
West	*****	*****
<b>Evidence of Medical Comorbidities Any Time Through Index Date</b>		
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	5.9	4.2
ADHD Only Subset	666	8.6%
ADHD and Other Behavior Disorders	2,166	28.0%
Alcohol Use Disorders	1,565	20.2%
Anxiety Disorders	5,339	69.0%
Bipolar Disorders	4,504	58.2%
Depression	5,736	74.2%
Depressive Disorders	4,756	61.5%
Drug Use Disorders	2,532	32.7%
Opioid Use Disorder (OUD) 1	593	7.7%
OUD 2	509	6.6%
OUD 3	393	5.1%
OUD 4	75	1.0%
Personality Disorders	1,938	25.1%
Schizophrenia	6,639	85.9%
Schizophrenia and Other Psychotic Disorders	6,950	89.9%
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>		
Lithium	1,098	14.2%
Atypical Antipsychotics	3,806	49.2%
Typical Antipsychotics	1,594	20.6%
Any Antipsychotic (Typical or Atypical)	4,497	58.2%
Antidepressants	4,004	51.8%
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>		
Mean number of ambulatory encounters	217.9	233.3
Mean number of emergency room encounters	9.9	18.3
Mean number of inpatient hospital encounters	3.2	5.3
Mean number of non-acute institutional encounters	4.7	7.1
Mean number of other ambulatory encounters	168.6	224.8
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>		
Mean number of unique drug classes	5.6	3.5
Mean number of generics	5.9	3.7
Mean number of filled prescriptions	7.4	5.8

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

**Table 1B.s: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

			Gaps between all ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	7,733						
Number of unique patients	7,543						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.0	15.4					
Age (years)	Number	Percent					
12-18	40	0.5%	14.2	12.3	7	13	15
19-35	1,718	22.2%	17.3	17.0	7	14	23
36-50	2,143	27.7%	16.4	15.7	7	14	21
51-64	2,289	29.6%	15.6	15.3	7	12	21
65-74	1,219	15.8%	14.3	14.1	7	9	17
75+	324	4.2%	13.4	12.1	7	9	15
Sex							
Female	3,058	40.5%	15.2	14.7	7	12	19
Male	4,485	59.5%	16.3	16.0	7	13	21
Race							
Unknown	1,259	16.7%	18.2	16.5	7	14	27
American Indian or Alaska Native	*****	*****	15.7	16.5	7	11	19
Asian	179	2.4%	18.3	16.7	7	14	26
Black or African American	878	11.6%	16.1	16.4	7	12	21
Native Hawaiian or Other Pacific Islander	*****	*****	24.1	20.0	9	25	32
White	5,131	68.0%	15.3	15.0	7	12	19
Ethnicity							
Not Hispanic	6,197	82.2%	15.5	15.3	7	12	20
Unknown	1,050	13.9%	18.3	16.2	7	14	27
Hispanic	296	3.9%	17.5	17.2	7	14	24
Year							
2020 Quarter 1	1,631	21.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	1,323	17.1%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	1,395	18.0%	N/A	N/A	N/A	N/A	N/A

**Table 1B.s: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	1,297	16.8%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	1,572	20.3%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	515	6.7%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	48.0	52.9	8	27	80
Midwest	2,172	28.1%	14.5	13.3	7	12	17
Missing	*****	*****	45.3	32.5	28	30	63
Northeast	1,953	25.3%	15.7	15.5	7	13	21
Other	0	0.0%					
South	2,124	27.5%	16.6	16.4	7	13	23
West	*****	*****	17.3	17.6	7	14	24
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	5.9	4.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	666	8.6%	15.2	15.0	7	13	17
ADHD and Other Behavior Disorders	2,166	28.0%	14.4	15.2	7	10	15
Alcohol Use Disorders	1,565	20.2%	15.3	15.6	7	12	18
Anxiety Disorders	5,339	69.0%	14.8	14.7	7	12	17
Bipolar Disorders	4,504	58.2%	14.9	14.9	7	12	17
Depression	5,736	74.2%	15.0	14.9	7	12	18
Depressive Disorders	4,756	61.5%	14.7	14.6	7	11	17
Drug Use Disorders	2,532	32.7%	15.0	15.6	7	11	17
Opioid Use Disorder (OUD) 1	593	7.7%	14.5	15.6	7	10	16
OUD 2	509	6.6%	14.7	16.0	7	10	16
OUD 3	393	5.1%	13.7	15.0	7	9	15
OUD 4	75	1.0%	15.1	15.8	7	13	15

**Table 1B.s: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

Gaps between all ANC Screenings							
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	1,938	25.1%	13.8	14.2	7	9	15
Schizophrenia	6,639	85.9%	15.8	15.5	7	13	21
Schizophrenia and Other Psychotic Disorders	6,950	89.9%	15.7	15.4	7	13	20
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,098	14.2%	16.0	16.3	7	13	19
Atypical Antipsychotics	3,806	49.2%	14.0	14.2	7	11	15
Typical Antipsychotics	1,594	20.6%	14.5	15.1	7	12	15
Any Antipsychotic (Typical or Atypical)	4,497	58.2%	14.3	14.4	7	12	15
Antidepressants	4,004	51.8%	14.9	14.7	7	12	17
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	217.9	233.3	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	9.9	18.3	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.2	5.3	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.7	7.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	168.6	224.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.4	5.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1C.s: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

			Number of ANC Screenings				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	7,733						
Number of unique patients	7,543						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.0	15.4					
Age (years)	Number	Percent					
12-18	40	0.5%	8.3	5.9	4	6	13
19-35	1,718	22.2%	7.0	5.6	3	6	10
36-50	2,143	27.7%	7.4	5.8	3	6	11
51-64	2,289	29.6%	7.7	6.2	3	6	10
65-74	1,219	15.8%	8.2	6.6	3	6	12
75+	324	4.2%	8.0	6.4	3	6	11
Sex							
Female	3,058	40.5%	7.8	6.1	3	6	11
Male	4,485	59.5%	7.4	6.0	3	6	10
Race							
Unknown	1,259	16.7%	6.3	5.0	2	5	8
American Indian or Alaska Native	*****	*****	7.6	6.3	3	6	11
Asian	179	2.4%	7.1	4.9	3	6	10
Black or African American	878	11.6%	7.6	6.1	3	6	11
Native Hawaiian or Other Pacific Islander	*****	*****	4.7	3.8	2	3	9
White	5,131	68.0%	7.9	6.2	3	6	11
Ethnicity							
Not Hispanic	6,197	82.2%	7.8	6.2	3	6	11
Unknown	1,050	13.9%	6.1	5.0	2	5	8
Hispanic	296	3.9%	7.0	5.2	3	6	9
Year							
2020 Quarter 1	1,631	21.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	1,323	17.1%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	1,395	18.0%	N/A	N/A	N/A	N/A	N/A

**Table 1C.s: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	1,297	16.8%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	1,572	20.3%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	515	6.7%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	1.7	0.6	1	2	2
Midwest	2,172	28.1%	8.5	6.3	4	7	12
Missing	*****	*****	3.0	.	3	3	3
Northeast	1,953	25.3%	7.7	6.2	3	6	11
Other	0	0.0%					
South	2,124	27.5%	7.0	5.9	3	6	9
West	*****	*****	6.9	5.4	3	6	9
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	5.9	4.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	666	8.6%	8.0	6.0	3	6	12
ADHD and Other Behavior Disorders	2,166	28.0%	8.4	6.5	3	7	12
Alcohol Use Disorders	1,565	20.2%	7.8	6.1	3	6	11
Anxiety Disorders	5,339	69.0%	8.1	6.3	3	6	12
Bipolar Disorders	4,504	58.2%	8.0	6.3	3	6	12
Depression	5,736	74.2%	8.0	6.3	3	6	12
Depressive Disorders	4,756	61.5%	8.1	6.4	3	6	12
Drug Use Disorders	2,532	32.7%	8.0	6.3	3	6	12
Opioid Use Disorder (OUD) 1	593	7.7%	8.3	6.6	3	6	12
OUD 2	509	6.6%	8.2	6.5	3	6	12
OUD 3	393	5.1%	8.9	6.8	4	7	13
OUD 4	75	1.0%	8.3	6.0	4	7	13

**Table 1C.s: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

	Number of ANC Screenings						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	1,938	25.1%	8.7	6.6	3	7	13
Schizophrenia	6,639	85.9%	7.6	6.1	3	6	11
Schizophrenia and Other Psychotic Disorders	6,950	89.9%	7.6	6.1	3	6	11
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,098	14.2%	7.8	6.2	3	6	11
Atypical Antipsychotics	3,806	49.2%	8.8	6.5	4	7	13
Typical Antipsychotics	1,594	20.6%	8.7	6.3	3	7	13
Any Antipsychotic (Typical or Atypical)	4,497	58.2%	8.6	6.4	3	7	13
Antidepressants	4,004	51.8%	8.1	6.3	3	6	12
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	217.9	233.3	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	9.9	18.3	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.2	5.3	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.7	7.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	168.6	224.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.4	5.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Table 1D.s: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

			Rate of ANC Screening Events per Month				
Characteristic <sup>1</sup>	Number		Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Number of episodes	7,733						
Number of unique patients	7,543						
Demographics	Mean	Standard Deviation					
Mean Age (years)	50.0	15.4					
Age (years)	Number	Percent					
12-18	40	0.5%	2.0	1.1	1	2.0	2
19-35	1,718	22.2%	1.6	1.1	1	1.2	2
36-50	2,143	27.7%	1.7	1.2	1	1.3	2
51-64	2,289	29.6%	1.8	1.3	1	1.3	2
65-74	1,219	15.8%	1.9	1.3	1	1.5	3
75+	324	4.2%	2.1	1.3	1	1.9	3
Sex							
Female	3,058	40.5%	1.8	1.2	1	1.5	2
Male	4,485	59.5%	1.7	1.2	1	1.3	2
Race							
Unknown	1,259	16.7%	1.5	1.1	1	1.2	2
American Indian or Alaska Native	*****	*****	1.7	1.2	1	1.5	2
Asian	179	2.4%	1.5	0.9	1	1.2	2
Black or African American	878	11.6%	1.7	1.2	1	1.3	2
Native Hawaiian or Other Pacific Islander	*****	*****	1.0	0.5	1	1.1	1
White	5,131	68.0%	1.8	1.2	1	1.4	2
Ethnicity							
Not Hispanic	6,197	82.2%	1.8	1.2	1	1.4	2
Unknown	1,050	13.9%	1.5	1.1	1	1.2	2
Hispanic	296	3.9%	1.6	1.0	1	1.3	2
Year							
2020 Quarter 1	1,631	21.1%	N/A*	N/A	N/A	N/A	N/A
2020 Quarter 2	1,323	17.1%	N/A	N/A	N/A	N/A	N/A
2020 Quarter 3	1,395	18.0%	N/A	N/A	N/A	N/A	N/A



**Table 1D.s: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
2020 Quarter 4	1,297	16.8%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 1	1,572	20.3%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 2	515	6.7%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 3	0	0.0%	N/A	N/A	N/A	N/A	N/A
2021 Quarter 4	0	0.0%	N/A	N/A	N/A	N/A	N/A
<b>Geographic Census Bureau Region</b>							
Invalid	*****	*****	0.8	0.9	0	0.3	2
Midwest	2,172	28.1%	1.9	1.2	1	1.6	3
Missing	*****	*****	0.5	.	0	0.5	0
Northeast	1,953	25.3%	1.8	1.4	1	1.4	2
Other	0	0.0%					
South	2,124	27.5%	1.7	1.2	1	1.3	2
West	*****	*****	1.6	1.1	1	1.2	2
<b>Date</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Mean</b>	<b>Standard Deviation</b>	<b>Quarter 1</b>	<b>Median</b>	<b>Quarter 3</b>
Charlson/Elixhauser Combined Comorbidity Score <sup>2</sup>	5.9	4.2					
	<b>Number</b>	<b>Percent</b>					
ADHD Only Subset	666	8.6%	1.8	1.2	1	1.6	2
ADHD and Other Behavior Disorders	2,166	28.0%	2.0	1.3	1	1.6	3
Alcohol Use Disorders	1,565	20.2%	1.8	1.2	1	1.5	2
Anxiety Disorders	5,339	69.0%	1.9	1.3	1	1.6	2
Bipolar Disorders	4,504	58.2%	1.9	1.3	1	1.5	2
Depression	5,736	74.2%	1.9	1.3	1	1.5	2
Depressive Disorders	4,756	61.5%	1.9	1.3	1	1.6	3
Drug Use Disorders	2,532	32.7%	1.9	1.3	1	1.6	2
Opioid Use Disorder (OUD) 1	593	7.7%	1.9	1.3	1	1.6	3
OUD 2	509	6.6%	1.9	1.3	1	1.6	3
OUD 3	393	5.1%	2.0	1.3	1	1.8	3
OUD 4	75	1.0%	1.9	1.2	1	1.9	2

**Table 1D.s: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database (SDD) from January 1, 2020 to October 31, 2021 (Look 3), by Baseline Characteristic**

	Rate of ANC Screening Events per Month						
	Number	Percent	Mean	Standard Deviation	Quarter 1	Median	Quarter 3
Personality Disorders	1,938	25.1%	2.0	1.3	1	1.8	3
Schizophrenia	6,639	85.9%	1.8	1.2	1	1.3	2
Schizophrenia and Other Psychotic Disorders	6,950	89.9%	1.8	1.2	1	1.3	2
<b>Evidence of Medical Product Use in the 30 Days Prior to or On Index</b>							
Lithium	1,098	14.2%	1.7	1.2	1	1.3	2
Atypical Antipsychotics	3,806	49.2%	2.0	1.2	1	1.9	3
Typical Antipsychotics	1,594	20.6%	1.9	1.2	1	1.8	3
Any Antipsychotic (Typical or Atypical)	4,497	58.2%	2.0	1.2	1	1.8	3
Antidepressants	4,004	51.8%	1.9	1.2	1	1.5	2
<b>Healthcare Encounter Utilization at Any Time Through the Index Date</b>							
	Mean	Standard Deviation					
Mean number of ambulatory encounters	217.9	233.3	N/A	N/A	N/A	N/A	N/A
Mean number of emergency room encounters	9.9	18.3	N/A	N/A	N/A	N/A	N/A
Mean number of inpatient hospital encounters	3.2	5.3	N/A	N/A	N/A	N/A	N/A
Mean number of non-acute institutional encounters	4.7	7.1	N/A	N/A	N/A	N/A	N/A
Mean number of other ambulatory encounters	168.6	224.8	N/A	N/A	N/A	N/A	N/A
<b>Medical Product Utilization Metrics From 30 Days Prior Through the Index Date</b>							
Mean number of unique drug classes	5.6	3.5	N/A	N/A	N/A	N/A	N/A
Mean number of generics	5.9	3.7	N/A	N/A	N/A	N/A	N/A
Mean number of filled prescriptions	7.4	5.8	N/A	N/A	N/A	N/A	N/A

<sup>1</sup>All metrics are based on total number of episodes per group, except for sex, race, and ethnicity which are based on total number of unique patients

<sup>2</sup>The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

\*\*\*\*\*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

\*N/A = Not Applicable

**Summary Table 1a. Summary of Clozapine Episodes that Met the REMS Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database (SDD), Gap between ANC Screenings**

	Clozapine Episodes <sup>A</sup>		Gaps between all ANC Screenings					
			≤ 10 day gap		≤ 17 day gap		≤ 33 day gap	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
<b>January 1, 2010 to September 30, 2015</b>								
Up to 6 months of clozapine use (Look 2)	82,235	100.0%	8,275	10.1%	17,524	21.3%	33,857	41.2%
6 months to 1 year of clozapine use (Look 3)	41,662	100.0%	1,876	4.5%	7,434	17.8%	18,181	43.6%
1-2 years of clozapine use (Look 4)	29,533	100.0%	636	2.2%	2,391	8.1%	10,308	34.9%
183-Day Washout Period (Look 2)	32,133	100.0%	5,368	16.7%	10,257	31.9%	14,803	46.1%
0-6 months for clozapine use of at least 6 months (Look 5)	41,662	100.0%	3,122	7.5%	7,885	18.9%	16,828	40.4%
7-12 months for clozapine use of at least 12 months (Look 6)	29,533	100.0%	841	2.8%	4,760	16.1%	12,676	42.9%
13-24 months for clozapine use of at least 24 months (Look 7)	17,411	100.0%	160	0.9%	894	5.1%	5,423	31.1%
<b>October 1, 2015 to December 31, 2019</b>								
Up to 6 months of clozapine use (Look 2)	75,063	100.0%	6,718	8.9%	14,835	19.8%	29,089	38.8%
6 months to 1 year of clozapine use (Look 3)	35,106	100.0%	979	2.8%	5,381	15.3%	14,334	40.8%
1-2 years of clozapine use (Look 4)	22,697	100.0%	311	1.4%	1,221	5.4%	6,957	30.7%
183-Day Washout Period (Look 2)	33,606	100.0%	4,810	14.3%	9,784	29.1%	14,775	44.0%
0-6 months for clozapine use of at least 6 months (Look 5)	35,106	100.0%	2,366	6.7%	6,298	17.9%	13,204	37.6%
7-12 months for clozapine use of at least 12 months (Look 6)	22,697	100.0%	353	1.6%	3,168	14.0%	9,126	40.2%
13-24 months for clozapine use of at least 24 months (Look 7)	10,341	100.0%	51	0.5%	266	2.6%	2,681	25.9%
<b>January 1, 2020 to October 31, 2021</b>								
Up to 6 months of clozapine use (Look 2)	20,266	100.0%	1,731	8.5%	3,715	18.3%	7,661	37.8%
6 months to 1 year of clozapine use (Look 3)	7,733	100.0%	295	3.8%	1,149	14.9%	3,091	40.0%

<sup>A</sup>Number of Clozapine Episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.

**Summary Table 1b. Summary Statistics of the Gap Between Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)**

	Clozapine Episodes <sup>B</sup>	Gaps between all ANC Screenings (days)						
	Number	Mean	Standard Deviation	Minimum	Quarter 1	Median	Quarter 3	Maximum
<b>January 1, 2010 to September 30, 2015</b>								
Up to 6 months of clozapine use (Look 2)	69,270	10.9	11.7	0	6	7	11	181
6 months to 1 year of clozapine use (Look 3)	38,347	13.3	12.1	0	7	9	15	181
1-2 years of clozapine use (Look 4)	27,843	17.4	16.1	0	7	14	28	364
183-Day Washout Period (Look 2)	27,091	8.3	8.8	0	6	7	7	181
0-6 months for clozapine use of at least 6 months (Look 5)	39,503	11.1	11.9	0	7	7	12	181
7-12 months for clozapine use of at least 12 months (Look 6)	28,287	13.5	12.1	0	7	9	15	181
13-24 months for clozapine use of at least 24 months (Look 7)	16,995	17.9	16.4	0	7	14	28	364
<b>October 1, 2015 to December 31, 2019</b>								
Up to 6 months of clozapine use (Look 2)	60,437	11.3	12.8	0	7	7	11	181
6 months to 1 year of clozapine use (Look 3)	31,023	14.5	13.5	0	7	12	16	181
1-2 years of clozapine use (Look 4)	20,680	19.8	18.8	0	7	15	28	364
183-Day Washout Period (Look 2)	27,336	8.8	9.9	0	6	7	8	181
0-6 months for clozapine use of at least 6 months (Look 5)	32,446	11.4	13.1	0	7	7	11	181
7-12 months for clozapine use of at least 12 months (Look 6)	21,204	14.7	13.7	0	7	13	16	181
13-24 months for clozapine use of at least 24 months (Look 7)	10,027	20.2	19.3	0	7	17	28	364
<b>January 1, 2020 to October 31, 2021</b>								
Up to 6 months of clozapine use (Look 2)	16,044	12.6	14.6	0	7	7	14	181
6 months to 1 year of clozapine use (Look 3)	6,613	15.8	15.5	0	7	13	21	181

<sup>B</sup>Only clozapine episodes with at least one ANC screening in the specified window are summarized in this table.

**Summary Table 2a. Summary of Clozapine Episodes that Met the REMS Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database (SDD), Number of ANC Screenings**

	Clozapine Episodes <sup>A</sup>		Number of ANC Screenings											
			≥ 1		1-4		5-7		8-11		12-14		15-20	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
<b>January 1, 2010 to September 30, 2015</b>														
30 days before clozapine initiation (Look 1)	82,235	100.0%	56,838	69.1%	N/A*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	41,662	100.0%	39,503	94.8%	3,285	7.9%	10,164	24.4%	4,685	11.2%	2,596	6.2%	3,704	8.9%
7-12 months for clozapine use of at least 12 months (Look 6)	29,533	100.0%	28,287	95.8%	1,867	6.3%	8,271	28.0%	4,605	15.6%	4,718	16.0%	4,194	14.2%
13-24 months for clozapine use of at least 24 months (Look 7)	17,411	100.0%	16,995	97.6%	503	2.9%	298	1.7%	1,553	8.9%	5,498	31.6%	4,281	24.6%
<b>October 1, 2015 to December 31, 2019</b>														
30 days before clozapine initiation (Look 1)	75,063	100.0%	49,434	65.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	35,106	100.0%	32,446	92.4%	3,512	10.0%	8,000	22.8%	3,607	10.3%	1,795	5.1%	3,330	9.5%
7-12 months for clozapine use of at least 12 months (Look 6)	22,697	100.0%	21,204	93.4%	2,002	8.8%	6,056	26.7%	3,630	16.0%	4,207	18.5%	3,003	13.2%
13-24 months for clozapine use of at least 24 months (Look 7)	10,341	100.0%	10,027	97.0%	426	4.1%	311	3.0%	1,108	10.7%	3,579	34.6%	2,607	25.2%
<b>January 1, 2020 to October 31, 2021</b>														
30 days before clozapine initiation (Look 1)	20,266	100.0%	13,056	64.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

<sup>A</sup>Number of Clozapine Episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.

\*N/A = Not Applicable

**Summary Table 2a. Summary of Clozapine Episodes that Met the REMS Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database (SDD), Number of ANC Screenings**

	Number of ANC Screenings													
	21-24		25-27		28-30		31-35		≥ 36		≥ 25		≥ 12	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
<b>January 1, 2010 to September 30, 2015</b>														
30 days before clozapine initiation (Look 1)	N/A*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	4,694	11.3%	7,656	18.4%	1,820	4.4%	585	1.4%	314	0.8%	10,375	24.9%	N/A	N/A
7-12 months for clozapine use of at least 12 months (Look 6)	1,691	5.7%	2,098	7.1%	508	1.7%	169	0.6%	166	0.6%	N/A	N/A	13,544	45.9%
13-24 months for clozapine use of at least 24 months (Look 7)	1,072	6.2%	972	5.6%	620	3.6%	500	2.9%	1,698	9.8%	N/A	N/A	14,641	84.1%
<b>October 1, 2015 to December 31, 2019</b>														
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	4,420	12.6%	6,359	18.1%	1,080	3.1%	246	0.7%	97	0.3%	7,782	22.2%	N/A	N/A
7-12 months for clozapine use of at least 12 months (Look 6)	982	4.3%	1,048	4.6%	193	0.9%	52	0.2%	31	0.1%	N/A	N/A	9,516	41.9%
13-24 months for clozapine use of at least 24 months (Look 7)	557	5.4%	345	3.3%	200	1.9%	200	1.9%	694	6.7%	N/A	N/A	8,182	79.1%
<b>January 1, 2020 to October 31, 2021</b>														
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

<sup>A</sup>Number of Clozapine Episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.  
 \*N/A = Not Applicable

**Summary Table 2b. Summary Statistics of the Number of Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)**

	Clozapine Episodes <sup>B</sup>	Number of ANC Screenings						
	Number	Mean	Standard Deviation	Minimum	Quarter 1	Median	Quarter 3	Maximum
<b>January 1, 2010 to September 30, 2015</b>								
30 days before clozapine initiation (Look 1)	56,838	1.7	1.2	1	1	1	2	30
0-6 months for clozapine use of at least 6 months (Look 5)	39,503	15.3	9.4	1	6	13	25	104
7-12 months for clozapine use of at least 12 months (Look 6)	28,287	12.4	7.5	1	7	11	16	80
13-24 months for clozapine use of at least 24 months (Look 7)	16,995	19.4	12.1	1	13	15	23	152
<b>October 1, 2015 to December 31, 2019</b>								
30 days before clozapine initiation (Look 1)	49,434	1.6	1.1	1	1	1	2	29
0-6 months for clozapine use of at least 6 months (Look 5)	32,446	14.8	9.2	1	6	13	24	72
7-12 months for clozapine use of at least 12 months (Look 6)	21,204	11.3	6.6	1	6	10	15	88
13-24 months for clozapine use of at least 24 months (Look 7)	10,027	17.0	10.3	1	12	14	18	171
<b>January 1, 2020 to October 31, 2021</b>								
30 days before clozapine initiation (Look 1)	13,056	1.6	1.1	1	1	1	2	14

<sup>B</sup>Only clozapine episodes with at least one ANC screening in the specified window are summarized in this table.

**Summary Table 3a. Summary of Clozapine Episodes that Met the REMS Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database (SDD), Rate of ANC Screening Events per Month**

	Clozapine Episodes <sup>A</sup>		Number of ANC Screenings per Month*					
			≥ 1		≥ 2		≥ 4	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
<b>January 1, 2010 to September 30, 2015</b>								
Up to 6 months of clozapine use (Look 2)	82,235	100.0%	53,979	65.6%	38,113	46.3%	18,714	22.8%
6 months to 1 year of clozapine use (Look 3)	41,662	100.0%	29,258	70.2%	17,273	41.5%	4,624	11.1%
1-2 years of clozapine use (Look 4)	29,533	100.0%	21,425	72.5%	7,233	24.5%	1,849	6.3%
183-Day Washout Period (Look 2)	32,133	100.0%	24,714	76.9%	21,576	67.1%	11,934	37.1%
0-6 months for clozapine use of at least 6 months (Look 5)	41,662	100.0%	29,308	70.3%	20,537	49.3%	10,375	24.9%
7-12 months for clozapine use of at least 12 months (Look 6)	29,533	100.0%	21,276	72.0%	12,342	41.8%	2,941	10.0%
13-24 months for clozapine use of at least 24 months (Look 7)	17,411	100.0%	13,082	75.1%	3,790	21.8%	855	4.9%
<b>October 1, 2015 to December 31, 2019</b>								
Up to 6 months of clozapine use (Look 2)	75,063	100.0%	45,779	61.0%	32,050	42.7%	14,159	18.9%
6 months to 1 year of clozapine use (Look 3)	35,106	100.0%	22,829	65.0%	12,556	35.8%	2,325	6.6%
1-2 years of clozapine use (Look 4)	22,697	100.0%	14,538	64.1%	3,606	15.9%	755	3.3%
183-Day Washout Period (Look 2)	33,606	100.0%	24,153	71.9%	20,588	61.3%	10,140	30.2%
0-6 months for clozapine use of at least 6 months (Look 5)	35,106	100.0%	23,304	66.4%	16,734	47.7%	7,782	22.2%
7-12 months for clozapine use of at least 12 months (Look 6)	22,697	100.0%	15,424	68.0%	8,432	37.2%	1,324	5.8%
13-24 months for clozapine use of at least 24 months (Look 7)	10,341	100.0%	7,173	69.4%	1,439	13.9%	292	2.8%
<b>January 1, 2020 to October 31, 2021</b>								
Up to 6 months of clozapine use (Look 2)	20,266	100.0%	11,302	55.8%	7,394	36.5%	2,893	14.3%
6 months to 1 year of clozapine use (Look 3)	7,733	100.0%	4,441	57.4%	2,221	28.7%	429	5.5%

\* Month=30 days

<sup>A</sup>Number of Clozapine Episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.



**Summary Table 3b. Summary Statistics of the Rate of Absolute Neutrophil Count (ANC) Screening during Clozapine Use in the Sentinel Distributed Database (SDD)**

	Clozapine Episodes <sup>B</sup>	Rate of ANC Screenings per Clozapine Episode per Month*						
	Number	Mean	Standard Deviation	Minimum	Quarter 1	Median	Quarter 3	Maximum
<b>January 1, 2010 to September 30, 2015</b>								
Up to 6 months of clozapine use (Look 2)	69,270	2.6	1.8	0	1	2.3	4	30
6 months to 1 year of clozapine use (Look 3)	38,347	2.1	1.4	0	1	1.8	3	30
1-2 years of clozapine use (Look 4)	27,843	1.7	1.2	0	1	1.3	2	30
183-Day Washout Period (Look 2)	27,091	3.4	1.7	0	2	3.8	4	30
0-6 months for clozapine use of at least 6 months (Look 5)	39,503	2.5	1.6	0	1	2.1	4	17
7-12 months for clozapine use of at least 12 months (Look 6)	28,287	2.0	1.2	0	1	1.8	3	13
13-24 months for clozapine use of at least 24 months (Look 7)	16,995	1.6	1.0	0	1	1.2	2	12
<b>October 1, 2015 to December 31, 2019</b>								
Up to 6 months of clozapine use (Look 2)	60,437	2.5	1.7	0	1	2.2	4	30
6 months to 1 year of clozapine use (Look 3)	31,023	1.9	1.3	0	1	1.6	2	30
1-2 years of clozapine use (Look 4)	20,680	1.5	1.0	0	1	1.2	2	30
183-Day Washout Period (Look 2)	27,336	3.2	1.6	0	2	3.6	4	30
0-6 months for clozapine use of at least 6 months (Look 5)	32,446	2.4	1.5	0	1	2.1	4	12
7-12 months for clozapine use of at least 12 months (Look 6)	21,204	1.9	1.1	0	1	1.6	2	15
13-24 months for clozapine use of at least 24 months (Look 7)	10,027	1.4	0.8	0	1	1.2	1	14
<b>January 1, 2020 to October 31, 2021</b>								
Up to 6 months of clozapine use (Look 2)	16,044	2.2	1.6	0	1	1.7	4	30
6 months to 1 year of clozapine use (Look 3)	6,613	1.8	1.2	0	1	1.3	2	15

\* Month=30 days

<sup>B</sup>Only clozapine episodes with at least one ANC screening in the specified window are summarized in this table.

**Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (August 15, 2022)**

---

DP ID	Start Date <sup>1</sup>	End Date <sup>1</sup>
DP01	01/01/2007	01/31/2022
DP02	01/01/2008	08/31/2021
DP03	01/01/2000	12/31/2020
DP04	01/01/2010	12/31/2021
DP05	01/01/2008	12/31/2021
DP06	01/01/2006	02/28/2022
DP07	01/01/2014	12/31/2018

<sup>1</sup>The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

**Appendix B. List of States and U.S. Territories per Census Bureau (CB) Region**

CB region	States and U.S. Territories
Midwest (MW)	Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
Northeast (NE)	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania
South (S)	Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia
West (W)	Arizona, Alaska, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming
Other	American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, Palau, Puerto Rico, U.S. Virgin Islands
Invalid	Recorded geographic location does not match any identifiers per the Sentinel Common Data Model definition
Missing	Missing from claims

**Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request**

Generic Name	Brand Name
	Clozapine
clozapine	Clozaril
clozapine	clozapine
clozapine	FazaClo
clozapine	Versacloz

**Appendix D. List of Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), and Revenue (RE) Codes Used to Define the Events of Interest in this Request**

Code	Description	Code Category	Code Type
<b>Absolute Neutrophil Count (ANC)</b>			
0305	Laboratory-Hematology	Procedure, Laboratory	RE
80050	General health panel This panel must include the following: Comprehensive metabolic panel (80053) Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Thyroid stimulating hormone (TSH) (84443)	Procedure, Laboratory	CPT-4
80055	Obstetric panel This panel must include the following: Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)	Procedure, Laboratory	CPT-4
85004	Blood count; automated differential WBC count	Procedure, Laboratory	CPT-4
85007	Blood count; blood smear, microscopic examination with manual differential WBC count	Procedure, Laboratory	CPT-4
85008	Blood count; blood smear, microscopic examination without manual differential WBC count	Procedure, Laboratory	CPT-4
85009	Blood count; manual differential WBC count, buffy coat	Procedure, Laboratory	CPT-4
85025	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	Procedure, Laboratory	CPT-4
85027	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	Procedure, Laboratory	CPT-4
85032	Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each	Procedure, Laboratory	CPT-4
85048	Blood count; leukocyte (WBC), automated	Procedure, Laboratory	CPT-4
G0306	Complete CBC, automated (Hgb, HCT, RBC, WBC, without platelet count) and automated WBC differential count	Procedure, Laboratory	HCPCS
G0307	Complete CBC, automated (Hgb, HCT, RBC, WBC; without platelet count)	Procedure, Laboratory	HCPCS

**Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request**

Generic Name	Brand Name
<b>Lithium</b>	
lithium citrate	lithium citrate
lithium carbonate	lithium carbonate
lithium carbonate	Lithobid
<b>Atypical Anti-Psychotics</b>	
aripiprazole	Abilify Maintena
aripiprazole	Abilify
aripiprazole	aripiprazole
aripiprazole	Abilify MyCite
aripiprazole	Abilify Discmelt
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
brexpiprazole	Rexulti
cariprazine HCl	Vraylar
iloperidone	Fanapt
lumeperone tosylate	Caplyta
lurasidone HCl	Latuda
olanzapine	Zyprexa
olanzapine	olanzapine
olanzapine	Zyprexa Zydis
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/fluoxetine HCl	Symbyax
olanzapine/samidorphan malate	Lybalvi
paliperidone	paliperidone
paliperidone	Invega
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
paliperidone palmitate	Invega Hafyera
pimavanserin tartrate	Nuplazid
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
risperidone	risperidone
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone microspheres	Risperdal Consta
ziprasidone HCl	Geodon

# Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	ziprasidone mesylate
ziprasidone mesylate	Geodon
<b>Typical Anti-Psychotics</b>	
chlorpromazine HCl	chlorpromazine
fluphenazine decanoate	fluphenazine decanoate
fluphenazine HCl	fluphenazine HCl
haloperidol	haloperidol
haloperidol decanoate	haloperidol decanoate
haloperidol decanoate	Haldol Decanoate
haloperidol lactate	haloperidol lactate
haloperidol lactate	Haldol
loxapine	Adasuve
loxapine succinate	loxapine succinate
loxapine succinate	Loxitane
molindone HCl	molindone
molindone HCl	Moban
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
pimozide	pimozide
pimozide	Orap
thioridazine HCl	thioridazine
thiothixene	thiothixene
thiothixene	Navane
trifluoperazine HCl	trifluoperazine
trifluoperazine HCl	trifluoperazine
trifluoperazine HCl	trifluoperazine
<b>All Anti-Psychotics (Typical and Atypical)</b>	
aripiprazole	Abilify Maintena
aripiprazole	Abilify
aripiprazole	aripiprazole
aripiprazole	Abilify MyCite
aripiprazole	Abilify Discmelt
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
brexpiprazole	Rexulti
cariprazine HCl	Vraylar

**Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request**

Generic Name	Brand Name
chlorpromazine HCl	chlorpromazine
fluphenazine decanoate	fluphenazine decanoate
fluphenazine HCl	fluphenazine HCl
haloperidol	haloperidol
haloperidol decanoate	haloperidol decanoate
haloperidol decanoate	Haldol Decanoate
haloperidol lactate	haloperidol lactate
haloperidol lactate	Haldol
iloperidone	Fanapt
loxapine	Adasuve
loxapine succinate	loxapine succinate
loxapine succinate	Loxitane
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda
molindone HCl	molindone
molindone HCl	Moban
olanzapine	Zyprexa
olanzapine	olanzapine
olanzapine	Zyprexa Zydis
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/fluoxetine HCl	Symbyax
olanzapine/samidorphan malate	Lybalvi
paliperidone	paliperidone
paliperidone	Invega
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
paliperidone palmitate	Invega Hafyera
perphenazine	perphenazine
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
pimavanserin tartrate	Nuplazid
pimozide	pimozide
pimozide	Orap
quetiapine fumarate	quetiapine
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
risperidone	risperidone
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone microspheres	Risperdal Consta
thioridazine HCl	thioridazine
thiothixene	thiothixene



**Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request**

Generic Name	Brand Name
thiothixene	Navane
trifluoperazine HCl	trifluoperazine
trifluoperazine HCl	trifluoperazine
trifluoperazine HCl	trifluoperazine
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	ziprasidone mesylate
ziprasidone mesylate	Geodon
<b>Anti-Depressants</b>	
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amitriptyline HCl/chlordiazepoxide	Limbitrol
amoxapine	amoxapine
brexanolone	Zulresso
bupropion HBr	Aplenzin
bupropion HCl	bupropion HCl
bupropion HCl	Wellbutrin XL
bupropion HCl	Wellbutrin SR
bupropion HCl	Forfivo XL
bupropion HCl	Wellbutrin
bupropion HCl	Budeprion XL
bupropion HCl	Budeprion SR
citalopram hydrobromide	citalopram
citalopram hydrobromide	Celexa
clomipramine HCl	clomipramine
clomipramine HCl	Anafranil
desipramine HCl	desipramine
desipramine HCl	Norpramin
desvenlafaxine	desvenlafaxine
desvenlafaxine	Khedezla
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
doxepin HCl	doxepin
doxepin HCl	Silenor
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	duloxetine
duloxetine HCl	Cymbalta
duloxetine HCl	Irenka
escitalopram oxalate	escitalopram oxalate
escitalopram oxalate	Lexapro
esketamine HCl	Spravato
fluoxetine HCl	fluoxetine
fluoxetine HCl	Prozac
fluoxetine HCl	Sarafem

**Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request**

<b>Generic Name</b>	<b>Brand Name</b>
fluoxetine HCl	Rapiflux
fluoxetine HCl	Selfemra
fluoxetine HCl	Prozac Weekly
fluvoxamine maleate	fluvoxamine
fluvoxamine maleate	Luvox CR
imipramine HCl	imipramine HCl
imipramine HCl	Tofranil
imipramine pamoate	imipramine pamoate
imipramine pamoate	Tofranil-PM
isocarboxazid	Marplan
maprotiline HCl	maprotiline
milnacipran HCl	Savella
mirtazapine	mirtazapine
mirtazapine	Remeron SolTab
mirtazapine	Remeron
nefazodone HCl	nefazodone
nortriptyline HCl	nortriptyline
nortriptyline HCl	Pamelor
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/fluoxetine HCl	Symbyax
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine HCl	Paxil
paroxetine mesylate	Pexeva
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	Duo-Vil 2-10
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
protriptyline HCl	protriptyline
protriptyline HCl	Vivactil
selegiline	Emsam
sertraline HCl	sertraline
sertraline HCl	Zoloft
tranylcypromine sulfate	tranylcypromine
tranylcypromine sulfate	Parnate
trazodone HCl	trazodone
trazodone HCl	Desyrel
trazodone HCl	Oleptro ER
trimipramine maleate	trimipramine
trimipramine maleate	Surmontil
venlafaxine HCl	venlafaxine
venlafaxine HCl	Effexor XR
venlafaxine HCl	Effexor
vortioxetine hydrobromide	Trintellix

**Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request**

<b>Generic Name</b>	<b>Brand Name</b>
vortioxetine hydrobromide	Brintellix
vilazodone HCl	Viibryd
levomilnacipran HCl	Fetzima
<b>Opioid Use Disorder (OUD 1) (defined as OUD 2, 3, or 4)<sup>1</sup></b>	
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine	Sublocade
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Zubsolv
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl	Subutex
<b>Opioid Use Disorder 4 (OUD 4)</b>	
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
buprenorphine	Sublocade
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl	Probuphine
buprenorphine HCl/naloxone HCl	Zubsolv
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl	Subutex

<sup>1</sup>See below and Appendix E for completion of definitions of OUD 2, 3, and 4

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
<b>ADHD and Other Behavior Disorders</b>			
312.00	Undersocialized conduct disorder, aggressive type, unspecified	Diagnosis	ICD-9-CM
312.01	Undersocialized conduct disorder, aggressive type, mild	Diagnosis	ICD-9-CM
312.02	Undersocialized conduct disorder, aggressive type, moderate	Diagnosis	ICD-9-CM
312.03	Undersocialized conduct disorder, aggressive type, severe	Diagnosis	ICD-9-CM
312.10	Undersocialized conduct disorder, unaggressive type, unspecified	Diagnosis	ICD-9-CM
312.11	Undersocialized conduct disorder, unaggressive type, mild	Diagnosis	ICD-9-CM
312.12	Undersocialized conduct disorder, unaggressive type, moderate	Diagnosis	ICD-9-CM
312.13	Undersocialized conduct disorder, unaggressive type, severe	Diagnosis	ICD-9-CM
312.20	Socialized conduct disorder, unspecified	Diagnosis	ICD-9-CM
312.21	Socialized conduct disorder, mild	Diagnosis	ICD-9-CM
312.22	Socialized conduct disorder, moderate	Diagnosis	ICD-9-CM
312.23	Socialized conduct disorder, severe	Diagnosis	ICD-9-CM
312.30	Impulse control disorder, unspecified	Diagnosis	ICD-9-CM
312.31	Pathological gambling	Diagnosis	ICD-9-CM
312.32	Kleptomania	Diagnosis	ICD-9-CM
312.33	Pyromania	Diagnosis	ICD-9-CM
312.34	Intermittent explosive disorder	Diagnosis	ICD-9-CM
312.35	Isolated explosive disorder	Diagnosis	ICD-9-CM
312.39	Other disorder of impulse control	Diagnosis	ICD-9-CM
312.4	Mixed disturbance of conduct and emotions	Diagnosis	ICD-9-CM
312.81	Conduct disorder, childhood onset type	Diagnosis	ICD-9-CM
312.82	Conduct disorder, adolescent onset type	Diagnosis	ICD-9-CM
312.89	Other specified disturbance of conduct, not elsewhere classified	Diagnosis	ICD-9-CM
312.9	Unspecified disturbance of conduct	Diagnosis	ICD-9-CM
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-9-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-9-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-9-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-9-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
F63.0	Pathological gambling	Diagnosis	ICD-10-CM
F63.1	Pyromania	Diagnosis	ICD-10-CM
F63.2	Kleptomania	Diagnosis	ICD-10-CM
F63.3	Trichotillomania	Diagnosis	ICD-10-CM
F63.81	Intermittent explosive disorder	Diagnosis	ICD-10-CM
F63.89	Other impulse disorders	Diagnosis	ICD-10-CM
F63.9	Impulse disorder, unspecified	Diagnosis	ICD-10-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
F91.0	Conduct disorder confined to family context	Diagnosis	ICD-10-CM
F91.1	Conduct disorder, childhood-onset type	Diagnosis	ICD-10-CM
F91.2	Conduct disorder, adolescent-onset type	Diagnosis	ICD-10-CM
F91.3	Oppositional defiant disorder	Diagnosis	ICD-10-CM
F91.8	Other conduct disorders	Diagnosis	ICD-10-CM
F91.9	Conduct disorder, unspecified	Diagnosis	ICD-10-CM
<b>ADHD Only Subset</b>			
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-9-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-9-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-9-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-9-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
<b>Alcohol Use Disorders</b>			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
P04.3	Newborn affected by maternal use of alcohol	Diagnosis	ICD-10-CM
Q86.0	Fetal alcohol syndrome (dysmorphic)	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Z71.42	Counseling for family member of alcoholic	Diagnosis	ICD-10-CM
<b>Anxiety Disorders</b>			
293.84	Anxiety disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
300.00	Anxiety state, unspecified	Diagnosis	ICD-9-CM
300.01	Panic disorder without agoraphobia	Diagnosis	ICD-9-CM
300.02	Generalized anxiety disorder	Diagnosis	ICD-9-CM
300.09	Other anxiety states	Diagnosis	ICD-9-CM
300.10	Hysteria, unspecified	Diagnosis	ICD-9-CM
300.20	Phobia, unspecified	Diagnosis	ICD-9-CM
300.21	Agoraphobia with panic disorder	Diagnosis	ICD-9-CM
300.22	Agoraphobia without mention of panic attacks	Diagnosis	ICD-9-CM
300.23	Social phobia	Diagnosis	ICD-9-CM
300.29	Other isolated or specific phobias	Diagnosis	ICD-9-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
300.3	Obsessive-compulsive disorders	Diagnosis	ICD-9-CM
300.5	Neurasthenia	Diagnosis	ICD-9-CM
300.89	Other somatoform disorders	Diagnosis	ICD-9-CM
300.9	Unspecified nonpsychotic mental disorder	Diagnosis	ICD-9-CM
308.0	Predominant disturbance of emotions	Diagnosis	ICD-9-CM
308.1	Predominant disturbance of consciousness as reaction to stress	Diagnosis	ICD-9-CM
308.2	Predominant psychomotor disturbance as reaction to stress	Diagnosis	ICD-9-CM
308.3	Other acute reactions to stress	Diagnosis	ICD-9-CM
308.4	Mixed disorders as reaction to stress	Diagnosis	ICD-9-CM
308.9	Unspecified acute reaction to stress	Diagnosis	ICD-9-CM
309.81	Posttraumatic stress disorder	Diagnosis	ICD-9-CM
313.0	Overanxious disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.1	Misery and unhappiness disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.21	Shyness disorder of childhood	Diagnosis	ICD-9-CM
313.22	Introverted disorder of childhood	Diagnosis	ICD-9-CM
313.3	Relationship problems specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.82	Identity disorder of childhood or adolescence	Diagnosis	ICD-9-CM
313.83	Academic underachievement disorder of childhood or adolescence	Diagnosis	ICD-9-CM
F06.4	Anxiety disorder due to known physiological condition	Diagnosis	ICD-10-CM
F40.00	Agoraphobia, unspecified	Diagnosis	ICD-10-CM
F40.01	Agoraphobia with panic disorder	Diagnosis	ICD-10-CM
F40.02	Agoraphobia without panic disorder	Diagnosis	ICD-10-CM
F40.10	Social phobia, unspecified	Diagnosis	ICD-10-CM
F40.11	Social phobia, generalized	Diagnosis	ICD-10-CM
F40.210	Arachnophobia	Diagnosis	ICD-10-CM
F40.218	Other animal type phobia	Diagnosis	ICD-10-CM
F40.220	Fear of thunderstorms	Diagnosis	ICD-10-CM
F40.228	Other natural environment type phobia	Diagnosis	ICD-10-CM
F40.230	Fear of blood	Diagnosis	ICD-10-CM
F40.231	Fear of injections and transfusions	Diagnosis	ICD-10-CM
F40.232	Fear of other medical care	Diagnosis	ICD-10-CM
F40.233	Fear of injury	Diagnosis	ICD-10-CM
F40.240	Claustrophobia	Diagnosis	ICD-10-CM
F40.241	Acrophobia	Diagnosis	ICD-10-CM
F40.242	Fear of bridges	Diagnosis	ICD-10-CM
F40.243	Fear of flying	Diagnosis	ICD-10-CM
F40.248	Other situational type phobia	Diagnosis	ICD-10-CM
F40.290	Androphobia	Diagnosis	ICD-10-CM
F40.291	Gynephobia	Diagnosis	ICD-10-CM
F40.298	Other specified phobia	Diagnosis	ICD-10-CM
F40.8	Other phobic anxiety disorders	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F40.9	Phobic anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F41.0	Panic disorder [episodic paroxysmal anxiety]	Diagnosis	ICD-10-CM
F41.1	Generalized anxiety disorder	Diagnosis	ICD-10-CM
F41.3	Other mixed anxiety disorders	Diagnosis	ICD-10-CM
F41.8	Other specified anxiety disorders	Diagnosis	ICD-10-CM
F41.9	Anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F42	Obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.2	Mixed obsessional thoughts and acts	Diagnosis	ICD-10-CM
F42.3	Hoarding disorder	Diagnosis	ICD-10-CM
F42.4	Excoriation (skin-picking) disorder	Diagnosis	ICD-10-CM
F42.8	Other obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.9	Obsessive-compulsive disorder, unspecified	Diagnosis	ICD-10-CM
F43.0	Acute stress reaction	Diagnosis	ICD-10-CM
F43.10	Post-traumatic stress disorder, unspecified	Diagnosis	ICD-10-CM
F43.11	Post-traumatic stress disorder, acute	Diagnosis	ICD-10-CM
F43.12	Post-traumatic stress disorder, chronic	Diagnosis	ICD-10-CM
F44.9	Dissociative and conversion disorder, unspecified	Diagnosis	ICD-10-CM
F45.8	Other somatoform disorders	Diagnosis	ICD-10-CM
F48.8	Other specified nonpsychotic mental disorders	Diagnosis	ICD-10-CM
F48.9	Nonpsychotic mental disorder, unspecified	Diagnosis	ICD-10-CM
F93.8	Other childhood emotional disorders	Diagnosis	ICD-10-CM
F99	Mental disorder, not otherwise specified	Diagnosis	ICD-10-CM
R45.2	Unhappiness	Diagnosis	ICD-10-CM
R45.5	Hostility	Diagnosis	ICD-10-CM
R45.6	Violent behavior	Diagnosis	ICD-10-CM
R45.7	State of emotional shock and stress, unspecified	Diagnosis	ICD-10-CM
<b>Bipolar Disorders</b>			
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-9-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-9-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-9-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic	Diagnosis	ICD-9-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-9-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-9-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-9-CM
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-9-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-9-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-9-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-9-CM
296.81	Atypical manic disorder	Diagnosis	ICD-9-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-9-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-9-CM
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity,	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
<b>Depression</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity,	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
<b>Depressive Disorders</b>			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
<b>Personality Disorders</b>			
301.0	Paranoid personality disorder	Diagnosis	ICD-9-CM
301.10	Affective personality disorder, unspecified	Diagnosis	ICD-9-CM
301.11	Chronic hypomanic personality disorder	Diagnosis	ICD-9-CM
301.12	Chronic depressive personality disorder	Diagnosis	ICD-9-CM
301.13	Cyclothymic disorder	Diagnosis	ICD-9-CM
301.20	Schizoid personality disorder, unspecified	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
301.21	Introverted personality	Diagnosis	ICD-9-CM
301.22	Schizotypal personality disorder	Diagnosis	ICD-9-CM
301.3	Explosive personality disorder	Diagnosis	ICD-9-CM
301.4	Obsessive-compulsive personality disorder	Diagnosis	ICD-9-CM
301.50	Histrionic personality disorder, unspecified	Diagnosis	ICD-9-CM
301.51	Chronic factitious illness with physical symptoms	Diagnosis	ICD-9-CM
301.59	Other histrionic personality disorder	Diagnosis	ICD-9-CM
301.6	Dependent personality disorder	Diagnosis	ICD-9-CM
301.7	Antisocial personality disorder	Diagnosis	ICD-9-CM
301.81	Narcissistic personality disorder	Diagnosis	ICD-9-CM
301.82	Avoidant personality disorder	Diagnosis	ICD-9-CM
301.83	Borderline personality disorder	Diagnosis	ICD-9-CM
301.84	Passive-aggressive personality	Diagnosis	ICD-9-CM
301.89	Other personality disorder	Diagnosis	ICD-9-CM
301.9	Unspecified personality disorder	Diagnosis	ICD-9-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F60.0	Paranoid personality disorder	Diagnosis	ICD-10-CM
F60.1	Schizoid personality disorder	Diagnosis	ICD-10-CM
F60.2	Antisocial personality disorder	Diagnosis	ICD-10-CM
F60.3	Borderline personality disorder	Diagnosis	ICD-10-CM
F60.4	Histrionic personality disorder	Diagnosis	ICD-10-CM
F60.5	Obsessive-compulsive personality disorder	Diagnosis	ICD-10-CM
F60.6	Avoidant personality disorder	Diagnosis	ICD-10-CM
F60.7	Dependent personality disorder	Diagnosis	ICD-10-CM
F60.81	Narcissistic personality disorder	Diagnosis	ICD-10-CM
F60.89	Other specific personality disorders	Diagnosis	ICD-10-CM
F60.9	Personality disorder, unspecified	Diagnosis	ICD-10-CM
F68.10	Factitious disorder imposed on self, unspecified	Diagnosis	ICD-10-CM
F68.11	Factitious disorder imposed on self, with predominantly psychological signs and symptoms	Diagnosis	ICD-10-CM
F68.12	Factitious disorder imposed on self, with predominantly physical signs and symptoms	Diagnosis	ICD-10-CM
F68.13	Factitious disorder imposed on self, with combined psychological and physical signs and symptoms	Diagnosis	ICD-10-CM
F69	Unspecified disorder of adult personality and behavior	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
<b>Drug Use Disorders</b>			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse,	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother,	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk,	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder,	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F55.0	Abuse of antacids	Diagnosis	ICD-10-CM
F55.1	Abuse of herbal or folk remedies	Diagnosis	ICD-10-CM
F55.2	Abuse of laxatives	Diagnosis	ICD-10-CM
F55.3	Abuse of steroids or hormones	Diagnosis	ICD-10-CM
F55.4	Abuse of vitamins	Diagnosis	ICD-10-CM
F55.8	Abuse of other non-psychoactive substances	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
O99.320	Drug use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.325	Drug use complicating the puerperium	Diagnosis	ICD-10-CM
P04.41	Newborn affected by maternal use of cocaine	Diagnosis	ICD-10-CM
P04.49	Newborn affected by maternal use of other drugs of addiction	Diagnosis	ICD-10-CM
P96.1	Neonatal withdrawal symptoms from maternal use of drugs of addiction	Diagnosis	ICD-10-CM
P96.2	Withdrawal symptoms from therapeutic use of drugs in newborn	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Z71.52	Counseling for family member of drug abuser	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
<b>Schizophrenia</b>			
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
<b>Schizophrenia and Other Psychotic Disorders</b>			
293.81	Psychotic disorder with delusions in conditions classified elsewhere	Diagnosis	ICD-9-CM
293.82	Psychotic disorder with hallucinations in conditions classified elsewhere	Diagnosis	ICD-9-CM
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
297.0	Paranoid state, simple	Diagnosis	ICD-9-CM
297.1	Delusional disorder	Diagnosis	ICD-9-CM
297.2	Paraphrenia	Diagnosis	ICD-9-CM
297.3	Shared psychotic disorder	Diagnosis	ICD-9-CM
297.8	Other specified paranoid states	Diagnosis	ICD-9-CM
297.9	Unspecified paranoid state	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
298.1	Excitatory type psychosis	Diagnosis	ICD-9-CM
298.2	Reactive confusion	Diagnosis	ICD-9-CM
298.3	Acute paranoid reaction	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
298.4	Psychogenic paranoid psychosis	Diagnosis	ICD-9-CM
298.8	Other and unspecified reactive psychosis	Diagnosis	ICD-9-CM
298.9	Unspecified psychosis	Diagnosis	ICD-9-CM
F06.0	Psychotic disorder with hallucinations due to known physiological condition	Diagnosis	ICD-10-CM
F06.2	Psychotic disorder with delusions due to known physiological condition	Diagnosis	ICD-10-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F22	Delusional disorders	Diagnosis	ICD-10-CM
F23	Brief psychotic disorder	Diagnosis	ICD-10-CM
F24	Shared psychotic disorder	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
F28	Other psychotic disorder not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F29	Unspecified psychosis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F44.89	Other dissociative and conversion disorders	Diagnosis	ICD-10-CM
<b>Opioid Use Disorder (OUD 1) (defined as OUD 2, 3, or 4)</b>			
304.0	Opioid type dependence	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk,	Diagnosis	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
970.1	Poisoning by opiate antagonists	Diagnosis	ICD-9-CM
E85.00	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E85.01	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E85.02	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E93.50	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E93.51	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E93.52	Other opiates and related narcotics causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E94.01	Opiate antagonists causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2078	Take home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
G2079	Take home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Procedure	HCPCS
HZ81ZZZ	Medication Management for Substance Abuse Treatment, Methadone	Procedure	ICD-10-PCS
HZ84ZZZ	Medication Management for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ85ZZZ	Medication Management for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ91ZZZ	Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ94ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ95ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
J0571	Buprenorphine, oral, 1 mg	Procedure	HCPCS
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	Procedure	HCPCS
J0573	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine	Procedure	HCPCS
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	Procedure	HCPCS
J0575	Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine	Procedure	HCPCS
J0592	Injection, buprenorphine HCl, 0.1 mg	Procedure	HCPCS
J1230	Injection, methadone HCl, up to 10 mg	Procedure	HCPCS
S0109	Methadone, oral, 5 mg	Procedure	HCPCS
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.0X1S	Poisoning by opium, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X3D	Poisoning by opium, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X3S	Poisoning by opium, assault, sequela	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.0X4S	Poisoning by opium, undetermined, sequela	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5D	Adverse effect of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.1X1S	Poisoning by heroin, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X3D	Poisoning by heroin, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X3S	Poisoning by heroin, assault, sequela	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X4S	Poisoning by heroin, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X1D	Poisoning by other opioids, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.2X1S	Poisoning by other opioids, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X3D	Poisoning by other opioids, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X3S	Poisoning by other opioids, assault, sequela	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X4D	Poisoning by other opioids, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X4S	Poisoning by other opioids, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X5A	Adverse effect of other opioids, initial encounter	Diagnosis	ICD-10-CM
T40.2X5D	Adverse effect of other opioids, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X5S	Adverse effect of other opioids, sequela	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X1D	Poisoning by methadone, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.3X1S	Poisoning by methadone, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X3D	Poisoning by methadone, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X3S	Poisoning by methadone, assault, sequela	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.3X4D	Poisoning by methadone, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X4S	Poisoning by methadone, undetermined, sequela	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5D	Adverse effect of methadone, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.411D	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.411S	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.413D	Poisoning by fentanyl or fentanyl analogs, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.413S	Poisoning by fentanyl or fentanyl analogs, assault, sequela	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.414D	Poisoning by fentanyl or fentanyl analogs, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.414S	Poisoning by fentanyl or fentanyl analogs, undetermined, sequela	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.415D	Adverse effect of fentanyl or fentanyl analogs, subsequent encounter	Diagnosis	ICD-10-CM
T40.415S	Adverse effect of fentanyl or fentanyl analogs, sequela	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.421D	Poisoning by tramadol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.421S	Poisoning by tramadol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.423D	Poisoning by tramadol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.423S	Poisoning by tramadol, assault, sequela	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.424D	Poisoning by tramadol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.424S	Poisoning by tramadol, undetermined, sequela	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.425D	Adverse effect of tramadol, subsequent encounter	Diagnosis	ICD-10-CM
T40.425S	Adverse effect of tramadol, sequela	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.491D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.491S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.493D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.493S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.494D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.494S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.495D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.495S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.4X1D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.4X1S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X3D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X3S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.4X4D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X4S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X5D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X5S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.601D	Poisoning by unspecified narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.601S	Poisoning by unspecified narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.603D	Poisoning by unspecified narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.603S	Poisoning by unspecified narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.604D	Poisoning by unspecified narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.604S	Poisoning by unspecified narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.605A	Adverse effect of unspecified narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.605D	Adverse effect of unspecified narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.605S	Adverse effect of unspecified narcotics, sequela	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.691D	Poisoning by other narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.691S	Poisoning by other narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.693D	Poisoning by other narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.693S	Poisoning by other narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.694D	Poisoning by other narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.694S	Poisoning by other narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.695A	Adverse effect of other narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.695D	Adverse effect of other narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.695S	Adverse effect of other narcotics, sequela	Diagnosis	ICD-10-CM
<b>Opioid Use Disorder 2 (OUD 2)</b>			
304.0	Opioid type dependence	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk,	Diagnosis	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E85.00	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E85.01	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E85.02	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E93.50	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E93.51	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
HZ81ZZZ	Medication Management for Substance Abuse Treatment, Methadone	Procedure	ICD-10-PCS
HZ84ZZZ	Medication Management for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ85ZZZ	Medication Management for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ91ZZZ	Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ94ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ95ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
<b>Opioid Use Disorder 3 (OUD 3)</b>			
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
970.1	Poisoning by opiate antagonists	Diagnosis	ICD-9-CM
E85.00	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E85.01	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E85.02	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E93.50	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E93.51	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E93.52	Other opiates and related narcotics causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
E94.01	Opiate antagonists causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM



**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.0X1S	Poisoning by opium, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X3D	Poisoning by opium, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X3S	Poisoning by opium, assault, sequela	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X4S	Poisoning by opium, undetermined, sequela	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5D	Adverse effect of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.1X1S	Poisoning by heroin, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X3D	Poisoning by heroin, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X3S	Poisoning by heroin, assault, sequela	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X4S	Poisoning by heroin, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X1D	Poisoning by other opioids, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.2X1S	Poisoning by other opioids, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X3D	Poisoning by other opioids, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X3S	Poisoning by other opioids, assault, sequela	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X4D	Poisoning by other opioids, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X4S	Poisoning by other opioids, undetermined, sequela	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.2X5A	Adverse effect of other opioids, initial encounter	Diagnosis	ICD-10-CM
T40.2X5D	Adverse effect of other opioids, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X5S	Adverse effect of other opioids, sequela	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X1D	Poisoning by methadone, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.3X1S	Poisoning by methadone, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X3D	Poisoning by methadone, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X3S	Poisoning by methadone, assault, sequela	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X4D	Poisoning by methadone, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X4S	Poisoning by methadone, undetermined, sequela	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5D	Adverse effect of methadone, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.411D	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.411S	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.413D	Poisoning by fentanyl or fentanyl analogs, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.413S	Poisoning by fentanyl or fentanyl analogs, assault, sequela	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.414D	Poisoning by fentanyl or fentanyl analogs, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.414S	Poisoning by fentanyl or fentanyl analogs, undetermined, sequela	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.415D	Adverse effect of fentanyl or fentanyl analogs, subsequent encounter	Diagnosis	ICD-10-CM
T40.415S	Adverse effect of fentanyl or fentanyl analogs, sequela	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.421D	Poisoning by tramadol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.421S	Poisoning by tramadol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.423D	Poisoning by tramadol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.423S	Poisoning by tramadol, assault, sequela	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.424D	Poisoning by tramadol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.424S	Poisoning by tramadol, undetermined, sequela	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.425D	Adverse effect of tramadol, subsequent encounter	Diagnosis	ICD-10-CM
T40.425S	Adverse effect of tramadol, sequela	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.491D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent	Diagnosis	ICD-10-CM
T40.491S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.493D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.493S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.494D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.494S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.495D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.495S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial	Diagnosis	ICD-10-CM
T40.4X1D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.4X1S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X3D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X3S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.4X4D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X4S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X5D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X5S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.601D	Poisoning by unspecified narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.601S	Poisoning by unspecified narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.603D	Poisoning by unspecified narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.603S	Poisoning by unspecified narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.604D	Poisoning by unspecified narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.604S	Poisoning by unspecified narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.605A	Adverse effect of unspecified narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.605D	Adverse effect of unspecified narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.605S	Adverse effect of unspecified narcotics, sequela	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.691D	Poisoning by other narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.691S	Poisoning by other narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.693D	Poisoning by other narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.693S	Poisoning by other narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.694D	Poisoning by other narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.694S	Poisoning by other narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.695A	Adverse effect of other narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.695D	Adverse effect of other narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.695S	Adverse effect of other narcotics, sequela	Diagnosis	ICD-10-CM

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

Code	Description	Code Category	Code Type
<b>Opioid Use Disorder 4 (OUD 4)</b>			
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2078	Take home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
G2079	Take home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Procedure	HCPCS
J0571	Buprenorphine, oral, 1 mg	Procedure	HCPCS

**Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	Procedure	HCPCS
J0573	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine	Procedure	HCPCS
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	Procedure	HCPCS
J0575	Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine	Procedure	HCPCS
J0592	Injection, buprenorphine HCl, 0.1 mg	Procedure	HCPCS
J1230	Injection, methadone HCl, up to 10 mg	Procedure	HCPCS
S0109	Methadone, oral, 5 mg	Procedure	HCPCS

# Appendix G. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) module, version 11.3.0 to estimate rates of ANC screening adherence among clozapine users in the Sentinel Distributed Database (SDD).

**Query period:** Multiple Query Periods, specified per scenario. See below.  
**Coverage requirement:** Medical & Drug Coverage  
**Pre-index enrollment requirement:** Multiple Pre-Index Enrollment Requirements. See below.  
**Post-index enrollment requirement:** 0 days  
**Post-episode enrollment requirement for Type 2 analyses:** 0 days  
**Enrollment gap:** 30 days  
**Age groups:** 12-18, 19-35, 36-50, 51-64, 65-74, 75+ years  
**Stratifications:** Year-quarter, Geographic Census region  
**Restrictions:** No  
**Envelope macro:** Reclassify encounters during inpatient stay as inpatient  
**Distribution of index-defining codes:** No  
**Never-exposed cohort:** No  
**Freeze data:** No

Exposure																
Scenario	Corresponding Look in	Query Period	Pre-Index Enrollment Requirement (days)	Multiple Events Episode	Index Exposure	Cohort definition	Incident exposure washout period (days)	Incident with respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Point?	Maximum Episode Duration (days)	Risk Evaluation Start (days)	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied
1	Look 1	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a**	n/a	30 days	0 days	1 day	n/a
2	Look 2	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
3	Look 5	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	6 months (184 days)	n/a



Appendix G. Specifications Defining Parameters for this Request

Exposure																
Scenario	Corresponding Look in cder_mpl1r_wp183	Query Period	Pre-Index Enrollment Requirement (days)	Multiple Events Episode	Index Exposure	Cohort definition	Incident exposure washout period (days)	Incident with respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Point?	Maximum Episode Duration (days)	Risk Evaluation Start (days)	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied
4	Look 3	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	6 months (184 days)	n/a
5	Look 6	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 year (366 days)	n/a
6	Look 4	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 year (366 days)	n/a
7	Look 7	01/01/2010 - 09/30/2015	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	2 years (731 days)	n/a
8	Look 2/ Sensitivity	01/01/2010 - 09/30/2015	183	Primary Episode	Clozapine	All valid exposure episodes during query period	183	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a



Appendix G. Specifications Defining Parameters for this Request

Exposure																
Scenario	Corresponding Look in cder_mpl1r_wp183	Query Period	Pre-Index Enrollment Requirement (days)	Multiple Events Episode	Index Exposure	Cohort definition	Incident exposure washout period (days)	Incident with respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Point?	Maximum Episode Duration (days)	Risk Evaluation Start (days)	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied
9	ANC	01/01/2010 - 09/30/2015	30	Secondary Episode	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a	n/a	n/a
10	Look 1	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
11	Look 2	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
12	Look 5	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	6 months (184 days)	n/a
13	Look 3	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	6 months (184 days)	n/a

Appendix G. Specifications Defining Parameters for this Request

Exposure																
Scenario	Corresponding Look in cder_mpl1r_wp183	Query Period	Pre-Index Enrollment Requirement (days)	Multiple Events Episode	Index Exposure	Cohort definition	Incident exposure washout period (days)	Incident with respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Point?	Maximum Episode Duration (days)	Risk Evaluation Start (days)	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied
14	Look 6	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 year (366 days)	n/a
15	Look 4	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 year (366 days)	n/a
16	Look 7	10/01/2015 - 12/31/2019	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	2 years (731 days)	n/a
17	Look 2/ Sensitivity	10/01/2015 - 12/31/2019	183	Primary Episode	Clozapine	All valid exposure episodes during query period	183	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
18	ANC	10/01/2015 - 12/31/2019	30	Secondary Episode	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a	n/a	n/a

Appendix G. Specifications Defining Parameters for this Request

Exposure																
Scenario	Corresponding Look in cder_mpl1r_wp183	Query Period	Pre-Index Enrollment Requirement (days)	Multiple Events Episode	Index Exposure	Cohort definition	Incident exposure washout period (days)	Incident with respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Point?	Maximum Episode Duration (days)	Risk Evaluation Start (days)	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied
19	Look 1	1/1/2020 - 10/31/2021	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
20	Look 2	1/1/2020 - 10/31/2021	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	1 day	n/a
21	Look 3	1/1/2020 - 10/31/2021	30	Primary Episode	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	n/a	30 days	0 days	6 months (184 days)	n/a
22	ANC	1/1/2020 - 10/31/2021	30	Secondary Episode	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a	n/a	n/a

Appendix G. Specifications Defining Parameters for this Request

Scenario	Exposure					Create Baseline Table?	Inclusion/Exclusion Criteria					
	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Censor treatment episode at evidence of:		Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end
1	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
2	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
3	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
4	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
5	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified

Appendix G. Specifications Defining Parameters for this Request

Scenario	Exposure					Create Baseline Table?	Inclusion/Exclusion Criteria						
	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Censor treatment episode at evidence of:		Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	
6	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
7	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
8	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
9	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	No	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
10	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	

Appendix G. Specifications Defining Parameters for this Request

Scenario	Exposure					Create Baseline Table?	Inclusion/Exclusion Criteria					
	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Censor treatment episode at evidence of:		Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end
11	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
12	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
13	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
14	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
15	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified

Appendix G. Specifications Defining Parameters for this Request

Scenario	Exposure					Create Baseline Table?	Inclusion/Exclusion Criteria						
	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Censor treatment episode at evidence of:		Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	
16	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
17	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
18	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	No	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
19	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	
20	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	

Appendix G. Specifications Defining Parameters for this Request

Scenario	Exposure					Create Baseline Table?	Inclusion/Exclusion Criteria					
	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings	Censor treatment episode at evidence of:		Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end
21	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Yes	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified
22	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	No	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified



Appendix G. Specifications Defining Parameters for this Request

Scenario	Inclusion/Exclusion Criteria			Multiple Events Assessment						
	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings	Secondary Episode	Observation From Anchor	Observation From (days)	Observation To Anchor	Observation To (days)	Minimum Adherence (days)	Minimum Adherence Scale
1	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count
2	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
3	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
4	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count
5	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count
6	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count

Appendix G. Specifications Defining Parameters for this Request

Scenario	Inclusion/Exclusion Criteria			Multiple Events Assessment						
	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings	Secondary Episode	Observation From Anchor	Observation From (days)	Observation To Anchor	Observation To (days)	Minimum Adherence (days)	Minimum Adherence Scale
7	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count
8	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
9	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	-	-	-	-	-	-	-
10	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count
11	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
12	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count

Appendix G. Specifications Defining Parameters for this Request

Scenario	Inclusion/Exclusion Criteria			Multiple Events Assessment						
	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings	Secondary Episode	Observation From Anchor	Observation From (days)	Observation To Anchor	Observation To (days)	Minimum Adherence (days)	Minimum Adherence Scale
13	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count
14	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count
15	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count
16	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count
17	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
18	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Inclusion/Exclusion Criteria			Multiple Events Assessment						
	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings	Secondary Episode	Observation From Anchor	Observation From (days)	Observation To Anchor	Observation To (days)	Minimum Adherence (days)	Minimum Adherence Scale
19	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_cov)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count
20	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_cov)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count
21	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	ANC Screening (ANC_cov)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count
22	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 1			Adherence Criterion 2			Adherence Criterion 3			Adherence Criterion 4			Adherence Criterion 5			Adherence Criterion 6		
	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)
	Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)	
1	EpiCount	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
3	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
4	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
5	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
6	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
7	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 1			Adherence Criterion 2			Adherence Criterion 3			Adherence Criterion 4			Adherence Criterion 5			Adherence Criterion 6		
	Adherence Type	Start (days)	Adherence End (days)	Adherence Type	Start (days)	Adherence End (days)	Adherence Type	Start (days)	Adherence End (days)	Adherence Type	Start (days)	Adherence End (days)	Adherence Type	Start (days)	Adherence End (days)	Adherence Type	Start (days)	Adherence End (days)
8	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	EpiCount	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
12	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
13	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
14	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
15	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 1			Adherence Criterion 2			Adherence Criterion 3			Adherence Criterion 4			Adherence Criterion 5			Adherence Criterion 6		
	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)	Adherence		End (days)
	Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)		Type	Start (days)	
16	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0	EpiCount	1	--	EpiCount	1	4
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
17	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	EpiCount	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
21	EpiGap	1	10	EpiGap	1	17	EpiGap	1	33	-	-	-	-	-	-	-	-	-
	EpiCount	1	-	EpiCount	1	-	EpiCount	1	-	-	-	-	-	-	-	-	-	-
22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 7			Adherence Criterion 8			Adherence Criterion 9			Adherence Criterion 10			Adherence Criterion 11			Adherence Criterion 12		
	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)
	Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)	
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27
4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27
6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27
8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27
13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27



Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 7			Adherence Criterion 8			Adherence Criterion 9			Adherence Criterion 10			Adherence Criterion 11			Adherence Criterion 12		
	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)	Adherence		Adherence End (days)
	Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)		Adherence Type	Start (days)	
15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	EpiCount	5	7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20	EpiCount	21	24	EpiCount	25	27
17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 13			Adherence Criterion 14			Adherence Criterion 15			Adherence Criterion 16		
	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)
1	-	-	-	-	-	-	-	-	-	-	-	-
2	-	-	-	-	-	-	-	-	-	-	-	-
3	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	25	--
4	-	-	-	-	-	-	-	-	-	-	-	-
5	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
6	-	-	-	-	-	-	-	-	-	-	-	-
7	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
8	-	-	-	-	-	-	-	-	-	-	-	-
9	-	-	-	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-	-	-	-
11	-	-	-	-	-	-	-	-	-	-	-	-
12	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	25	--
13	-	-	-	-	-	-	-	-	-	-	-	-
14	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
15	-	-	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request

Scenario	Adherence Criterion 13			Adherence Criterion 14			Adherence Criterion 15			Adherence Criterion 16		
	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)	Adherence Type	Adherence Start (days)	Adherence End (days)
16	EpiCount	28	30	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
17	-	-	-	-	-	-	-	-	-	-	-	-
18	-	-	-	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-	-	-	-
20	-	-	-	-	-	-	-	-	-	-	-	-
21	-	-	-	-	-	-	-	-	-	-	-	-
22	-	-	-	-	-	-	-	-	-	-	-	-

**Appendix G. Specifications Defining Parameters for this Request**

Scenario	Rate Criterion 17/4 (Criteria 17, 18, and 19 for the first two monitoring periods; Criteria 4, 5, and 6 for the third monitoring period)					Rate Criterion 18/5					Rate Criterion 19/6				
	Adherence Type	Rate Unit	Number of Days/Month	Adherence Start (days)	Adherence End (days)	Adherence Type	Rate Unit	Number of Days/Month	Adherence Start (days)	Adherence End (days)	Adherence Type	Rate Unit	Number of Days/Month	Adherence Start (days)	Adherence End (days)
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
3	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
4	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
5	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
6	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
7	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
8	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
12	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
13	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
14	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
15	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
16	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
17	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
21	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-	EpiRate	Month	30	1	-
22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<p>*Separate testing in Merative™ MarketScan® will be conducted by altering query period start between 4/1/2020 and 1/1/2020</p> <p>International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) codes are provided by Optum360.</p> <p>National Drug Codes (NDC) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."</p> <p>**N/A = Not Applicable</p>															

# Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request

Baseline Characteristics							
Covariate	Care setting	Principal diagnosis position	Evaluation period start (days)	Evaluation period end (days)	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
Lithium	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Atypical antipsychotics	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Typical antipsychotics	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
All antipsychotics (typical and atypical)	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Antidepressants	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
ADHD and other behavior disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Alcohol Use Disorders	DX codes: IP	Any	Ever	0	n/a	1	n/a
	DX codes: AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
	PX codes: Any	Any	Ever	0	n/a	1	n/a

# Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request

Baseline Characteristics							
Covariate	Care setting	Principal diagnosis position	Evaluation period start (days)	Evaluation period end (days)	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
Anxiety Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Bipolar Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Depression	Any	Any	Ever	0	n/a	1	n/a
Depressive Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Drug Use Disorders	DX codes: IP	Any	Ever	0	n/a	1	n/a
	DX codes: AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
	PX codes: Any	Any	Ever	0	n/a	1	n/a
Opioid Use Disorder (OUD) 1 (defined as OUD 2, 3 or 4)	n/a	n/a	n/a	n/a	n/a	n/a	n/a
OUD 2	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a

# Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request

Baseline Characteristics							
Covariate	Care setting	Principal diagnosis position	Evaluation period start (days)	Evaluation period end (days)	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
OU D 3	IP/ED	Any	Ever	0	n/a	1	n/a
OU D 4 (RX and PX only)	Any	Any	Ever	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Personality Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Schizophrenia	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Schizophrenia and Other Psychotic Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
ADHD Only Subset	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a

\*N/A = Not Applicable

IP = Inpatient Hospital Stay

AV = Ambulatory Visit

OA = Other Ambulatory Visit

ED = Emergency Department

IS = Non-Acute Institutional Stay

# Appendix I. Specifications Defining Medical Utilization and Comorbidity Score Parameters for this Request

## Utilization

Medical utilization evaluation period start (days)	Medical utilization evaluation period end (days)	Medical visit care settings	Drug utilization evaluation period start (days)	Drug utilization evaluation period end (days)
Ever	0	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	-30	0

## Comorbidity Score

Evaluation period start (days)	Evaluation period end (days)
Ever	0



## Appendix J. Specifications Defining Stockpiling Parameters Used for this Request

Stockpiling					
Stockpiling group	Same day dispensing processing for days supplied	Same day dispensing processing for amount supplied	Range of allowable days supplied values	Range of allowable amount supplied values	Overlap percentage
clozapine	Uses maximum	Uses maximum	Value must be greater than 0 (0<-HIGH)	Value must be greater than 0 (0<-HIGH)	n/a*

\*N/A = Not Applicable

# Appendix K. Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)

		Observation window (Day*)			
		-30 to 0	1 to 182	183 to 364	365 to 729
Total episode duration (number of days)	1 to 183	Look 1	Look 2		
	184 to 365				
	366 to 730			Look 3	Look 4
	>730				

\*Day 0 refers to the date of clozapine dispensing preceded by no evidence of clozapine days supply in the prior 30 days


		Observation window (Day*)			
		-30 to 0	1 to 182	183 to 364	365 to 729
Total episode duration (number of days)	1 to 183				
	184 to 365		Look 5		
	366 to 730			Look 6	
	>730				Look 7

\*Day 0 refers to the date of clozapine dispensing preceded by no evidence of clozapine days supply in the prior 30 days


Gap Adherence: all ANC screening gaps  $\leq 10$  days<sup>1</sup> in [1, earliest of 182 or clozapine episode censoring\*]

# clozapine episodes with gaps of 1-10 days between ANC screenings during 0-6 months<sup>2</sup> of clozapine use

% adherent episodes =  $\frac{\text{\# clozapine episodes with gaps of 1-10 days between ANC screenings during 0-6 months}^2 \text{ of clozapine use}}{\text{\# clozapine episodes of any duration}}$



- <sup>1</sup> Other ANC screening gaps include  $\leq 17$  days and  $\leq 33$  days
- <sup>2</sup> Observation window varies based on Look. This request contains the following windows:
- 0 to 6 months ([1, 182])
  - 6 months to 1 year ([183, 364])
  - 1 to 2 years ([365, 729])



# Appendix K. Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)

